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ABSTRACT 
 
Until recently, CD4+ T Helper (TH) cells were thought to be permanently committed to a 
single lineage (e.g. TH1, TH17, TH2 etc.).  However there is now increasing evidence that TH 
cells are plastic in nature and can gain phenotypic features of other TH subsets.  Within this 
study I have investigated the overlap and plasticity of TH1 cells and their presence in health 
and in the inflammatory setting of multiple sclerosis.  
It has been recently shown that TH17 cells stimulated in an IL-12 rich environment can 
become CCR6+IFNγ+IL-17+ cells1. The expression of the TH1 and TH17 transcription factors, T-
bet and RORC respectively, was initially investigated in different cytokine secreting subsets 
using multicolour flow cytometry. IFNγ+IL-17+ cells expressed both T-bet and RORC at a 
protein level.   
Although CCR6 is considered a TH17 marker there are other TH cell subsets that express 
CCR62.  Using peripheral blood T cells isolated from healthy volunteer donors a novel subset 
of TH1 cells has been identified that express functional CCR6.  Using multicolour flow 
cytometry it was shown that CCR6+TH1 cells did not secrete any other TH17 related cytokines 
(i.e. IL-22, IL-17F and IL-21) but expressed the TH1 associated chemokine receptor CXCR3.  
These cells share phenotypic features of a TH1 cell but transcriptionally express ‘TH17’-
related genes.  Optimisation of a cytokine capture technique allowed the isolation of viable 
CCR6+IFNγ+, CCR6+IL-17+ and CCR6+IFNγ+IL-17+ cells as well as CCR6-IFNγ+ cells.  Comparisons 
were made between the different subsets at a transcriptional level using qRT-PCR.  CCR6+TH1 
  
cells expressed ‘TH17’-related genes (e.g. RORC, IL-23R and IL4I1) similar to IL-17A secreting 
cells but also expressed T-bet and IL-12Rβ2 and no IL-1R1, similar to CCR6-TH1 cells.  At a 
protein and transcriptional level CCR6+TH1 cells were distinct from CCR6
+IFNγ+IL-17+ cells.  In 
addition, using a microarray screening method, candidate miRNAs that may play a role in 
controlling phenotypic features of these cells have been identified.   
TH17 cells have been implicated in the pathogenesis of multiple sclerosis and enter the 
cerebrospinal fluid through CCR6-dependent migration.  CCR6+IFNγ+ cells were increased 
within the cerebrospinal fluid of patients with multiple sclerosis compared to the peripheral 
blood.  Upon stimulation the CCR6+TH1 and CCR6
-TH1 cells were a source of GM-CSF, a 
cytokine know to be important for the pathogenesis of the mouse model of MS, 
experimental autoimmune encephalomyelitis.  Further research is needed to confirm if 
CCR6+TH1 play a role in the pathogenesis of the disease.  
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CHAPTER 1 
INTRODUCTION 
1.1 The Immune System 
There are an extensive variety of pathogens that can infect the body and cause damage.  
They come in all shapes and sizes; tiny viruses (20-200nm), bacteria (~0.2-2µm), fungal 
infections (~100-1000 µm) and helminths such as tapeworms that can grow to a few meters 
in length.  These different pathogens not only vary in size but also how they enter the body 
and their ideal site of infection.  To protect the body from this diverse group of pathogens 
the immune system has evolved in to a complex multidimensional system.    
There is a fine line that the immune system must walk.  Protection against the pathogens to 
prevent infection is vital; however, this must be done without causing significant damage to 
the body.  This is never clearer than in autoimmune diseases.  Self-antigens are not tolerated 
by their own immune system and this can cause irrevocable and long lasting damage to the 
body.  To truly understand why and how autoimmunity occurs we must first understand the 
cellular and molecular foundation of an immune response.  Increasing our understanding of 
the immune system will help lead to effective treatments for not just autoimmunity but also 
other immune related diseases.    
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1.2 The Components of the Immune System 
The human immune system works on three levels.  The initial level is a physical defence 
against invading pathogens.  The skin and mucosal tissue, which is open to the external 
environment, forms a physical barrier to prevent entry of the large majority of pathogens.  
Secondly, if the pathogen gets past the first physical barrier, there is the innate immune 
system.  The first line of defence against infection made up of rapidly reacting cells.  These 
innate cells use the same mechanisms to protect the body irrelevant of the type of infection.  
The complement system makes up the molecular arm to the innate system and also has 
similar feature to the innate cells, in that it is rapid in reacting and is non-specific.  Thirdly, 
there are the adaptive immune systems; made up of specialized cells that react in a more 
directed manner, releasing molecules such as antibodies and cytokines in a more focussed 
way, and retaining memory of infection that can lead the fight against future re-infections.   
All immune cells originate from a common precursor in the bone marrow, the pluripotent 
hematopoietic stem cell.  These cells mature within the bone marrow and differentiate into 
either a common lymphoid progenitor3 or a common myeloid progenitor4.  It is at this stage 
the difference between the innate and adaptive immune cells starts to develop.  Common 
myeloid progenitors will differentiate to become one of several different innate cell types; a 
granulocyte, mast cell, monocyte or dendritic cell4.  Common lymphoid progenitor will 
become adaptive immune cells; T, B or natural killer (NK) cells3.   
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1.2.1 Innate Immunity 
The innate immune system consists of molecular elements, such as the complement system, 
and cellular components, such as macrophages and neutrophils.  As mentioned, innate 
immune cells are the first cells to recognise the infectious agent, they all express pattern-
recognition receptors (PRR).  At least 5 classes of PRRs have been identified including Toll-
like receptors (TLRs), C-type lectin receptors (CLRs) and cytosolic DNA receptors (CDRs).  The 
PRR recognise pathogen associated molecular patterns (PAMP) which are conserved 
molecular structures that are vital for the survival of the infectious agent but are not found 
in mammalian biology.  Examples of PAMP are;  
 lipopolysaccharides (LPS), a major component of Gram-negative bacterial cell wall, 
 lypoteichoic acid, a vital component of Gram-positive bacterial cell wall, 
 mannans, part of the fungal cell wall, 
 DNA motifs, 
  dsRNA, involved in some virus’s transcription.   
PAMP will activate PRR to initiate a cascade of signals within the cell and induce activation.  
There is heterogeneous expression of these receptors on the different innate cell types5. 
The innate granulocytes (neutrophils, eosinophils, basophils) express granules containing 
enzymes and inflammatory proteins.  Neutrophils are present in abundance in the human 
blood and are the first effector cells to appear at the site of an infection.  As well as being  
important antimicrobial effector cells they also secrete cytokines and chemokines to 
orchestrate the immune response6.  As they release lytic granules eosinophils and basophils 
Introduction 
4 
 
make up part of the immune response against multi-cellular parasites, although both cell 
types also play a role in allergic responses.  Mast cells are also associated with allergic 
responses, as upon activation these cells release granules containing chemicals such as 
histamine and heparin that effect vascular permeability.  Mast cells can become activated 
via the complement system or through crosslinking of IgE on their cell surface.  Mast cells 
are resident in most tissues surrounding blood vessels and nerves, as well as at mucosal 
surfaces such as the gut and lungs. 
Although NK cells are a type of cytotoxic lymphocytes and differentiate from a common 
lymphoid progenitor they are classically seen as an innate cell as they provide a rapid 
response to infections.  These cells provide surveillance against virally infected cells and 
tumour cells.  Their mechanisms of action are slightly different to other innate cells as 
instead of being activated by PAMP or binding to a major histocompatibility complex 
(MHC)/peptide complex, NK cells recognises ‘stressed’ body cells which have down 
regulated MHC.  NK cells secrete interferon gamma (IFNγ) and release lytic granules to direct 
the killing of ‘stressed’ targeted cells.  Alongside this method of activation NK cells also 
express activator and inhibitory receptors, such as NKG2D (activator) or killer-cell 
immunoglobulin-like receptors (KIRs - inhibitor).  CD161 (cluster of differentiation 161) is an 
inhibitory NK cell receptor (also known as killer cell lectin-like receptor, B1) which when 
activated by its ligand, lectin like transcript 1 (LLT1), inhibits NK cell cytotoxicity and IFNγ 
secretion7.  CD161 can also be expressed on a subset of lymphocytes8.   
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In addition to the release of immune-stimulating molecules, such as cytokines or lytic 
granules, phagocytosis is another important function of innate immune cells.  Phagocytosis 
involves the recognition and internalisation of a recognised pathogen or harmful substance.  
Upon internalisation of the pathogen the vesicle will fuse to a lysosome.  The digestive 
enzymes in the lysosome will break down the pathogen within the vesicle.  The process of 
recognition of pathogens for phagocytosis is aided in part by the complement system and 
antibodies, both of which assist in the process of opsonising the pathogen.  Neutrophils, 
macrophages and dendritic cells (DC) are all phagocytic cells. 
Macrophages and DC use phagocytosis as a way of obtaining peptide sequences from the 
pathogen to present to the adaptive immune system with the aim of activating it.  These 
innate cells are considered antigen presenting cells (APC) and alert adaptive immune cells to 
the presence of an infection.  Once an APC has encountered an invading organism it will 
mature.  A monocyte matures in to either an inflammatory DC9 or a macrophage, and a DC in 
to a mature DC.  DC will migrate through tissues and the blood stream until it encounters an 
antigen10.  Once mature the DC will migrate to draining lymphoid organs to present a 
peptide (antigen) in a MHC on their cell surface to an adaptive immune cell.  Macrophages in 
general will stay within the tissue to present antigens to T cells to re-activate them.  MHC 
molecules are specific to individuals, giving a mechanism that the body can identify non-self-
cells as well as a way to present antigens to the immune system11.  
   
  
Introduction 
6 
 
1.2.2 Adaptive Immunity 
Adaptive cells produce a specific, directed attack on infectious agents and are able to 
develop memory so that any re-infection will be recognised and dealt with efficiently.  
Although innate cells such as macrophages and neutrophils are efficient at removing 
microorganisms from the body, there are instances in which these cells just cannot provide 
the response needed to remove the infection.  In cases like this the adaptive immune cells 
will become involved and provide additional mechanisms to remove the threat.   
T and B cells make up the adaptive immune cells.  Unlike innate cells, which carrying several 
different receptors to recognise various pathogens, the adaptive cells emerge into the blood 
carrying only one receptor.  The cells express an antigen receptor with a single specificity.  
This receptor was produced through a process of rearrangement of a variety of different 
gene segments that code for different parts of the receptor.  This process has the potential 
to code for millions of different combinations of the same receptor, giving the adaptive cells 
the ability to recognise different pathogens and a large repertoire of antigens.  Only cells 
that meet an antigen that their receptor recognises with sufficient affinity will start to 
proliferate and gain an effector function.   
The B cells carry a similar receptor to T cells but once activated the (B cell receptor) BcR has 
a very different function.  Activation induces proliferation and differentiation of the B cell 
into plasma cells, which produce high quantities of the soluble form of the BcR, known as an 
antibody.  Also, unlike a T cell, a B cell can sample antigens that have not being processed or 
presented by an APC.  The antibodies made by B cells make up an important part of the 
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humoral immune response which will bind the antigen and act as a neutralising agent or will 
opsonise any pathogen in part with the innate complement system.   
There are different subsets of B cells aside from the plasma cell.  Memory B cells are 
activated cells that are long lived, and upon reencounter of the antigen are very quickly 
reactivated, similar to memory T cells.  There are different B cells depending on which part 
of the secondary lymphoid structure the cell resides; differentiated based on surface 
receptor expression.  CD21 and CD1 are used to detect marginal B cells, while 
Immunoglobulin M (IgM), IgD and CD23 denote follicular B cells.  B-1 cells express IgM to a 
greater extent than IgG and are found predominantly in the peritoneal and pleural cavities12.  
There are also B regulatory cells (BREGS) that are involved in immune regulation
13 via 
mechanisms such as release of immunosuppressive cytokine like TGF-β and IL-1014.   
Within an immune response T cells have a broader function compared to B cells.  T cells can 
be grouped based on the surface expression of either CD8 or CD4, and in general are defined 
by the cytokines they secrete once they have been activated.  Cytokines are small, soluble, 
signalling molecules that can directly affect the function of the cells in the vicinity.   
  
1.3 T Cells 
1.3.1 Thymic T Cell Production 
T cells develop in the thymus, after migrating from the bone marrow as lymphoid 
progenitors.  Once a T cell has migrated to the thymus it undergoes a process of gene 
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segment rearrangement to produce an antigen specific T cell receptor (TcR).  The TcR 
consists of a linked hetro-dimer of αβ (~95% peripheral T cell) or γδ chains.  The hetro-dimer 
will complex with an invariant CD3 complex (made up of a γ, δ, two ε chains and two ζ 
chains).  The TcR’s specific conformation allows it to recognise a specific peptide sequence.  
Within the thymus the cells will undergo a process that will check the proficiency of the TcR 
construction, evaluating if the TcR will recognise self MHC molecules but not recognise self-
peptides (positive and negative selection respectively).  This process is not as binary as 
suggested and there is more of a sliding scale of affinities of the TcR for MHC molecules.  Any 
cells that do not recognise MHC enough or recognise self-peptide too strongly will be 
removed by apoptosis.  This is a tolerance mechanism which the body uses to protect 
against autoimmune disease15. 
Within the thymus thymocytes will express both CD4 and CD816.  However before leaving 
the thymus a T cell will down-regulate expression of one to become either single CD8+, or 
single CD4+ T cell.  After the T cell has undergone these processes it will exit the thymus a 
naïve T cell and circulate between the blood and the secondary lymphoid organs of the 
body.   
 
1.3.2 T Cell Activation and Memory  
A naïve T cell (CD45RA+CCR7+) circulates through the peripheral lymphoid tissues sampling 
antigens:MHC complexes on dendritic cells at the T cell zone17.  The T cell will continue to do 
this until it encounters an antigen that it recognises.  Dendritic cells are thought to initiate 
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most, if not all, of the T cell activation in vivo18,19.  The mature DC will increase MHC 
expression and display the pathogen derived peptides20 (Signal 1), along with co-stimulatory 
molecules (Signal 2)21–23.  The types of inflammatory cytokines (Signal 3) that are released by 
the mature DC depend on the type of pathogen that the DC has encountered.  It is vital for a 
T cell to receive all three signals to effectively differentiate(reviewed in 24).  There is a further 
signal the cells need to enter the site of infection, sometimes called signal 4.  Chemokine 
receptors can be markers of polarized T cell subsets and flexible programs of chemokine 
receptor gene expression can control tissue-specific migration of effector T cells25. Signal 4 is 
the interaction between the chemokines and their respective chemokine receptors on the 
surface of the T cell. Chemokines are secreted by the stromal cells and inflammatory cells at 
the site of an inflammatory reaction.  
CD3 associates with the TcR and CD4 or CD8 within a lipid raft on the surface of a T cell.  This 
association is important for initiation of the signalling cascade involving molecules such as 
mitogen activation protein kinase (MAPK) and phospholipase Cγ (PLCγ).  The activation of 
these signalling molecules induce intracellular Ca2+ release, activation of the protein kinase C 
(PKC) pathway, activation of transcription factors such as AP-1, NFAT, and NFκB.  The 
downstream effects of all of this is changes in gene expression26.   
For effective activation of the T cells co-stimulatory molecules need to associate with their 
respective receptors on APC.  CD2822, ICOS (Inducible co-stimulator)23, LFA-1 (lymphocyte 
function-associated molecule-1) and VLA-4 (very late antigen-4) are all co-stimulatory 
molecules expressed on T cells.  Respective receptors to these co-stimulatory molecules are 
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unregulated on APC due to signalling from PRR.  This is a mechanism to prevent unnecessary 
activation of T cells where there is no ‘danger’ signals.  If the secondary signals are not 
provided alongside TcR activation the cell either undergoes apoptosis or becomes unable to 
respond to subsequent activating signals (anergic)27.  Upon activation cell surface marker 
such as CD69, CD71 and CD40L are up-regulated on the T cell, which are often used as a 
marker for recently activated cells. 
A CD8+ T cell can identify antigen presented on a MHC class I molecule.   MHC I is expressed 
on all nucleated cells of the body.  If an infection occurs antigens are presented on the 
surface of an APC in a MHC:peptide complex and co-stimulator molecules will be up 
regulated.  CD8+ T cells recognize cytosolic proteins from intracellular infections such as 
viruses or tumour antigens.  Being able to identify infected cell allows the CD8+ T cells to 
effectively kill them though apoptosis, CD4+ T cell are unable to directly kill infected cells. 
CD4+ T cells recognize MHC class II molecules and the antigen presented in them.  The 
expression of MHC II is restricted to APC, such as dendritic cells, macrophages and B cells 
which can present both internally and externally sourced antigen.  CD4+ T cells can respond 
to a wide range of pathogens and secrete cytokine to modulate the immune system to guide 
a more specific immune response.   
Once a T cell has been sufficiently activated it will burst in to action by proliferating and 
acquiring a number of effector functions, such as expression of cytokines or cytotoxic ability.  
The cell will switch expression of the lymphocyte common antigen CD45, from the long 
glycosylated isoform CD45RA to the shorter isoform, CD45RO.  CD45 contains an 
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intracellular protein tyrosine phosphatase domain that under rest conditions 
dephosphorylated P56lck , upon TcR engagement CD45 disassociates with P56lck and this 
means it can be phosphorylated and aids effective TcR signalling28.  The shortening of the 
isoform to CD45RO may allow for easier binding the TcR:MHC complex29. 
The combined intracellular signalling cascades that are induced from the TcR engagement, 
co-stimulatory molecules and cytokines are diverse, but all lead to effects on transcriptional 
regulation.  Signal transducer and activator of transcription (STAT) proteins bridge the gap 
between the cytokine receptors at the cell surface and the nucleus. STAT proteins are 
phosphorylated and activated by stimulated cytokine receptors30 at which point they 
translocate to the nucleus.  Once in the nucleus, STAT proteins alongside other transcription 
factors orchestrate the differentiation of T cells24.  Transcription factors are proteins that 
bind to specific genes and alter DNA transcription.  Through suppression and transcription of 
lineage specific genes a phenotype is carved out for the cell.   
Once activated, as well as shortening CD45, the naïve T cell may lose CCR7 expression.  This 
chemokine receptor allows T cells to enter high endothelial vessels and migrate into 
secondary lymphoid tissue.  Thus the expression of CCR7 on memory T cells can be used to 
further divide the CD45R0+ cells based on their broad function as a memory cell.  Central 
memory T cells (TCM) are CD45RO
+ and express CCR7.  TCM cells do not produce much 
effector cytokines, such as IFNγ and Interleukin 4 (IL-4), but produces a lot of IL-2.  Only once 
the TCM cell has experienced antigen again will it start to proliferate and produce effector 
cytokines.  Although TCM cells do not initially produce effector cytokines, they have been 
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shown to be primed to differentiate into specific TH subsets.  CD45RO
+CCR7- effector 
Memory (TEM) T cells have the capacity to express large quantities of effector cytokines.  
These two subsets of cells form our antigenic memory and are vital to provide the quick 
response to a second infection31.  CD8+ T cells can further re-express CD45RA to become 
revertant memory T cells (TEMRA) but are still CCR7
-.  Under resting conditions CD8 TEMRA 
proliferate at a slow rate in response to γ–chain cytokines (e.g.  IL-2, IL-7, IL-15 etc.) and 
maintains CD8+ T cell memory 32.    
 
1.3.3 T Cell Migration to the Site of Infection 
There are many other chemokine receptors, along with CCR7, expressed on T cells that are 
critical mediators of cell migration in immune surveillance and inflammation.  Chemokines 
are able to bind to several different receptors and as most chemokine receptors are able to 
bind to multiple chemokines.  Chemokine receptor signalling results in cell chemotaxis.  
All chemokine receptors are 7-transmembrane proteins coupled to G-protein signalling 
molecule33,34.  They are classified into 4 groups based on the positioning of highly conserved 
cysteine of the amino acid sequence (CXC, CX3C, CC, and C).   Binding of the chemokine leads 
to activation of a cascade of signalling proteins, including G protein coupled receptor kinases 
(GRKs), phospholipase C-β (PLC-β) and phosphatidylinositol 4,5-bisphosphate (PIP2) leading 
to mobilization of calcium and activation of various protein kinase C (PKC).  These signals will 
ultimately lead to actin polarisation, shape changes, and directed cell movement.  Once the 
chemokine receptor has become appropriately activated it will become partially or totally 
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desensitised to repetitive stimulation by chemokines.  In some cases the receptors will 
internalise, a vital mechanism to maintain the ability to detect a chemokine gradient 35. 
Within CD4+ T cells there is differential expression of chemokine receptors on different T 
helper subsets.  For example TH1 cells preferentially express CXCR3 and CCR5, TH2 cells 
express CCR425,36 and TH17 cells express CCR6
37.  Chemokine receptor expression on T helper 
subsets will be covered in more detail later when each T helper subset is individually 
discussed.   
 
1.4 CD8+ T Cells 
CD8+ T cells have cytotoxic components that allow them to efficiently destroy infected cells.  
Recognition of an antigen presented in the MHC will lead to activation, proliferation and 
differentiation of the CD8+ T cell and the production and release of lytic granules.  These 
granules contain perforin and granzyme38; enzymes that will induce controlled cell death 
(apoptosis) in the infected cell.  Also Fas ligand on the CD8+ T cell binds to Fas on the target 
cell to initiate intra-cellular caspase signalling pathways to kill the cell39.  CD8+ T cells also 
release IFNγ, TNF-α and TGF-β which contribute to the defence in several ways.  IFNγ can 
initiate anti-viral responses in infected cells and activate macrophages.  TNF-α and TGF-β 
also aid in the killing of infected cells via their receptors and in the activation of 
macrophages.    
Interestingly, there is also a small but detectible population of CD8+ T cells that secrete the 
inflammatory protein IL-17 (Tc17).  These cells express, alongside IL-17, fewer lytic granules 
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than their IFNγ secreting counterparts40.  There are also dual, IL-17/IFNγ secreting CD8+ T 
cells suggesting a level of plasticity comparable to the CD4+ counterparts.  STAT-3 and other 
TH17 polarising cytokines (IL-6, IL-23, IL-1β
40) are important to the induction of Tc17 cells41.  
Tc17 cells have been shown in vivo to be important part of the immunity in influenza 
challenged mice42 and are found in the murine model of multiple sclerosis, experimental 
autoimmune encephalomyelitis (EAE)40. 
 
1.5 CD4+ T Helper Cell Subsets 
Once the T cell migrates into the site of infection it will be the APC that re-activates the T 
cell.  The cytokines secreted by the APC will drive any changes in T cell differentiation.   
Innate cells produce cytokine tailored to deal with the different infection.  The initial innate 
response leads to the differentiation of a T helper cell which will complement the innate 
response.  For example, in response to intracellular bacteria, such as mycobacteria, this will 
induce IFNγ expression in NK cells and IL-12 expression in macrophages.  These cytokines 
specifically induce a T Helper 1 Cell (TH1) phenotype in an activated T cell.  The production of 
IFNγ by the TH1 cell will further activate and optimise the response of macrophages to 
destroy the bacterial insult.  More details of the induction, differentiation and maintenance 
of the different T helper subsets are given below (Figure 1.1).    
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1.5.1 T Helper 1 Cell  
It was initially thought that there were two differentiation inflammatory paths a CD4+ T cell 
could take in response to a pathogenic insult.  In 1986 Mossman and Coffman described 
these as TH1 and TH2 CD4
+ T cells43.  These cells were identified based on the cytokines they 
produced.  A TH1 cell expresses IFNγ while a TH2 cell secretes IL-4.   
As mentioned above, TH1 cells develop in response to intracellular pathogens such as 
Mycobacterium tuberculosis and Mycobacterium leprae.  In healthy humans when ex-vivo 
PBMC are stimulated with PMA and ionomycin approximately 30% of the memory CD4+ T 
cells secrete IFNγ.  TH1 cells are heavily involved in mounting cellular immunity through the 
release of IFNγ and are crucial for activation of macrophages44 and optimising the CD8+ 
cytotoxic attack.  IFNγ is a type II interferon cytokine originally discovered for its anti-viral 
activities45.  IFNγ exists as a homo-dimer and although is part of a larger family of interferon 
cytokine has little homology with the Type I interferons, IFN-β or the other various IFN-α 
cytokines.  TH1 cells selectively migrate towards the ligands CXCL9, 10 and 11 due to their 
expression of the chemokine receptor CXCR336.   
TH1 cells are induced in an IFNγ and IL-12 rich environment, in both humans
46 and mice.  The 
binding of IFNγ to its receptor (IFNγR), along with TcR stimulation, will lead to 
phosphorylation of Jak proteins associated with the IFNGR, resulting in activation of STAT-1.  
STAT-1 in turn will induce the expression of the TH1 lineage defining T-box transcription 
factor, T-bet.  T-bet was discovered by Laurie Glimcher et al.  by using yeast one-hybrid 
screening, a method of assessing protein-DNA interactions in a simplified model47.  STAT-1-/- 
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and T-bet-/- mice cannot respond to IFNγ and die due to excessive mycobacterial and viral 
infections, highlighting the dependency of TH1 cells on T-bet and STAT-1 signalling
48–51.  
Interestingly CD8+ T cells do not rely on T-bet for their IFNγ production, though NK cells do52.   
T-bet directly induces Ifng gene expression and IFNγ secretion in CD4+ T cells, which acts as a 
feedback mechanism for the TH1 phenotype and is the main functional cytokine produced by 
TH1 cells.  T-bet can induce H2.0-like homeobox protein, a transcription factor from the Hlx 
gene which will also stabilise the TH1 phenotype
53.   
 IL-12 is well documented to enhance TH1 development.  IFNγ activation of T-bet up-
regulates IL-12Rβ2 expression54 which is not expressed on naïve CD4+ T cells55,56.  Binding of 
IL-12 to its receptor activates STAT-4 which reinforces T-bet expression and therefore the 
TH1  phenotype.  
TH1 cells have long been associated with autoimmunity, though the discovery of TH17 cells 
(covered in Section 1.5.3) has led to the idea that they may not be as important as initially 
thought57.   
 
1.5.2 T Helper 2 Cell (TH2)  
TH2 cells provide humoral immunity against protozoa infections such as Leishmania major
58 
and intestinal nematodes.  Cytokines released by TH2 cells favour the production and 
activation of mast cells and eosinophils.  The cytokines also stimulate B cell growth, 
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differentiation, and isotype switching to IgE and IgG59.  TH2 cells express CCR3 and CCR4, 
giving them the ability to migrate towards chemokines including RANTES (CCL5) and CCL11. 
GATA-3 is the transcription factor that is necessary for a TH2 phenotype.  Discovered in 1997, 
GATA-3 was shown to be expressed in naïve T cells, with decreased expression in TH1 
committed cells and transgenic expression of GATA-3 induces a TH2 cytokine profile.  Flavell 
et al.  showed that GATA-3 controlled IL-4 expression by using an IL-4 promoter luciferase 
reporter gene60 and later others showed GATA-3 directly activates IL-5 and IL-13 promoter 
regions as well61. 
There are two pathways able to induce a TH2 phenotype.  Firstly IL-4 is a cytokine that can 
activate STAT-6 which leads to GATA-3 activation62.  The second induction pathway for TH2 
lineage commitment is via an IL-4 independent pathway.  This can occur in the absence of 
STAT-6, through the Notch signalling system and can induce GATA-3, although at a reduced 
level63.  IL-2  signalling via STAT-5 is an important factor in TH2 induction by allowing the IL-4 
gene to be more stably expressed64.  Ikaros is another transcription factor which although 
has other roles in lymphocyte development acts to promote TH2 lineage and repress TH1 
factors such as T-bet65.   
Germ line deletion of GATA-3 results in embryonic lethality, demonstrating GATA-3 non-
redundant role in foetal development.  The only viable way to remove GATA-3 transcription 
is to selectively knock-out the gene in the cell of interest.  T cell-specific GATA-3-/- mice, 
produced by inserting a Cre-loxP system between exon 4 and 5 of GATA-3 gene of the mouse 
and crossing it with a Cre-CD4 transgenic mouse, cannot polarise to a TH2 phenotype and 
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even in TH2 polarising conditions produce IFNγ.  IL-5 and IL-13 production is abolished in the 
GATA-3-/-, however IL-4 is not66.  This might suggest that the default phenotype of a CD4+ T 
cells is that of a TH1 cell.   
Upon publishing their discovery Coffman and Mossman expressed the opinion that there 
were probably other phenotypes of a CD4+ T cell that were undiscovered43.  We now know 
that there are several other subsets based on cytokine production and transcription factor 
expression.  The TH17 cell is defined by secreting IL-17A and expressing the transcription 
factor RORC in humans.   Several other lineage such as TH22, T follicular helper cells, TH9 and 
regulatory cells (TREG) also exist and further research is on-going to understanding these 
cells.   
 
1.5.3 T Helper 17 Cell (TH17) 
Since the discovery of TH17 cells there has been a scramble to understand these cells 
because of their presence and potential role in many autoimmune diseases.  TH17 cells were 
discovered, not by looking for IL-17 expressing TH cells, but after researching a murine model 
of the autoimmune disease multiple sclerosis (MS); experimental autoimmune 
encephalomyelitis (EAE). The model was thought to be controlled by an IFNγ dominated TH1 
response, induced by IL-12.  Contrary to this initial hypothesis mice that lacked IFNγ were 
not only still susceptible to EAE, but their morbidity was significantly poorer and more mice 
died67. 
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IL-12 is a heterodimer protein composed of a p35 and a p40 subunit.  IL-12 was found to 
have a common p40 subunit with the cytokine IL-23 (Figure 1.2) 68,69, a cytokine shown to 
play a role in IL-17 production by T cells.  A comparison of EAE induction in mice genetically 
engineered to not express p35 or p40 identified that IL-12 was redundant in the induction of 
EAE as p35-/- mice were still susceptible to EAE70.  Mice with a p40-/- were resistant to the 
induction of EAE  identifying IL-23 as the critical factor 57,71.  After initial experiments it was 
thought IL-23 was an inducer of IL-17 expression, due to the association of IL-23 and TH17 
cells in EAE.  Contrary to this the IL-23R is not expressed on naïve T cells.  This demonstrates 
that although IL-23 plays a role in TH17 cells maintenance it is not involved in the initial 
induction of the TH17 cell phenotype
72,73. 
 
1.5.3.1 IL-17 Cytokine 
IL-17 was first cloned in 1993 and it was discovered to have 6 different isoforms (IL-17A-F)74.  
The two isoforms produced by CD4+ T cells are IL-17A and IL-17F as well as a heterodimer of 
the two (IL-17A-IL-17F)75.  TH17 cells always express IL-17A and co-secrete IL-17F in about 
20% of the cells. 
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Figure 1.1: CD4+ T Helper Cell Differentiation and Plasticity. APC present 
antigen and activate naïve CD4+ T cells which leads to their differentiation 
down one of several different TH phenotypes. It is the cytokine within the 
immediate environment that is the driving force behind which phenotype 
the T cell acquires. The TH phenotype is defined by the cytokines expressed 
by the cells (key cytokine highlighted within the cell) and the lineage 
defining transcription factor. Until recently these were thought to be a 
stable phenotype.  However, there has been evidence of TH cells expressing 
two different lineage defining cytokine, and the associated transcription 
factors.  Significant work has been done to understand if these changes in 
phenotype are transient or permanent. IFNγ+TH1 cells have been found to 
express RORC, the TH17 transcription factor.  It is unknown if these cells are 
ex-TH17 cells or TH1 cells gaining TH17 functions. Dotted arrows show the 
direction in which plasticity is through to occur.   
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IL-17A and IL-17F and their heterodimer bind on T cells through a heteromeric receptor 
complex of IL-17RA and IL-17RC.  These trans-membrane protein receptors are expressed by 
a variety of human cells including epithelial cells, fibroblasts.  IL-17RA can be bound by IL-
17A and IL-17F, but with 10-fold more afﬁnity for IL-17A.  Although these two isoforms of IL-
17 bind to the same receptor they have different biological effects76.  Only IL-17A-/- mice are 
susceptible to C.albicans infections even though the mice have normal levels of IL-17F 77.  
Only IL-17A is capable of inducing cytokine production by macrophages while both IL-17A 
and IL-17F can both activate epithelial innate immune responses78.  This suggests that 
although similar, IL-17A has a non-redundant role in immunity that IL-17F cannot replicate.    
IL-17A acts on ﬁbroblasts, endothelial cells, macrophages, epithelial cells and astrocytes.  
This cytokine induces anti-microbial peptides and neutrophil activating peptides79.  IL-17A is 
also produced by a variety of innate cells such as NKT cells, macrophages and lymphoid 
tissue-inducer cell (LTi).   
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Figure 1.2: IL-23R and IL-12R structure and signalling. IL-23 is a 
heterodimer cytokine composed of p40 and p19 subunits. The p40 
subunit is also shared with IL-12 and is paired with p35. The two 
receptors have a common IL-12Rβ1 subunit. The IL-12Rβ1 is paired 
with IL-12Rβ2 to make a functional IL-12R. The activated Jak2 
phosphorylates STAT-4 allowing it to translocate to the nucleus 
where it aids in the transcription of genes associated with TH1 
phenotype. When IL-23 binds to its receptor, the Jak2 phosphorylates 
STAT-3 which translocate to the nucleus where it aids in the 
transcription of genes associated with TH17 phenotype.    
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Although IL-17 has been labelled a ‘pathogenic’ cytokine due to its presence in many 
autoimmune diseases it plays a vital role in protecting the body against fungal and bacterial 
infections.  Its actions are mainly through the recruitment and activation of neutrophils.  The 
production of IL-17 by CD4+ T cells in response to an infectious agent was first discovered in 
response to Borrelia burgdorferi, identifying IL-6 as a possible factor for the induction of this 
effector cytokine80.  The need for IL-17 dependent induction of chemokines in the lung, 
responsible for neutrophil recruitment, was demonstrated using a murine model of 
Klebsiella pneumoniae lung infection.  Human IL-17 also induces the expression of GM-CSF in 
cells such as fibroblasts, which promotes neutrophil maturation from CD34+ hematopoietic 
progenitor in the bone marrow81.  Adequate numbers of neutrophils are required for 
protection against fungal infections82.  This is why TH17 and the cytokine IL-17A play an 
important role , through neutrophil recruitment, in the removal of fungal infections, such as 
Candida albicans, from the body83.   
The lineage defining transcription factor for TH17 cells is the steroid orphan nuclear receptor, 
RAR-related orphan receptor C (RORC)84.  A slice variant of RORC, RORγt, is expressed in 
mice.  RORC has been shown to directly bind to an il17 gene promoter and also control the 
expression of CD161 85, IL-23R and IL-1R, although it is not known if this is through direct 
effects on the genes.  RORα is another variation of the orphan nuclear receptor and has 
been shown to be expressed in TH17 cells.  RORα can enhance IL-17 production but has been 
shown not to be necessary for TH17 induction
86.  Aryl hydrocarbon receptor (Ahr) is a 
transcription factor associated with IL-22 production in TH17 cells
87.   
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The TH17 transcription factor RORγt is also expressed in immature CD4
+/CD8+ T cells in the 
thymus and promotes thymocyte survival88.  Lymphoid tissue inducer (LTi) cells are involved 
in the formation of secondary lymphoid organs and during lymph node and Peyes patch 
development it is vital for LTi cells to express RORγt 89.   
 
1.5.3.2 Induction of TH17 Cell Phenotype 
A substantial amount of work has been done to identify the factors that induce TH17 cells.  
Very early on it was noted that the TH1 programme, and IFNγ, acted as a potent inhibitor of 
the TH17 differentiation programme, instead of it being a shared developmental pathway
90.  
At this point it is important to distinguish the difference in mice and human TH17 cells 
differentiation.  Although this study considers human TH17 differentiation, a lot of the work 
done in this area is in murine models of disease and TH differentiation so it is important to 
understand the workings of both systems.   
Murine naïve cells require a combination of inflammatory cytokines to induce a TH17 
phenotype.  Transforming growth factor (TGF)-β is key for the induction of TH17 in mice 
along with IL-691,92.  IL-6 up-regulates IL-23R and IL-21 production.  IL-21 is involved in a 
feedback loop which also itself up-regulates IL-23R93.  This responsiveness is dependent on 
RORγt expression.  The sensitivity of these cells to IL-23 is important for the survival and 
maintenance of a TH17 phenotype
73.   IL-1 and TNF-α are also important co-factors for the 
induction of a TH17 phenotype
94.   
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In mice it has been suggested that the cytokines required for effective TH17 differentiation is 
dependent on the anatomical location that the T cells are activated in.  IL-1β was shown to 
be vital at all sites of the body, whereas IL-6 was needed for skin and mucosal TH17 priming 
but not needed in the spleen95.  Whether this finding of difference in induction at different 
anatomical locations translates to the human system is unknown. 
TGF-β plays a role not just in the induction of TH17 cells in mice but also TREG.  In the 
presence of pro-inflammatory cytokines, such as IL-6 and IL-21, TGF-β at low concentrations 
induces RORC and TH17 phenotype
92.  At high concentrations TGF-β has an antagonistic 
relationship and favours the induction of FoxP3 and a regulatory phenotype96.  TGF-β in mice 
does not directly promote TH17 phenotype or RORγt.  TGF-β in this setting suppresses STAT-
4 and GATA-3, preventing competition from the TH1 and TH2 lineage.  In STAT-6
-/-, T-bet-/- 
mice only required IL-6 to differentiate naïve CD4+ T cells to express IL-17 and RORγt97.    
Human TH17 cell differentiation appears to be more elusive, especially when compared to 
the relatively easy differentiation of murine naïve cells to a TH17 phenotype.  IL-6, which 
signals through STAT-3, and IL-1β are strong inducers of IL-17 expression in naive T cells and 
are important for the initial expression of RORC in human T cells98.  TGF-β and IL-21 were 
suggested to convert peripheral naïve cells into TH17 cells.  The effects of TGF-β on naïve T 
cells in culture were hotly debated as conflicting papers were published98,99.  It was decided 
that the effect of TGF-β is a balancing act between the inductions of TREG or TH17 phenotype.  
Low concentrations of TGF-β and other inflammatory cytokines can induce TH17 cells.  
Conversely, high levels of TGF-β will induce FoxP3 and a suppressive phenotype99, similar to 
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mice.  Large doses of IL-2 can suppress the induction of IL-17 in naive T cells98.  IL-23 
maintains the human memory TH17 phenotype, signalling through STAT-3.  Hyper IgE 
syndrome, in which there is a genetic defect in STAT-3, results in the absence of TH17 cells 
and recurrent fungal infections100.  STAT-3 directly binds to the IL-17 promoter and can 
induce IL-23R expression.    
The level of TcR activation by either anti-CD3/anti-CD28 beads or antigen pulsed DC changes 
the number of IL-17 secreting cells in CD4+ T cells.  After culture with TH17 polarising 
cytokines low TcR activation of T cells favoured TH17 cell induction.  High TcR activation led 
to the induction of FoxP3 expression and β–latency-associated peptide (LAP) expression.  
Nuclear translocation of nuclear factor of activated T cells (NFATc1) is induced with both low 
and high TcR activation.  However, it will only bind to the IL-17 promoter with low TcR 
activation101.  Furthermore, in vivo activated monocytes from inflamed joints of RA 
patients102 or TLR activated DC98, but not monocyte derived DC were potent TH17 polarising 
cells.  Naïve cells expressing IL-1R are more susceptible to conversion to TH17 phenotype, 
due to their responsiveness to IL-1103.   
There have been some remarkable papers identifying cells that are more susceptible at 
acquiring a TH17 phenotype.  In umbilical cord blood and in the thymus a small percentage of 
naïve T cells, identified by the surface expression of CD161 (NKR-P1A), can convert to IL-17 
producing cells in response to IL-1β and IL-23.  The CD161+ population in peripheral blood 
was enriched for IL-17A, IL-23R, CCR6 and RORC gene expression compared to the CD161-
Introduction 
27 
 
CD4+ population.  Lenti-viral transduction of RORC in CD161-CD4+ cells from UCB induced 
CD161 expression as well as IL-23R, CCR6 and IL-17 expression8.   
Leading on from the idea that there are pre-committed TH17 cells, naturally occurring TH17 
(nTH17) cells have been discovered.  In mice nTH17 cells acquire effector function in the 
thymus before they have encountered peripheral antigen.  Their development is 
independent of STAT3 and IL-6, though still partially dependent on IL-23, and nTH17 still 
expresses the lineage defining transcription factor RORγt.  It is unclear whether these nTH17 
cells are as plastic as inducible TH17 cells and if nTH17 can convert to TREG phenotype like its 
peripheral counterpart.   
 
1.5.3.3 Molecular Signatures of TH17 cells 
In humans by definition an IL-17 secreting cell that expresses the transcription factor RORC is 
a TH17 cell.  However, due to the need to isolate viable cells and the emergence of plasticity 
in TH differentiation the expression of these two molecules may not be enough to identify 
TH17 cells.  A surface marker that can define a discrete population of TH17 cells or cells with 
TH17 phenotypes is necessary, although unfortunately not identified yet.   
As mentioned in the section above, IL-23 plays an important role in the maintenance of TH17 
cells.  RORC can induce the expression of IL-23R in a positive feed-back loop.  IL-23R is 
significantly up-regulated on TH17 cells.  Using an antibody to stain for IL-23R is rarely used in 
the literature and regularly people use an up-regulation of IL-23R at gene expression level as 
a sign of TH17 differentiation.    
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IL4I1 is the gene for a secreted phenylalanine oxidase that is expressed in TH17 cells but 
thought not to be expressed by TH1 cells.  This protein is associated with reduced expression 
of parts of the TcR CD3 chains.  This effectively leads to reduced activation of the IL-2 
promoter and reduced proliferation of TH17 cells compared to other TH subsets
104.  IL4I1 
expression is identified through increased relative expression via qRT-PCR in the 
literature105.  This molecule can also be secreted by DC to affect T cells directly106.   
As outlined above there are cells found in the thymus and naïve cord blood that are CD161+ 
and are already RORC positive8.  In humans CD161+ cells are highly enriched with IL-17 
secreting cells, though not all IL-17+ cells express CD161.  Curiously, adding to the argument 
that human TH17 cells are different to murine TH17 cells, murine TH17 cells do not express 
the equivalent receptor (NK1.1) on IL-17 producing cells.  A member of the C-type lectin 
superfamily, whose ligand is LLT-1, CD161 is not exclusively expressed on CD4+ T cells.  NK 
cells express CD161, and binding of LLT-1 to this receptor leads to inhibition of NK cell 
mediated cytotoxicity.  Engagement of CD161 can inhibit TNF-α production by TCR activated 
CD8 T cells.  TC17 are CD8
+ T cells that express IL-17 and are contained within the CD161++ 
population107.  CD161 expression on B cells and DC is thought to be involved in NK cell-APC 
interactions108.   The functional consequences of CD161 binding to its ligand in T cells is not 
known8, though CD161 expression might have something to do with migration of these cells 
through the endothelium109, increased IFNγ production and possibly a role in co-stimulation 
of T cells7.   
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The chemokine receptor CCR6 is strongly associated with TH17 cells
1,37.  All IL-17 secreting 
cells express CCR6, though not all CCR6 expressing cells make IL-17.  Other chemokine 
receptors are more promiscuous, binding to several different chemokines, whereas CCR6+ 
cells, as far as we know, only migrate towards one chemokine - CCL20 (MIP1α)110.  In 
humans CCR6 has been used to identify cells that have characteristic of TH17 cells in other 
populations.  Within peripheral blood there are CCR6+TREG cells that are RORC
+FoxP3+ and 
express IL-17 but have suppressive potential111.  It is not known if these cells express CD161 
as well.  CCR6 is expressed on B cells and is important for B cell differentiation and 
maturation86,89. 
 
1.5.4 T Helper 22 Cell (TH22) 
Initial studies identified IL-22 as a TH17 associated cytokine
113.  However, CD4+ T cells have 
now been identified that only secrete IL-22 without it being co-secreted with IL-17A or IFNγ.  
IL-22 had potent effects on keratinocytes, hepatocytes and other mucosal sites but is mainly 
associated with immunity and disease in the skin.  TH22 cells express homing markers such as 
CCR10, CCR6 and CCR4114.  IL-22 in the skin can induce production of antimicrobial peptides, 
and can induce anti-apoptotic and pro-proliferative effects in responding cells115,116.  A 
transcriptome analysis of TH22 compared to TH1 and TH17 cells to determine if they were a 
separate lineage identified several genes that were unique to TH22 cells.  Many of these 
unique genes encoded proteins involved in tissue remodelling, such as FGF’s, and 
chemokines involved in fibrosis and angiogenesis, such as CCL7 and CCL15116 .  
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From naïve T cells TGF-β and IL-6 will drive a TH22 phenotype and the induction of the ligand 
activated transcription factor, Ahr, which drives the expression of IL-22114.  IL-23 seems to be 
responsible for amplification of IL-22 but cannot restore IL-22 induction in Ahr deficient TH17 
cells.  There are subsets of NK cells that express IL-22(Nk-22) and also express Ahr117.   
 
1.5.5 T Follicular Helper cell (TFH) 
Within the lymphoid tissue there is a subset of antigen experienced T cells that play a role in 
aiding B cell activation.  They express CXCR5 and are known as T follicular helper cells 
(TFH)
118.  CXCR5 is the chemokine receptor for CXCL13 which is highly expressed in the B cell 
zones of secondary lymphoid structures and attracts B cells as well as TFH cells.  These cells 
aid in the formation and maintenance of germinal centres (regions of secondary lymphoid 
tissue that help B cell immunity).  The expression of IL-21, ICOS and CD40L by TFH is 
important in this process and in aiding isotype switching in B cells.  Bcl6 is a transcriptional 
repressor associated with TFH cells but considered the master regulator of the subset.  It 
represses the lineage defining transcription of other subsets such as T-bet and GATA-3.  An 
interesting aspect of TFH is that these cells can also express characteristic of other TH cells 
types such as signature cytokines of TH1 or TH2 and TH17 cells.   
 
1.5.6 Regulatory T cells (TREG) 
Regulatory T cells are a vital subset of CD4+ T cells that induce both tolerance to self and 
control otherwise pathogenic immunity.  The main function of TREG is to use an arsenal of 
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mechanisms to suppress the immune response.  They make up 5-10% of the CD4+ T cell 
population and can be produced in the thymus (nTREG) or induced in the periphery (iTREG).  
They are primarily characterised by the expression of a gene known as Forkhead Box P3 
(FoxP3)119 and the IL-2 receptor α chain (CD25)120.   Similar to other T cells, they have a TcR 
specific for a cognate antigen; although the antigen is frequently a self-peptide.  The 
importance of the transcription factor FoxP3 within the TREG is demonstrated in the genetic 
disease immunedysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX), in 
which the sufferers lack functional FoxP3121.  The phenotype of this disorder is a severe and 
extensive auto-immune disease.    
TREG cells employ a variety of different mechanisms to suppress T effector cell activation and 
proliferation.  TREG secrete the anti-inflammatory cytokines IL-10, IL-35 and TGF-β.  TREG can 
release protease enzymes such as granzyme and perforin that leads to destruction of 
effector cells.  TREG can also cause metabolic disturbances such as cytokine depletion by the 
high affinity receptor CD25, adenosine generation via CD73 and CD39 receptors and cAMP 
mediated inhibition of proliferation.  Finally, TREG can target dendritic cells function through 
CTLA-4 binding and removal, via trans-endocytosis, of CD80/86122 from the surface of the 
cell.  This affects  maturation of effector cells and reduces their proliferative ability123.   
Naturally occurring regulatory T cells (nTREG) are differentiated within the thymic medullary 
region in a MHC class II dependent process124.  The self-reactive TcR that TREG frequently 
carry is activated and causes expression of FoxP3.  A murine model using a transgenic TcR 
specific for a self-peptide generated large numbers of TREG while mice that did not express 
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the antigen could not produce any.  There are clearly other signals that control TREG 
differentiation as not every cell that expressed the transgenic TcR became a TREG
125.   
iTREG are induced in the periphery, with early evidence of adoptive transfer experiments 
showing conversion of naïve cells to a TREG phenotype.  Naïve CD4
+CD25- T cells injected into 
lymphopenic mice increase in number and a small proportion gain TREG cell markers such as 
CD25, CTLA-4 and FoxP3 expression.  iTREG development has been defined as dependent on 
antigen stimulation, IL-2 and TGF-β in vitro126,127.  However the in vivo environment for iTREG 
induction has not been completely defined.  TGF-β relies on SMAD3 and the nuclear factor of 
activated T-cells (NFAT) to induce FoxP3, while the IL-2 lifts the TGF-β anti-proliferative 
effect.  TGF-β has been shown to be less important to nTREG development.  IL-2 in addition 
does not play a vital role in nTREG development and is dispensable, and can be replaced by IL-
15 in IL-2-/- mice.   
Additional suppressive populations are the TR1 and TH3 cells.  TR1 cells express IL-10 and TGF-
β, which they employ as their main mechanism of suppression, although they do not express 
stable FoxP3.  They are induced from naïve T cells in an IL-10 rich environment128.  TH3 
produce TGF-β and play an important role in mucosal immunity and tolerance to antigens 
within the gut.  Although there are no specific markers for TH3 to allow for analysis of these 
cells, it is thought they are induced in a TGF-β rich gut environment129.   
There are many cytokines that can antagonise iTREG induction.  Cytokines from other T helper 
subsets (IFN-γ, IL-4, IL-17 etc.) can all inhibit induction.  However a small subset of CD103+ 
Introduction 
33 
 
DC found in the small intestine and mesenteric lymph nodes can overcome this inhibition, 
with the co-production of TGF-β with retinoic acid130,131.   
There are arguments about the functional differences of nTREG and iTREG.  The iTREG seem to 
be able to suppress T effector cells as well as nTREG.  However on re-stimulation in a TGF-β 
depleted environment the iTREG loose FoxP3 expression whereas the nTREG do not.  This 
suggests differences in the epigenetics and stability of iTREG phenotype
132,133.  Overall 
however, it is generally accepted that nTREG play a role in general tolerance and protection 
against autoimmune disease, while iTREG are important in mucosal tolerance including the 
gut. 
 
1.6 Maintenance of T Helper Lineages  
There are several levels at which a cell’s phenotype can be controlled.  TH phenotype is 
induced by the cytokines and the type of stimulation that a cell receives upon activation.  
Additionally, there are internal pathways and transcriptional mechanisms in place to either 
maintain or alter the cells effector function once it has differentiated.   
TH1 and TH17 have several feedback mechanisms that allow maintenance of their phenotype.  
TH1 induced by IFNγ and IL-12 produce IFNγ themselves, which acts in a feed forward 
amplification loop with STAT-1 and T-bet.  T-bet up-regulates IL-12Rβ2, making the cells 
more responsive to environmental IL-1254.  TH17 cells are induced through cytokines that 
signal through STAT-3, which induces RORC.  RORC can activate the cell to express IL-23R 
and produce IL-21.  Both IL-21 (autocrine)93 and IL-23 (environmental)72 maintain the TH17 
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phenotype and RORC expression.  IL-2 can actually promote TH1 and TH2 phenotypes and 
suppress TH17, its signalling through STAT-5 leading to alterations in important gene 
expressions such as IL-4 receptor α and IL-12Rβ2 and suppression of IL-6 receptor134. 
To further maintain a phenotype cells also have transcriptional mechanisms to suppress 
other TH phenotypes.  TH1 and TH17 can repress the phenotype of the other TH cell.  IFNγ has 
been shown to suppress a TH17 phenotype while IL-17 and RORC can suppress T-bet and a 
TH1 phenotype
90.  Jenner et.  al.  showed that T-bet and GATA-3 can occupy many of the 
same gene targets.  The group identified GATA-3 binding to target genes within TH1 cells.  
For example, in a TH1 cell, T-bet could bind to IFNG and activate the gene while binding to 
the IL4 gene and directly repressing its expression.  GATA-3 could act to oppose that by 
activation of the IL4 gene and repressing IFNG gene135.  GATA-3 has been shown to suppress 
IL-12Rβ2 expression to weaken T-bet expression56.  As well as the lineage defining 
transcription factors (T-bet, GATA-3, RORC etc.) there are other transcription factors and 
mediators that are induced to aid in the suppression of other phenotype.  Runx3 is activated 
by T-bet to suppress the IL4 gene and contribute to the stability of the TH1 lineage
136.  Runx1 
is needed for the transactivation of RORγt and if T-bet is present it will bind Runx1 and 
suppress RORγt expression137.   
 
1.7 Plasticity of T Helper Lineage 
Maintenance of an appropriate immune response is vital to ensure that the pathogen is 
effectively removed.  Until recently differentiated TH cells were thought to be permanently 
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committed to a single lineage.  However, there is now increasing evidence that CD4+ TH cells 
can be plastic in nature.  Appropriate stimulation can switch a memory CD4+ T cell’s 
phenotype to a different TH lineage.  There are examples in the literature of different lineage 
defining cytokines being co-expressed in a single cell, both in vitro and in vivo.  Lineage 
defining transcription factors can also be found to be co-expressed in certain situations138 
(Figure 1.1). 
 
1.7.1 Populations of TH Cells that Exhibit Plasticity 
TREG have been shown to be a particularly plastic population as mentioned in Section 1.5.3.2.  
There is a strong link in mice between the induction of TREG and TH17 cells.  TGF-β at high 
concentrations induces FoxP3, yet TGF-β with other inflammatory cytokines such as IL-6 
induces a TH17 phenotype.  This is confirmed by TGF-β
-/- mice being unable to develop either 
TREG or TH17.   This suggests a link in the differentiation of these two very different effector 
subsets58,96.   
FoxP3 can inhibit RORγt activity by direct binding.  Despite this there is evidence that cells 
can co-express these lineage defining transcription factors with both having an effect on the 
phenotype of the cell.  Voo et. al identified CCR6+ cells that expressed RORγt and FoxP3.  
They maintained their suppressive ability but upon stimulation produced IL-17111.  Using a 
ROR-GFP knock-in mouse Zhou et al.  showed that a small proportion of cultured cells 
treated with TGF-β could express both transcription factors RORγt and FoxP3.  These co-
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expressing cells are also found in vivo.  A small percentage of cells that expressed FoxP3 had 
differentiated into IL-17 expressing cells, suggesting a lineage change139.   
TREG can express characteristics of other pro-inflammatory subsets.  Koch et al.  proposed 
that CXCR3, a chemokine receptor expressed on TH1 cells, can be a marker in TREG of T-bet 
expression.  FoxP3+CXCR3+ cells were shown, in mice, to play a role in controlling infection in 
a TH1 immune response.  The T-bet
+ TREG cells still possess regulatory phenotypic markers 
and suppressive capabilities.  The expression of T-bet appears to improve the homeostatic 
capacity of the TREG in TH1 environmental conditions
140.   
Conversely, there appears to be situations where TH1 cells can produce IL-10, a regulatory 
cytokine normally attributed to a TREG cell.  In a murine model of T.gondii infection IL-10 
producing CD4+ T cells could co-produce IFNγ and expressed T-bet.   IL-10+IFNγ+ cells can 
suppress T.  gondii growth with high levels of nitric oxide produced by APC (induced by IFNγ), 
but suppress IL-12 production in APC (through IL-10 suppression).  These cells were FoxP3-
CD25- and could proliferate, suggesting they did not have a TREG/TR1 phenotype or 
background 141. 
TH2/TH17 cells have also been detected at both a very low level in healthy controls, and at 
higher proportion in patients with asthma.  High levels of TH2/TH17 cells in asthma patients 
makes sense as the TH2/TH17 cells have been shown to have a greater ability to induce IgE, 
which is involved in the pathology of this disease.  TH17 clones which were stimulated in a 
TH2 polarising environment were induced to become TH2/TH17 cells.  TH2 cells could not 
become IL-17 producing under TH17 stimulating environment.   
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Unexpectedly, during an infection of the TH1 promoting- lymphocytic choriomeningitis virus 
(LCMV) TH2 cells in mice can be reprogrammed to express both GATA-3 and T-bet along with 
IL-4 and IFNγ.  Without this switch, brought on by IL-12 and interferon’s, the mice 
succumbed to fatal immunopathology142.   
TH17 cells that co-express IFNγ are easily detected in the peripheral blood of healthy 
controls.  Surprisingly both TH17 and TH17/TH1 clones have been shown to express both 
RORC and T-bet at mRNA level.  When TH17 clones were re-stimulated in the presence of IL-
12 it induced IFNγ production.  IL-23, IL-12 or IL-2 could not induce TH1 clones to produce or 
up-regulate IL-17, at mRNA or protein level.  This suggests again more plasticity in the TH17 
lineage than the TH1.  TH17/TH1 cells express the same phenotypic markers as TH17 such as 
CCR6, and IL-23R.  Interestingly, TH17 cells isolated and cultured ex vivo with IL-12 could not 
switch on IFNγ production143.  Only when IL-12R was up-regulated did these cells convert144.  
This suggests that memory cell’s ability to respond to cytokines is a vital factor in their 
phenotype stability.   
From many diseases it has been the suggested that the plasticity of TH17 may play a role in 
the pathogenesis of the disease.  CD161+IFNγ+IL-17+ cells were found in the synovial fluid 
(SF) of juvenile idiopathic arthritis (JIA) patients, and the number of these cells correlated 
with disease activity 145.  These TH1/TH17 cells were also present in the gut of people with 
Crohn’s disease1.    
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Within the literature there is a debate as to whether cells with a dual phenotype have 
transiently been able to acquire the additional features or if they are being directed down a 
permanent path. 
Experiments using reporter mice gives scientist the ability to follow a single cells  through its 
differentiation path146.   An IL-17-YFP reporter mouse was used to determine the fate of 
TH17 cells in two inflammatory situations, a chronic EAE model and an acute cutaneous 
infection of Candida albicans.  In cells that express or have expressed IL-17A, these cells 
would appear YFP+.  Interestingly, there was a switch of some of the TH17 cells (YFP
+) in EAE 
to secrete IFNγ, while the resolving Candida infection only resulted in IL-17 for a short time, 
with no IFNγ production from these cells.  The interesting thing about the TH1 cells within 
the spinal cord in the EAE model was that they were almost all YFP+IFNγ+ but were IL-17-.  
This suggests in a highly inflammatory situation TH17 cells can convert to TH1 cells.  They 
suggest that the switch to secreting IFNγ in TH17 cells was down to their responsiveness to 
IL-23146.   
In humans TH1 cells with phenotypic feature of a TH17 cell have been described as 
CD161+IFNγ+ cells.  Francesco Annunziato’s group suggests that the non-classical TH1 cells 
are TH17 derived, as they share expression of RORC, IL-23R, IL4I1 along-side T-bet and IL-
12Rβ2.  These cells however are no longer secreting IL-17.  The non-classical cells were 
found to be present in the SF of JIA patients105.   
Using humans CD4+ T cells Sallusto et. al investigated the type of TH17 response that results 
from exposure to C.albicans and Staphylococcus aureus.  Monocytes were pulsed with either 
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of these pathogens and cultured with naïve CD4+ T cells.  The resulting IL-17 secreting cells 
differed.  In response to C. albicans TH17 cells secreted IFNγ, whereas S. aureus induced a IL-
10 secreting TH17 cell.
147 This result suggests that different inflammatory situations will illicit 
different profiles in TH17 cells.  Although this experiment demonstrates the possibility to 
express more than one lineage defining cytokine at once it does not answer whether TH cells 
are plastic or just transiently up regulate other cytokines.    
Within human systems it is always going to be extremely hard to find out the true fate of a 
cell.  The only method of assessing the phenotype is to extract the cell and manipulate them 
ex vivo.  This is not ideal, especially for TH17 cells as we are still unsure as to the true 
differentiation pathway in vivo.  The best approach is to make sure that the population is as 
homogeneous as possible.  Purity of the population has to be assured by vigorous cell sorting 
to avoid potential contaminants147,148. 
All the examples of cells co-secreting two lineage defining cytokines or transcription factors 
goes against the paradigm of repression of the different lineage.  This demonstrates that 
there is a certain level of flexibility in the differentiation process.  Whether this is flexibility in 
the initial differentiation or once the cell has already differentiated is still unknown.  The 
next step is to understand when and where these cells come into play.  Are they in transition 
or are they a stable phenotype? Han et al. recently tested if poly-functional T cells were a 
true reflection of an immune response over time.  They added one cell to a nano-well and 
sampled the supernatant for IFNγ, TNF-α and IL-2 every hour after stimulation.  They showed 
that cells only transiently secreted two cytokines.  This was the intermediate stages between 
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switching off one cytokine and switching on another.  The delayed response of some cells to 
the stimulus meant that the production of cytokine overall was poly-functional but individual 
cells were rarely a true dual secretor149.  However, as the murine fate mapping model146 
showed plasticity of a TH phenotype might be different in a situation of chronic 
inflammation.   
 
1.7.2 Control of Plasticity in CD4+ T Cells 
There is no sufficient evidence to show that the expression of lineage-specific transcription 
factors does not have exclusive expression patterns to the different lineage.  There is a scale 
of transcription factor expression rather than the binary on/off expression that was initially 
proposed.   
It is important to understand what induces the transcription factors and repressors and the 
effects these molecules have on the cells.  Therefore, although we look at transcription 
factor expression it might also be important to look at other factors such as the relative level 
of transcription factor expression, epigenetics such as methylation of genes and post 
transcriptional modifications like miRNAs.  This will help understand to what extent the 
transcription factors are controlling the cell’s phenotype. 
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1.7.3 Why it is Important to Understand Plasticity? 
Within many autoimmune diseases, such as arthritis, MS and Graves disease, CD4+ T cells are 
considered key in the pathogenesis of the disease.  Initial understanding which CD4+ T cells 
cause the disease is important.  Understanding the plastic element of these cells will give the 
potential to ‘reset the clock’ on some of the disease causing subsets.  So, for example, if TH17 
cells are vital to the onset of MS then understanding the factors that leads to these cells 
becoming TREG can lead to therapeutic potential
150. 
On the flip side there are therapies coming to trial now that use cells from the patient’s own 
blood to treat diseases like cancer.  If we do not understand the factors that will switch 
these cells to other subsets, then the beneficial TREG that could be inserted to treat the 
cancer could differentiate into harmful TH1.  This could cause more damage than the disease 
it is trying to treat.   
Finally, working on T cells offers a great system to model plasticity.  Understanding how 
plasticity occurs within T cells may lead to us to further understand plasticity in other organs 
of the body that are less accessible.  
 
1.8 Autoimmunity 
Multiple sclerosis is an autoimmune disease of the central nervous system.  The disease is 
thought to be caused by auto-reactive adaptive immune cells responding against a neuron 
antigen leading to demyelination of neurons and causing neurological dysfunction.  T cells, 
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specifically TH1 and TH17 cells have been implicated in playing an important role in the 
pathology of MS.   
 
1.8.1 Anatomy of Central Nervous System 
The central nervous system (CNS) is made up of the brain, spinal cord, optic nerve and the 
retina, which are all encapsulated with the bony structures of the skull and spinal cord.  The 
brain parenchyma and spinal cord is encapsulated within the meninges.  This structure is 
made of three membranes; in contact with the brain is the Pia mater, then the Arachnoid 
and finally the Dura mater next to the skull.  Between the Pia mater and the Arachnoid is the 
subarachnoid space; a fluid filled space containing cerebrospinal fluid (CSF).   
CSF is an important fluid for the protection of the brain and spinal cord but also for the 
metabolism and homeostasis of the CNS.  CSF is a fluid generated by a structure within the 
ventricles of the brain called the choroid plexus (Figure 1.3).  The choroid plexus is made up 
of a web of capillaries with special endothelia and surrounded by stroma.  These structures 
are covered by a monolayer of epithelial cells and these cells control the movement of 
solutes and fluid, through diffusion and active transport, from the blood into the arachnoid 
space to make up the CSF.  Interstitial fluid from the brain parenchyma also makes up a small 
portion of the CSF.   
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Figure 1.3: A Cartoon Version of the Central Nervous System. The brain 
parenchyma is surrounded by the fluid filled subarachnoid space. The 
choroid plexus within the cerebral ventricle is contains the ependymal 
cells that secrete the CSF fluid into the subarachnoid space. The T cells 
from the peripheral blood can enter the CNS through the choroid 
plexus, using CCR6 dependent migration. APC within the subarachnoid 
space will not leave the CNS, however soluble antigen from the brain 
parenchyma can be found in peripheral lymph nodes.      
 
Within the brain parenchyma there is the white and grey matter of the brain.  The white 
matter contains the glial cell and mylinated axons while the grey area of the brain consisting 
of neuronal cell bodies, neutrophil, glial cells and capillaries. 
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1.8.2 Immune System Within the CNS 
The CNS has evolved as an immune privilege site, meaning there are mechanisms in place 
that will prevent inflammation to reduce the chance of damage to this vital organ.  Immune 
privilege within the CNS can be verified by placing material such as tumour cells, viruses151 or 
bacteria152 in the brain parenchyma of mice.  If done carefully there will be no cell mediated 
response to the material as antigen-carrying APC from the parenchyma will not reach 
peripheral lymph nodes to prime an immune response.  This effectively means the brain is 
hidden from the peripherally immune system.  However, when the antigen (in this case 
Bacillus Calmette–Guérin (BCG)) was injected peripherally in mice that had been exposed to 
BCG in the brain (with no response), there was a delayed type hypersensitivity response 
within the brain and demyelination of the nerves took place153.  This suggests that it is the 
afferent arm of the immune response, the priming of antigen presenting cells that is 
prevented in the CNS.  The efferent arm, primed antigen specific cells that have migrated 
into the site of infection, functions normally.  It is the blood brain barrier (BBB) that keeps 
the fluid and cells of the brain parenchyma as a separate entity from the peripheral blood.  
The blood brain barrier is made up of special tight junctions in the capillaries in the brain, 
and surrounding these capillaries is a barrier of astrocyte foot processes (known as the glia 
limituns) (Figure 1.4).  Soluble antigens are able to drain from the CNS in to the deep cervical 
lymph nodes 154(Figure 1.3) while APC are not to be able to migrate out of the CNS.   
Introduction 
45 
 
Figure 1.4: Components of the Blood Brain Barrier. The peripheral vascular 
system is kept separate from the brain parenchyma by the blood brain barrier 
(BBB). The capillaries in the brain have special tight junctions in there 
endothelium and surrounding these capillaries is a barrier of astrocyte foot 
processes (known as the glia limituns). Pericytes help sustain the blood–brain 
barrier. 
 
Microglial cells, a resident macrophage within the brain, in healthy individuals are in a non-
activated state due to the immunosuppressive environment of the parenchyma155.  Neither 
CSF nor the CNS parenchyma contains naive T cells under physiological circumstances, and 
classical studies suggest that primary immune responses are not primed in the 
parenchyma156.  In a healthy individual the CSF only contains T cells and a few B cells, with 
some monocytes, but no granulocytes.    
 
1.8.3 Migration of T Cells into the CNS 
The microglial cells within the brain parenchyma are a resident cell population which are 
replaced via proliferation of the resident cells.  T cells within the blood however need to 
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somehow migrate into the CNS.  T cells enter from the periphery into the CSF via the choroid 
plexus (Figure 1.3).  This process is controlled through a few selective chemokine and 
migratory receptors.  CCR6 has been shown to be very important for T cell migration, 
especially in the disease setting of EAE157.  TH17 and TREG have been shown to express this 
chemokine receptor, though these are not the only cells to express it.  P-selectin and α4 
integrin is also important both in disease and in health of T cell migration into the 
brain158,159.   
Primed T cells need to be re-activated at the site of inflammation and using a Lewis rat 
model of EAE it was shown that only if APC are present in the subarachnoid space, to prime 
the T cells, can antigen specific T cells enter the brain parenchyma160.  However once the 
BBB has been activated other T cells can migrate into the brain, highlighted by the presence 
of CCR6- cells found after the first initial wave of inflammation in murine EAE157.   
 
1.9 Multiple Sclerosis  
MS is an autoimmune disease of the central nervous system.  The first association of the 
appearance of demyelinated lesions in the brain to neurological dysfunction were in 1868161.   
The majority of patients have an initial clinically isolated syndrome, followed by a period of 
what is known as remission, where their symptoms abate.  If a series of relapses of 
symptoms occur this would be diagnosed as relapsing remitting multiple sclerosis (RRMS).  
Throughout the relapses the sufferer’s disability will return back to baseline level.  However 
within remission the patient will gradually gain further disability.  This is known as Secondary 
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Progressive MS (SPMS).  10-15% of patients will go through primary progressive disease in 
which there will be no remissions or relapses they will just gradual gain disability over time.   
Diagnosis of MS is now undertaken through the visualisation of the lesions within the brain 
using magnetic resonance imaging (MRI).  Samples of CSF can also be taken to look for the 
presence of oligo-clonal bands 162, highlighting the presence of antibodies in the CSF. 
 
1.9.1 Disease Prevalence  
Multiple sclerosis affects around 2.5 million people around the world, with the age of 
diagnosis being 20-40 years.  MS is twice as likely to occur in women as men.  The 
distribution of MS sufferers worldwide is not evenly spread, with more people being 
diagnosed the further from the equator.  This has led to the hypothesis that Vitamin D, 
produced by the skin in response to sunlight and obtained through diet, may have a 
protective role163.  There are certain ethnic groups that have lower incidents of MS, such as 
Inuit, Aborigines and Maoris.  It is more common in Caucasians of northern European 
ancestry164.   
 
1.9.2 Risk Factors 
1.9.2.1 Genetics 
MS is not an inherited disease although there have been suggestions that there may be a 
genetic element.  There is only about a 2% chance of a child developing MS if they have a 
parent with MS. 
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Genome wide association studies (GWAS) have become an important tool in understanding 
MS.  GWAS analyses the whole genome of patients for small nuclear polymorphisms (SNP), 
changes in the nucleotide sequence of genes that are found in the patient cohort to a 
greater extent than in the general public.   
HLADRB1*1501 (encode for a subunit of human leukocyte antigen) has repeatedly appeared 
in GWAS studies for MS.  Other susceptibility loci are in the IL2RA and IL7RA genes165: both 
genes associated with TREG function.  The next step for GWAS studies is to link the SNP to a 
functional consequence for MS.    
 
1.9.2.2 Environment 
As mentioned above Vitamin D is thought to play a part in the prevalence of MS.  A 
prospective study of a large cohort of women indicated that Vitamin D had a protective 
effect against MS163.  The mechanism of action of Vitamin D is thought to be its ability to 
repress TH1 cells and promote TREG
166,167.   
Many people have tried to associate infectious agents with onset of MS.  Several different 
viruses have been suggested, including rabies, herpes simplex virus, measles, corona virus, 
Epstein-Barr virus and others, although none have been confirmed.  To date the most 
promising candidate appears to be the Epstein-Barr virus as there is a greater risk of 
developing MS if the person has had late onset infectious mononucleosis (IM)168.   
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1.9.3 Immunopathology 
Multiple sclerosis is characterised by subcortical or periventricular white matter focal 
inflammatory demyelinating lesions.  Within an active lesion there are CD8+ T cells, with less 
CD4+ T cells, monocytes and B cells although the major inflammatory cell type within a lesion 
are macrophages169.  Once MS has become progressive the lesions gradually expand 
overtime with macrophage only at the periphery of the lesion.    
B cells have been identified as playing an important role in MS with antibodies involved in 
the demyelination process169.  Ectopic lymphoid follicles have been identified within the 
meninges of MS suffers170, suggesting the presence of an antigen to maintain the follicle.  
Currently no antigen has been identified.   
T cells and specifically CD4+ T cells are thought to be the initiators of the inflammation.  T 
cells migrating in to the brain across the BBB will initiate inflammation which is thought to 
affect the BBB effectiveness.  The results in more inflammatory cells entering the 
parenchyma resulting in continued inflammation and demyelination of the nerves of the 
brain and spinal cord.      
Experimental autoimmune encephalomyelitis (EAE) is a murine model of MS.  Demyelination 
of the nerves is induced with an injection of a brain antigen (e.g.  a myelin oligodendrocyte 
glycoprotein (MOG) or myelin basic protein (MBP) etc.) along with complete Freud adjuvant 
(CFA) and pertussis toxin (PT).  The CFA induces an immune response to the antigen and the 
PT will act to break down the blood brain barrier (BBB) to allow immune cells into the CNS.  
Other methods of inducing a MS like responses include using a transgenic TcR model specific 
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for MOG protein and injecting MOG into the mice, or introducing MOG specific T cells into a 
RAG-/- mice.   
The CNS is a site of immune privilege as the BBB tightly controls the entrance of cells in to 
the CNS.  Because of this there has been a focus on understanding the mechanisms by which 
inflammatory cells enter the CNS in EAE and MS.   The removal of CCR6, the TH17 associated 
chemokine receptor, was protective against EAE induction.  The CCR6 ligand CCL20 was 
expressed on the choroid plexus and was important for the first wave of auto-reactive T cells 
to enter the CNS.  During the initial disease CCR6+TH17 and CCR6
+TH1 cells were absent from 
the CNS157.  VLA-4 (α4β1) is also involved in T cell migration into the brain parenchyma, and 
this finding in EAE171 lead to the use of natalizumab a  monoclonal antibody against VLA-4 
intergrin172.   
IL-23 has a non-redundant function in EAE initiation57 leading to the interest shifting from 
TH1 cells to TH17 cells.  Stimulating TH17 cells with IL-23 promotes GM-CSF which is also 
necessary for EAE induction173.   GM-CSF acts on dendritic cells (DC) to enhance production 
of IL-23 and other inflammatory cytokines which in turn promotes further activation of TH17 
cells.  Like TH17 cells, TH1 cells are dependent on GM-CSF production for initiating EAE
173, 
although the mechanisms that drive GM-CSF under TH1 conditions remain unclear.  Further 
data suggested that TH17 cells cannot induce disease unless they have responded to IL-23, or 
TGF-β3.  These ‘pathogenic’ TH17 cells induced EAE and have a different transcriptional 
profile to ‘conventional’ TH17.  Pathogenic TH17 cells contain both transcription factors 
RORγt and T-bet174.  Removal of TIM-3, a negative regulator of TH1 and TH17 cytokine 
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secretion, leads to exacerbation of EAE.  A defect in TIM-3 has been found in patients with 
MS175,176.   
CD39, an ectonucleotidase which hydrolyses ATP, is expressed by some TREG and these are 
specifically able to suppress TH17 cells.  The mechanism of suppression is thought to be a 
contact dependent one177.  ATP has been shown to increase IL-17 production178 suggesting 
the CD39 mediated break down of ATP may play a role in the reduction of IL-17 production 
by TH17 cell.  Furthermore using a blocking antibody against LAP (Latency Associated 
Peptide), a protein that binds TGF-β and is expressed on CD39+TREG, reduces the suppressive 
effects of CD39+TREG on TH17 cells in culture
179. Within RRMS patients these CD39+ TREG have 
been shown to have impaired function and a reduced ability to suppress TH17 cells.  
Furthermore, RRMS patients had a high percentage of IFNγ secreting TREG cells compared to 
controls.  These FoxP3+IFNγ+ cells, induced through culture of  TREG with IL-12, had reduced 
suppressive function180.  This identifies mechanisms in which inflammation in RRMS patients 
can go unchecked by peripheral tolerance.   
 
1.10 MicroRNA 
miRNA are small, endogenous, non-coding RNA molecules.  They play a vital role in post 
transcriptional modification of gene transcription.  miRNA are partially complementary to 
mRNA, and they function by down regulating the expression of the mRNA by either 
translational repression, mRNA degradation or deadenylation181.   To date over 2000 human 
miRNA are known.   
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Large precursor miRNA are transcribed by RNase II  enzyme182.  miRNA start their life as pre-
miRNA, a double stranded hairpin structure of ~70 nucleotide in length.  A complex of 
several molecules process the pre-miRNA, in the nucleus, consisting of the RNase III enzyme 
Drosha183, and the double-stranded-RNA-binding protein Pasha184.  The pre-miRNA is then 
actively transported to the cytoplasm for further processing by the RNAse III enzyme Dicer.   
A double-stranded miRNA of approximately 22 nucleotides in length will be the end product.  
Dicer also initiates the formation of the RNA-induced silencing complex (RISC).  RISC is the 
multicomponent nuclease, which the mRNA are directed to by the miRNA that destroys the 
mRNA181.   
MicroRNA molecules were only recently discovered 185.  However, their importance in the 
negative regulation of genes has become apparent in many different systems.  Using a T cell 
specific Dicer or Dorsha deficient mice demonstrated the role of miRNA in proliferation, 
survival and differentiation in CD4+ T cells186,187.  Knockdowns of Dicer lead to extensive 
autoimmune disease which was shown to be due to the lack of stability of TREG cells.  
Although the TREG in the thymus developed normally they were unable to maintain their 
phenotype in the periphery 188.  The cluster of miRNA, miR-17 – 92, were overexpressed in 
human lymphomas, and shown to have anti-apoptotic effects through T cell proliferation 
and growth189.   
There has been a great interest in the role of miRNA in T helper cell differentiation, 
specifically in TH cells in a disease setting due to their potential as a therapeutic target.  T-
bet, the TH1 lineage defining transcription factor is vital of the stability and maintenance of 
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TH1 phenotype.  In mice miR-29 has been implicated in regulating T-bet and the downstream 
effector cytokine IFNγ.  IFNγ was shown to regulate miR-29 expression in what seems a 
negative feedback loop in TH1 cells, via effects on T-bet and Eomes
190, in direct competition 
with IFNγ/STAT-1/T-bet positive feedback loop.  An increase in miR-29 was found in MS 
patients, and removal of miR-29 lead to exaggerated IFNγ production and EAE191.   
Figure 1.5 Processing and action of microRNAs. MicroRNA are 
transcribed as pre-miRNA that are activly spliced, by RNAse III enzyme 
Dicer in to double stranded miRNA.  RNA-induced silencing complex 
(RISC), a nuclease will direct the miRNA to its target mRNA. The 
binding of the miRNA to it’s target mRNA leads to reduced 
transcription, either due to its degredation or effects on the 
transcription of the mRNA. 
 
The miR-29 has also been shown to be up-regulated in other T helper subsets, and is not 
exclusively expressed in TH1 cells.   
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Due to the involvement of TH17 cells in EAE there have been a few miRNA that are not only 
associated with TH17 differentiation but also the pathogenesis of EAE.  miR-155 expression in 
T cells is vital for the full development of EAE due to its involvement in induction of the T 
helper subsets TH17 and TH1
192.  Several genes vital for TH17 differentiation were shown to 
be lacking in miR-155-/- mice, such as IL-23R.  This makes TH17 cells hypo-responsive to IL-23, 
which is an important cytokine for maintenance of TH17 phenotype and RORγt maintenance.  
Ets, a negative regulator of the TH17 phenotype, was also shown to be repressed by miR-155.   
miR-155 has been shown to also target IFNγ193.  Ets-1 is also a target for miR-326194. The 
generation of miR-155 has also been shown to play a role in TREG and TH17 induction. This 
miRNA also targets SOCS1. SOCS1 can block IL-6 dependent STAT-3 activation, and complete 
removal of SOCS1 expression in mice resulted in more FoxP3 cells within the thymus of the 
animal.   
In mice where T cells were stimulated with the myelin auto antigen, MOG, there was an up 
regulation of miR-301-a, miR-21 and miR-155.  MicroRNA-301a is involved in the negative 
regulation of a STAT-3 inhibitor PIAS3, which was involved in Th17 cells induction in this EAE 
model195.    
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THESIS AIMS 
CD4+ T helper cells are a vital part of the adaptive immune system. Initially it was thought 
that CD4+ T cells were stable in their phenotype.  However it is now clear that there is an 
element of plasticity in CD4+ T cell differentiation.  At the start of this study there was 
information about the cytokine and transcription factors expressed by individual TH subsets.  
However, very little was known about T cell plasticity and the overlap of different T helper 
subsets. Therefore, the first aim of this study was to:   
1) Phenotype CD4+ T cells that co-expressed two lineage defining cytokine, with a 
particular interest in cells that co-expressed IFNγ and IL-17.   
It has now been shown that TH17 cells can switch on IFNγ production and express T-bet.  It is 
still unknown if IFNγ+IL-17+ cells can develop in to ‘ex-TH17’ cells that only secrete IFNγ. CCR6 
and CD161 are surface markers used to enrich CD4+ T cells for TH17 cells. These markers are 
expressed by a subset of TH1 cells. Therefore, this thesis also aims to:  
2) Identify if CCR6 or CD161 expression on TH1 cells is a marker of a ‘TH17-related’ 
phenotype.  
3) Compare the phenotype and functional feature of CCR6+TH1 cells to CCR6
-TH1 and 
TH17 cells.  
4) Identify novel miRNAs that could be involved in controlling T cell plasticity in TH1 
and TH17 cells.  
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Migration of CCR6+TH17 cells across the choroid plexus plays a role in initiating inflammation 
in multiple sclerosis. The fourth aim of this thesis is to: 
5) Identify if CCR6+TH1 cells are present in the blood and CSF of MS patients.  
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CHAPTER 2 
MATERIALS AND METHODS 
2.1 List of Reagents 
2.1.1 Media and Solutions 
RPMI: RPMI (Roswell Park Memorial Institute) 1640 [Sigma-Aldrich Irvine, UK], 1% 
GPS (2mM l-glutamine, 100U/ml penicillin, 100ug/ml streptomycin) 
[HyClone, Northumberland, UK] 1% HEPES (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid) [Sigma-Aldrich] 
RPMI/10% HIFCS:       RPMI 1640 medium, 10% Heat Inactivated Fetal Calf Serum (HIFCS) 
[Biosera, Ringmer, UK] 
RPMI/1% BSA: RPMI 1640 medium, 1% Bovine serum albumin (BSA) [Sigma-Aldrich] 
X-VIVO: X-Vivo 15 [Lonza], 1% GPS (2mM l-glutamine, 100U/ml penicillin, 100ug/ml 
streptomycin) [HyClone, Northumberland, UK] 
PBS: Phosphate buffered saline contains 8g/l NaCl, 0.26/l KCl, 1.15g/l NA2HPO4, 
0.2g/ml KH2PO4 in distilled H20; prepared as 1 PBS tablet per 100ml H20 
[Oxoid, Basinstoke,UK]  
Macs buffer:           PBS, 2mM ethylenediamine tetra-acetic acid (EDTA) [Sigma-Aldrich], 0.5% 
BSA   
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2.1.2 Antibodies 
Target Conjugate Isotype Clone Company Cat No Dilution  
CD3 APC-eFlour IgG1κ UCHT1 eBioscience 47-0038-42 1/100 
CD4 PE/Cy7 IgG2a,κ OKT4 Biolegend 317414 1/160 
 APC IgG2b,κ OKT4 eBioscience 17-0048-42 1/40 
CD8 Brilliant Violet IgG1κ RPA-T8 Biolegend 301047 1/80 
CD14 APC-eFlour 780 IgG1κ 61D3 eBioscience 47-0149-42 1/20 
CD25 PerCp/Cy5.5 IgG1κ BC96 Biolegend 302626 1/20 
CD45RA PE CF594 IgG2a,κ HI100 BD Horizon 562298 1/40 
CD45RO PE CF594 IgG2a,κ UCHL1 BD Horizon 562299 1/40 
CD69 APC Cy7 IgG1κ FNSO Biolegend 310914 1/80 
CD127 FITC IgG1κ eBioRDR5 eBioscience 11-1278-42 1/40 
CD161 PeCy7 IgG1 HP-3G10 eBioscience 25-1619-42 1/ 
CCR6 PE IgG2b,κ G034E3 Biolegend 353410 1/40 
 AF 648 IgG2b,κ G034E3 Biolegend 353404 1/40 
CCR7 AF 488 IgG2a,κ G043H7 Biolegend 353206 1/40 
CXCR3  AF 647 IgG1κ G025H7 Biolegend 353712 1/80 
       
*Isotypes used at the concentration of the matched antibody 
Table 2.1 Primary antibodies used for flow cytometry-against surface molecules.  
Abbreviations used Alexa Fluor (AF), Allophycocyanin (APC), Cyanine 5.5 (Cy5.5), Cyanine 7 
(Cy7), Fluorescein isothiocyanate (FITC), Phycoerythrin (PE), Phycoerythrin Texas Red (PETR). 
All antibodies raised in mouse.  
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Target Conjugate Species Isotype Clone Company Cat No Dilution 
IFNγ  eFlour 450 Mouse IgG1κ 45.B3 eBioscience 48-7319-42 1/80 
 APC Mouse IgG1κ 45.B3 eBioscience 17-7319-82 1/40 
TNFα PE Mouse IgG1 MAb11 R&D IC210P 1/120 
 PerCP-Cy5.5 Mouse IgG1κ MAb11 eBioscience 45-7349-42 1/80 
IL-5 PE Mouse  IgG2a,κ JES1-39D10 Biolegend 500904 1/20 
IL-10 PE Rat IgG1κ JES3-9D7 eBioscience 12-7108-82 1/20 
IL-17a  Mouse  IgG1κ eBio64DEC17 eBioscience 53-7179-42 1/20 
IL-22 eFlour 660 Mouse IgG1κ 22URT1 eBioscience 50-7229-42 1/20 
 PE Mouse IgG1κ 22URT1 eBioscience 12-7229-42 1/40 
IL-21 PE Mouse  IgG1κ eBio3A3-N2 eBioscience 12-7219-42 1/40 
GM-CSF PE Rat IgG2a BVD2-21C11 BD Pharmingen 554507 1/160 
IL-2 PE Rat IgG2a,κ MQ1-17H12 eBioscience 12-7029-82 1/120 
IL-17f PE Rat IgG1κ SHLR17 eBioscience 12-7169-41 1/20 
        
Table 2.2 Primary antibodies used for flow cytometry against intracellular cytokines.  
Abbreviations used Allophycocyanin (APC), Cyanine 5.5 (Cy5.5), Phycoerythrin (PE). 
Target Conjugate Species Isotype Clone Company Cat No Dilution 
Tbet  AF 647 Mouse IgG1κ 4B10 Biolegend 64480 1/80 
 PE Mouse IgG1κ eBio4B10 eBioscience 12-5825-82 1/80 
GATA-3 AF 488 Mouse IgG1κ L50-823 BD Pharmingen 560163 1/20 
 PE Mouse IgG1κ L50-823 BD Pharmingen 560074 1/40 
FoxP3 PE Rat IgG2a PCH101 eBioscience 12-4776-73 1/20 
RORγt/RORC PE Rat IgG2a AFKJS-9 eBioscience 12-6988-82 1/80 
Table 2.3 Primary antibodies used for flow cytometry against intracellular transcription 
factors.  Abbreviations used Alexa Fluor (AF), Phycoerythrin (PE). 
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2.2 Ethics 
Blood from healthy controls were taken under the ethics, “T cell differentiation and 
function”. Ethical review ERN_10-0728, approved by the Life and Health Sciences Ethical 
Review Committee, UoB. 
Bloods and CSF from multiple sclerosis patients were taken the ethics, “Analysis of 
pathogenic and regulatory T cells in relapsing-remitting multiple sclerosis”.  Ethics reference: 
ERN_10-0762, collected through Human Biomaterials Resource Centre, UoB. 
2.3 Multiple Sclerosis Patient and Control Samples  
CSF/Blood Diagnosis Age 
B RRMS  59 
B SPMS/RRMS  48 
B RRMS  34 
B SPMS (With relapses)  59 
B RRMS  26 
B SPMS  43 
B/CSF Other Neurological Disease 38 
B/CSF MS 56 
B/CSF MS 31 
B/CSF Undiagnosed 52 
B/CSF Undiagnosed 45 
B/CSF Undiagnosed 50 
B SPMS (With relapses)  54 
B RRMS (no relapse 2yrs)  51 
B/CSF Small Vessel Disease Unknown 
B/CSF Inter-cranial Hypertension Unknown 
B/CSF Neuro-inflammation Unknown 
B Undiagnosed Unknown 
B Undiagnosed Unknown 
Table 2.4. Demographics of suspected MS patient. Information about age of patient and 
diagnosis of conditions were obtained after analysis due to lumber puncture being for 
diagnosis purpose.  SPMS-Secondary progressive MS, RRMS – Relapsing remitting MS, CSF-
cerebralspinal fluid, Blood- Peripheral Blood.  
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Blood/CSF Sex Age 
B F 21 
B F 31 
B F 26 
B F 25 
B F 25 
B F 23 
B F 24 
B M 55 
Table 2.5 Healthy control demographics. Age and sex of healthy controls. 
2.4 Purification of Cell Subsets 
In this section, unless otherwise stated, where it is mentioned that the cells are washed it 
was at 300xg, for 8 minutes at 20°C and then the supernatant was removed.  All work in this 
section was undertaken in a category II safety cabinet.  
 
2.4.1 Peripheral Blood Mononuclear Cell (PBMC) Extraction from Whole 
Blood 
Peripheral blood samples were obtained in Heparin Sodium [Wockhardt, Wrexham, UK] 
from healthy donors (recruited from amongst work colleagues).  Informed consent was 
taken in accordance with the Human Tissue Act 2004.  The blood was diluted at a ratio of 1:1 
with RPMI medium.  18mls of the diluted blood was layered on top of 8mls of Ficol-Paque 
Plus [GE Healthcare Bioscience] in a 25ml tube.  The tube was centrifuged at 300xg, 20°C for 
30 minutes without brake.  The mononuclear cell layer containing the PBMC was removed 
and was washed three times in RPMI/10% HIFCS.  The cells were counted using an Improved 
Neubauer haemocytometer [Weber Scientific].   The yield of PBMC was calculated as 
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described by the manufacturer.  The range of yield was 5 x 105 – 1.5 x 106 per ml of 
peripheral blood. 
 
2.4.2 Positive Selection of CD4+ T cells from PBMC 
PBMC were washed in filter-sterilized cold MACS buffer (2-8°C) and the supernatant was 
removed to leave a dry pellet.  The cell pellet was resuspended in 80μL of MACS buffer/10⁷ 
total cells and 20μL of CD4+ T Cell Microbeads [Miltenyi Biotech]/10⁷ total cells.  The cells 
were mixed well and incubated for 20 minutes in the refrigerator (2−8 °C).   
The cell and bead mixture was washed in cold MACS buffer and resuspended in 500μL of 
MACS buffer.  The cell suspension was added to a pre-rinsed MS column [Miltenyi Biotech] 
on a MiniMACS separator magnet [Miltenyi Biotech].  The unlabelled cell fraction 
(everything but CD4+ cells) in the effluent was collected and the column was washed with 1 
mL of cold MACS buffer.  The unlabelled cells were re-added to the column for a second 
selection process to improve the yield of CD4+ cells.  The column was washed three times 
with 1ml of cold MACS buffer.  Total effluent was collected.  This was the unlabelled pre-
enriched CD4- cell fraction.  The column was then removed from the magnet and the CD4+ 
fraction eluted with 1ml MACS buffer and firm pressure on the column from a plunger.  
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Figure 2.1 Representative purity check of CD4+ T cell isolation from PBMC. Gated on a 
mononuclear cell gate, plots show PBMC before CD4+ isolation and the positive and negative 
fractions after CD4 T cell isolation.  
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The range of yield was 2 x 105 – 5 x 105/106 of PBMC.  These populations were highly 
enriched for CD4+ cells, with a purity of >95 (Figure 2.1).The populations were analysed for 
the percentage of cells expressing CD4. Values shown represent the percentage of CD4+ cells 
within the gate.  
 
2.4.3 Purification of CD4+CD25- cells  
CD4+CD25- T cell were isolated using a two-step separation (CD4+CD25+ Regulatory T Cell 
Isolation Kit, human [Miltenyi Biotech]).  In the first step all cells not expressing CD4+ were 
removed and in the second step the CD25+ cells (TREG enriched) were isolated from the CD4
+ 
fraction.    
In the first negative selection step the PBMC cell pellet was re-suspended in 90μL of cold 
MACS buffer/10⁷ total cells and 10μL of CD4+ T Cell Biotin-Antibody Cocktail /10⁷ total cells.  
This cocktail contained biotinylated antibodies against all the other cell types (CD8, CD14, 
CD15, CD16, CD19, CD36, CD56, CD123, TCRγ/δ and CD235a (glycophorin A)) within PBMC.  
The cell suspension was mixed well and incubated for 5 minutes in the refrigerator (2−8 °C).   
20μL of Anti-Biotin MicroBeads per 10⁷ cells was then added, which bound to the 
biotinylated antibodies attached to the cells from the last step.   The cell suspension was 
mixed well and incubated for an additional 10 minutes in the refrigerator (2−8 °C).  The 
volume of liquid was adjusted to a minimum of 500μL of buffer if needed. 
The cell suspension was added to a pre-rinsed LD column [Miltenyi Biotech] placed on a 
QuadroMACS separator magnet [Miltenyi Biotech].  Unlabelled cells were collected in the 
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effluent and the column was washed with 1 mL of MACS buffer.  The unlabelled cells were 
re-added to the column for a second selection process to improve purity.  The column was 
washed three times with 1ml of cold MACS buffer.  Total effluent was collected.  This was 
the unlabelled pre-enriched CD4+ cell fraction.   
The unlabelled CD4+ cells were positively labelled to isolate the CD25+ T cells.  The CD4+ T 
cells were counted, washed and the cell pellet was resuspended in 90μL of buffer/10⁷ total 
cells and 10μL of CD25 MicroBeads /107 cells.  This mixture was incubated for 15 minutes in 
the refrigerator (2−8 °C).  The cells were washed and the supernatant was aspirated off 
completely.  The cell pellet was resuspended up to 10⁸ cells in 500μL of buffer. 
The cell suspension was applied onto the MACS column.  The flow-through containing 
unlabelled cells was collected.  The column was wash three times with 500μL of cold MACS 
buffer.  The magnetically labelled CD25+ cells were flush out by the addition of 1 mL of cold 
MACS buffer added to the column and immediately forced through using the plunger 
provided. 
The yield was 2x105 – 5x105 /106 of PBMC.  These populations were highly enriched for CD4 
with a purity of >95% (Figure 2.2).  The yield of CD25+ cells was between 1x104-5x104 per 106 
PBMC with a purity of between 40-60%., with the CD4+CD25- fraction >90% pure. 
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Figure 2.2 Representative purity check of a CD4+CD25- T cell isolation from PBMC. Gated on 
a mononuclear cell gate, plots show PBMC before CD4+ isolation, the CD4+CD25- fraction and 
the CD4+CD25+ fraction. The populations were analysed for the percentage of cells 
expressing CD4, CD25 and CD127. Values shown represent the percentage of cells within the 
gate. 
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2.4.4 Purification of cytokine secreting cells 
For all the cytokine capture experiments CD4+CD25- T cells were isolated and left overnight 
in the fridge.  On day two once the CD4+CD25- T cells had been washed they were stimulated 
for 3 hours with Phorbol 12-myristate 13-acetate (PMA) [Sigma] and Ionomycin [Sigma] 
(50ng/ml and 500ng/ml respectively).   At this stage if CCR6 cells were being isolated the 
cells were pre-stained for CCR6 as in section 2.4.1.1.  PBMC were used only when 
stimulating with Staphylococcal Enterotoxin B (SEB) and Cytostim and where indicated with 
PMA/ionomycin.  PBMC were stimulated on the day of isolation and not left in the fridge 
overnight. 
Cells were cultured in 6 well plate [Corning] at a density of 5x106 cells/cm2.   The cells were 
stimulated with either Cytostim (20μl/ml) [Miltenyi Biotech] or SEB (500ng/ml) or PMA 
(50μl/ml) with ionomycin (500μl/ml) for 3 hours at 37°C, 5% CO2.  Cytostim is an antibody-
based reagent that acts similarly to a super-antigen but independently of certain Vβ domains 
of the TcR.  Cytostim cross-links the TcR of a T cell to an MHC molecule of an antigen-
presenting cell.  SEB is an enterotoxin produced by the bacterium Staphylococcus aureus.   
The cells were collected from the plate by washing each well with cold MACS buffer (2-4°C) 
apart from if PMA/ionomycin was used in which case the cells were washed three times.  A 
pipette was used to collect as many cells as possible from the bottom of each well of a 6 well 
plate.  The cells were transferred to a 15ml tube and washed with 10ml of cold MACS buffer.  
The supernatant was carefully pipetted off to prevent cells loss.  80μl/107 cells of cold MACS 
buffer along with 20μl/107 of the cytokine catch reagent (Cytokine Secretion Assay-Cell 
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Enrichment and Detection Kit [Miltenyi Biotech, Surrey, UK]) were added to the tube.  This 
combination was mixed well and incubated on ice for 5 minutes.  If the protocol was for a 
double cytokine capture 10μl/107 was used of each capture reagent.  RPMI/10% HIFCS, that 
had been warmed for 10 minutes in a water bath at 35°C, was added to dilute the cells at 
1x105 cells/ml.  These cells were incubated for 45 minutes in the incubator, (37°C, 5% CO2) 
spinning on a MACS Rotator [Miltenyi Biotech]. 
Cells were kept on ice for 10 minutes then washed in cold MACS buffer, centrifuged (300xg, 
10 minutes, 4°C) and re-suspended in cold buffer at a concentration of 80μl/107 cells with 
20μl/107 cells of the cytokine detection antibody.  Again, if it was a double cytokine secretion 
assay 10μl/107 cells of each antibody was used (conjugated to PE, APC or FITC).  This was 
then incubated on ice for 10 minutes and a final wash step of 10mls of cold MACS buffer was 
carried out.   
At this stage the cells could either be further stained for other cell markers (e.g. CCR6, 
CD45RO) and analysed using flow cytometry or the cytokine secreting cells could be isolated.  
The cells were sorted for the cytokine positive cells using either FACS (Fluorescent Activating 
Cell Sorting) or MACS cell sorter columns.   
The stained cells were passed through a damp Pre-Separation Filter (30µm) [Miltenyi 
Biotech] in 1ml of MACS buffer and the filter was then washed with a further 1ml of MACS 
buffer.  The cells were passed through a FACS Mo-Flo Cell sorter [Beckman Coulter].  Single 
colour compensation tubes were required to compensate for fluorescence overlap.  The 
FACS uses a method of isolating individual cell into droplets and administering a charge to 
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the cells of interest depending on their fluorescent profile.  The charged cells can then be 
separated from the rest of the cells. 
 
2.4.5 Markers of Recent Activation 
Total PBMC were stained for CD4, CD45RO and either CD69 or CD71 in sterile PBS/2% BSA. 
After being left for 15 minutes on ice the cells were washed and placed in 1ml of sterile 
PBS/2%BSA.  The different populations of interest were isolated on the MoFlo Cell Sorter. 
Once sorted the cells were stimulated and stained as in Section below (Section 2.4).   
 
2.5 Surface and Intracellular Lymphocyte Staining 
2.5.1 Surface Marker Staining 
0.5x106-1.5x106 cells were re-suspended in 50μl of RPMI/10% HIFCS in a single well of a 96 
well plate.  To stimulate the cells to produce cytokine PMA and Ionomycin were both added 
at a concentration of 50ng/ml and 500ng/ml, respectively.  Only RPMI/10% HIFCS was added 
to any non-stimulated wells.  To prevent cytokine release 2μg/ml of Brefeldin A was added 
to all the wells including the non-stimulated portion.  The wells were made up to 200μl with 
RPMI/10% HIFCS or stimulation solution of PMA and ionomycin and left in the incubator at 
37°C, 5% CO2, for 3 hours.   
The plate was centrifuged for 4 minutes at 4°C and 300xg and the supernatant was flicked 
off.   Antibodies specific for surface molecules were made up to 50μl in PBS/2%BSA and 
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added to the relevant wells.  The plate was left on ice at 0-2°C, in the dark for 15 minutes.  
The wells were washed with 100μl of PBS/2%BSA and centrifuged for 4 minutes at 300xg.  
The cells were then fixed and permeabalised as detailed below (Section 2.4.2).  
Compensation beads [BD Pharmingen] were used for fluorescence compensation purposes. 
 
2.4.1.1 CCR6 Surface Staining 
When cells were stimulated with PMA/ionomycin there was a down regulation of CCR6 
expression on the surface of the cell.  To correct for this surface staining of CCR6 was done 
before and after stimulation.  PBMC were added to a plate and were centrifuge for 4 
minutes at 4°C and 300 x g and the supernatant was flicked off.   CCR6 antibody was made 
up to 50μl in PBS/2%BSA and added to the relevant wells.   The plate was kept at room 
temperature in the dark for 15 minutes.  The wells were washed with 100μl of PBS/2%BSA 
and centrifuged for 4 minutes at 300xg.  The cells were then stimulated with 
PMA/Ionomycin in the presence of Brefeldin A for 3 hours, as described above.  The cells 
were then further stained for extracellular antibodies as described above (Section 2.4.1), 
with the addition of the CCR6 antibody.  The only alteration made to the protocol was that 
the cells were incubated at room temperature, in the dark, instead of on ice.  The protocol 
for fix and permeabilisation of the cells was kept the same. 
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2.5.2 Cell Permeabilisation   
The supernatant was removed by flicking the plate and the cells were re-suspended in 50μl 
of Reaction Buffer A [FIX & PERM®, Invitrogen].  The plate was left at room temperature and 
kept in the dark for 15 minutes.  The wells were washed with 100μl of PBS/2%BSA and 
centrifuged.  The antibodies for intracellular staining were made up to 50μl using Reaction 
Buffer B [FIX & PERM®] and added to the wells.  They were left for 15-20 minutes in the dark 
at room temperature.  The wells were then washed with 100μl of PBS/2%BSA and 
centrifuged.  Once the cells had been re-suspended in 300μl of PBS/2% BSA they were then 
analysed. 
 
2.6 Flow Cytometry Analysis 
Cells were analysed by a nine colour flow cytometry on a Dako-Cyan.  Data analysis was 
carried out using Kaluza® Flow Cytometry Analysis Software from Beckman Coulter.  The 
number of events analysed per sample was between 10,000 and 500,000.  The gating 
strategy for identification of memory CD4+ and CD8+ T cells is shown in Figure 2.3.  For the 
transcription factor staining a matched isotype on the same fluorochrome and from the 
same company was used to set the negative gate. The negative gates for the cytokine 
staining were set as shown in Figure 2.4 using stained unstimulated control cells.  
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Figure 2.3 Gating strategies used to identify CD8+ and CD4+ memory T cells. (A) Live cells 
were gated by FSC vs SSC. (B) Single cells were selected by low pulse width. (C) CD4+CD8- or 
CD4-CD8+ cells were gated for and based on the different populations either (D) 
CD4+CD45RO+ expression or (E) CD8+CD45RO+ cells were analysed.    
Forward Scatter  
P
u
ls
e 
W
id
th
 
CD4 
C
D
8
 
CD8 
C
D
4
5
R
O
 
CD4 
C
D
4
5
R
O
 
62.42% 
99.42% 
 
24.73% 
41.58% 
Forward Scatter  
Si
d
e 
Sc
at
te
r 
 20.95%  
63.54% 
A B 
C 
D E 
CD4
+ 
T Cell Cytokine and Transcription Factor Expression  
73 
 
 
 
 
 
Figure 2.4 Cytokine unstimulated controls. PBMC were left unstimulated for 3 hours in the 
presence of Brefeldin A. All plots are gated on CD4
+
CD45RO
+
 cells. The cells were stained for 
the cytokines shown (A) GM-CSF and IL-2 (B) IL-2 and IL-5. (C) IL-17A and IL-22 (D) IL-10 and 
IFNγ and (E) IFNγ and IL-21. These plots were used to set the gates for the stimulated 
controls. Values represent percentage of cells in the gate.  
    
IL-2  
G
M
-C
SF
 
0.05% 
 
  
0.23% 0.00% 
IL-5 
IL
-2
 
 
0.01% 
 
 
0.54% 
0.26% 
 
0.00% 
 
 
0.00% 
0.18% 
IL-22 
IL
-1
7
A
 
IFNγ  
IL
-1
0
 
 
0.03% 
 
0.02% 
 0.04% 
IFNγ  
IL
-2
1
 
0.10% 0.00% 
0.00% 
 
  
A B C 
D E 
CD4
+ 
T Cell Cytokine and Transcription Factor Expression  
74 
 
2.7 Image Stream  
PBMC were processed as described above as appropriate, apart from the addition of Po-pro 
1 just before analysis (330nmol/500 µl - left on ice for 10 minutes).  The cells were run on 
Image StreamX [Amnis] with 10,000-100,000 cells analysed.  Data analysis was carried out 
using IDEAS® software from Amnis. 
 
2.8 Cell culture 
2.8.1 Analysis of Proliferation 
To analyse proliferation within a culture cells were pre-stained with Cell Proliferation Dye 
eFluor® 450 [eBioscience].  With every round of proliferation the cells passed on half the 
amount of dye to their daughter cells meaning the cells that have divided can be identified.  
Cells were stained following manufacturer’s instructions.  Briefly, the cells were washed 
three times in PBS to remove any serum to increase the efficiency of staining.  The cells were 
then diluted in PBS (room temperature) at a concentration of 20x106/ml.  A 20µM solution 
of Cell Proliferation Dye eFluor® 450 in PBS was made up and was mixed 1:1 with the cell 
suspension.  The suspension was vortexed and incubated in the dark at 37°C with 2% CO2 for 
10 minutes.  To stop the labelling 20ml of cold RPMI/10% HIFCS was added to the cells and 
left on ice, in the dark, for 5 minutes.  The cells were washed 3 times with RPMI/10% HIFCS 
and then transferred to culture conditions.  The analysis of proliferation was undertaken on 
the Cyan in the V1 channel.   
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2.8.2 TH17 Polarisation 
Isolated cells were washed in X-vivo/1% GPS and placed into a round bottomed 96 well plate 
at a density of 5x104 cells per well, where possible. Anti- CD3, anti-CD28 Dynal Beads 
[Invitrogen] were washed as recommended by the manufacture and placed in to the well at 
1:3 or 1:32 bead to cell ratio.  For neutral culturing conditions IL-2 at 50U/ml was added 
alongside the beads.  For TH17 polarising environment the Table 2.6 shows the cytokines 
added. 
 
 
 
 
 
Table 2.6.  TH17 polarising cytokines and the concentration within  
cultures.  All cytokines [Peprotech] have been reconstituted in PBS 
0.1% BSA.  The concentrations shown are the final concentration 
required in the culture.  
 
Cytokine Concentration 
IL-1β 10 ng/ml 
IL-2 10 ng/ml 
IL-6 20 ng/ml 
IL-23 10 ng/ml 
anti-IFNγ 100 ng/ml 
anti-IL-4 100 ng/ml 
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Cells were cultured for 5 days at 37°C, 5% CO2.  After 5 days the cells were washed, 
stimulated with PMA/Ionomycin and stained using the intracellular staining protocol. All 
TH17 polarising cultures were in x-vivo media with 1% GPS.  
 
2.9 Migration Assay 
CD4+ T cells were positively isolated from PBMC as stated above in section 2.3.2.  The CD4+ T 
cells were counted and then washed by centrifugation at 300xg for 10 minutes.  The cells 
were resuspended in RPMI/2%BSA (with GPS) at 200,000 cells/75μl.  The chemokines, CCL20 
[Peprotech] and CXCL12 [Peprotech], were diluted to the desired concentration with RPMI/ 
2% BSA.   
To set up the plate 150μl of the chemokines were added to the bottom well of the 
MultiScreen Migration Invasion and Chemotaxis Filter Plate (5.0 µm) [Millipore].  To 
equilibrate the plate and the cells they were both placed in an incubator at 37°C, 2% CO2, for 
30 minutes.  75µl of the cell suspension was slowly dribbled down the side of the top well of 
the migration plate to prevent putting force on the cells and pushing them through the top 
well membrane.  The complete plate was then placed back in the incubator at 37°C, 2% CO2, 
for two hours.   
The plate was taken apart and the liquid from the bottom and top compartments were 
carefully collected into separate tubes.  The cells from the top and bottom wells were then 
washed and added to a 96 well plate.  The collected cells were stimulated for 3 hours with 
PMA and Ionomycin in the presence of Brefeldin A, as stated above in Section 2.4.1.  The 
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cells were then stained for intracellular IFNγ and IL-17 expression and analysed using flow 
cytometry.  Counting beads were added to the flow cytometry tube to analyse the actual 
number of cells that had migrated from the top well towards the chemokine in the bottom 
well.   
2.10 Gene Expression Analysis 
2.10.1 RNA Extraction and Reverse Transcription 
RNA isolation and cDNA synthesis were performed using the µMACS One-step cDNA Kit 
[Miltenyi Biotech].  The method was performed as manufacturer’s instructions.  MoFlo 
sorted cells were washed in cold PBS and then pelleted by centrifugation at 300xg for 8 
minutes in a 1.5ml ependorff tube.  1 ml of Lysis/Binding buffer was added to the cells.   To 
reduce viscosity of the lysate, mechanical shearing of DNA was performed by forcing the 
lysate 2-3 times with maximum pressure through a 21G needle attached to a 1-5ml syringe 
so no ‘fuzzy’ material or clumps remain in the lysate.  The foam generated during lysate was 
removed by centrifuging the lysate for 1-3mins (13000xg).  At this stage the lysate was 
pelleted and stored at -70°C until needed.  The mechanical shearing was preformed again 
after the cells had been defrosted to be sure that all the cells had lysed.  The lysate was 
applied to the top of a LysateClear column and centrifuged at 13,000xg for 3 mins.  A µMACS 
column was placed in a magnetic field and rinsed with 100µl of Lysis/Binding buffer.  
Oligo(dT) Microbeads (50µl- pre 1ml lysate) were added to the lysate and mixed by pipetting 
up and down 2-3 times.  These magnetic beads bind to the polyA tail of the mRNA.  The 
lysate was added to the top of the LysateClear column resulting in the magnetically labelled 
mRNA being retained on column.  To clear off any excess DNA or proteins left on the column 
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it was rinsed with 2x200µl Lysis/Binding buffer and then rinsed with 4x 100µl Wash Buffer to 
remove further rRNA and DNA. 
 2x100µl of Equilibration/Wash Buffer was added into the column matrix.  The Lyophilised 
Enzyme Mix was then resuspended in 20µl Re-suspension Buffer (only pipette up and down 
twice) and added to the top of the column.  To avoid evaporation 1µl of the sealing solution 
was added directly on top of the column matrix.  The thermoMACS Separator was set to 
42°C and incubated for 1 hour.  Following from this 2x100µl of Equilibration/Wash buffer 
was added to the column before 20µl of the cDNA Release Solution is added.  This was 
incubated for 10mins at 42°C and then the synthesized cDNA was eluted from the column 
and collected with 50µl cDNA Elution Buffer.  The cDNA was then frozen at -70°C until it was 
used for qRT-PCR.   
 
  
CD4
+ 
T Cell Cytokine and Transcription Factor Expression  
79 
 
2.10.2 Real Time Quantitative Polymerase Chain Reaction (RT-qPCR) 
 
All Gene Assays were from Applied Bioscience. 
 
Gene Code Fluorochrome 
GAPDH Hs02758991_g1 VIC 
T-bet Hs00203436_m1 FAM 
RORC Hs01076122_m1 FAM 
IFNγ Hs00989291_m1 FAM 
IL-17A Hs00174383_m1 FAM 
IL-23R Hs00332759_m1 FAM 
IL-12Rβ2 Hs01548202_m1 FAM 
IL4I1 Hs00541746_m1 FAM 
IL-1R1 Hs00991002_m1 FAM 
Table 2.7 Human Gene Assays from Applied Bioscience 
 
Reactions were performed in duplex, with both GAPDH and the target gene in one well, in a 
384 well plate FastStart TaqMan® Probe Master (Rox) [Roche], a 2x concentrated master 
mix, in which 2.5μl was used.  0.35μl of the gene assay was added along with the desired 
quantity of cDNA, RNase free water was used to make the reaction volume to 5μl.   All RT-
PCR reactions were performed on the Light Cycler 480 [Roche] and analysed using the Light 
Cycler® 480 SW 1.5 software.   
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Stage/ Cycle Temperature Time Ramp Rate 
Pre-incubation 95°C 10 minute 4.4°C/s 
Amplification 
/50 Cycles 
95°C 15 sec 2.2 °C/s 
 60°C 1 minutes 4.4°C/s 
 72°C 1 sec 4.4°C/s 
Melt Curve 
/ 1 cycle 
40°C 10 sec 2.5°C/s 
 80°C 30 sec 0.6°C/s 
 40°C Hold 2 °C/s 
 40°C 10sec 2 °C/s 
Table 2.8 qRT-PCR programme on the Light Cycler 480 
 
2.10.3 Gene expression analysis 
Relative gene expression (R) was analysed using the equation below.  Ct= Cycle Threshold, 
Sample=Target gene, Control= GAPDH,  
R = 2- [ ΔCt sample – ΔCt control] 
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2.11 QuantiGene Plex 2.0 Assay, Luminex [BioPlex] 
The QuantiGene Plex 2.0 Assay [Affemetrix, Panomics] system was used to directly analyse 
the expression levels of RNA of specific genes from cell lysates.  This system allowed for the 
RNA levels of several genes to be measured in one sample without reverse transcription.  
The genes of interest were, RORC (SA-14729), Tbx21 (SA-98001), IL-17A (SA-12176), IL-17F ( 
SA-23157) , IFNG (SA-10807), RUNX1 (SA-11783), IL-12Rβ2 (SA- 45601) and IL-23R (SA-
50266).  GAPDH (SA-10001) and HPRT1 (hypoxanthine phosporibosyltransferase 1-SA-10030) 
were used as controls.   
The isolated cells were thawed and 400 cells/µl of Lysis Mixture was added directly to the 
cell pellet.  This was mixed 10-15 times and vortexed for 1 minute.  It was incubated at 50-
55°C (water bath) for 30 minutes.  After incubation the lysed cells were vortexed at max 
speed for 1 min and the viscosity was compared to the lysis mixture.  The lysate was stored 
at -80°C for later use.   
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The working bead mixture for the Luminex was made up as stated in the table below.   
Order of 
Addition 
Reagent 1 well (µl) 
1 Nuclease-free H20 5.2 
2 Lysis Mix 6.6 
3 Blocking reagent 2 
4 Proteinase K 0.2 
5 Capture beads (vortex 
before adding- 30sec) 
1 
6 2.0 Probe Set 5 
Total  20 
 
The working bead mixture was made up and vortexed for 10 seconds.  20µl was then 
pipetted into each well of the Hybridization Plate.  80µl lysate was added to each well of the 
Hybridization Plate that contained the working bead mix bringing the total volume of the 
well to 100ul.  To add a negative control to the plate a well containing 80ul of diluent Lysis 
Mixture was added to 3 wells.  The Hybridization plate was sealed using the pressure seal 
and incubated for 22 hours at 54°C at 600rpm.   
Pre-Amplifier Hybridization 
0.6ml of Wash Buffer Component 1 and 10ml of Wash Buffer Component 2 was mixed with 
189ml of nuclease free water.  Using a 15 ml tube, 36ul of 2.0 Pre-Amplifier was added to 
12ml of Amplifier Diluent.  This mixture was inverted several times to mix it, but it was not 
vortexed.   
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Wash Step 
The hybridization plate was removed from incubator and the temperature of the incubator 
was adjusted to 50°C.  The Hybridization Plate was centrifuged at 240xg for 1 minute at 
room temp and the plate seal was removed.  The mixture in each well was disrupted by 
pipetting up and down 5 times and transferred from the Hybridization Plate to a Magnetic 
Separation Plate.  The magnetic separation plate was used to wash the samples by inserting 
the plate into the hand held Magnetic plate washer.  The plate was locked into place and the 
magnetic beads were allowed to settle on the bottom of well for 1 minute.  The solution was 
removed from the wells by quickly inverting it over a sink and gently blotting onto a paper 
towel.  100µl of the 1xWash Buffer was added into each well and after 15 sec removed by 
quickly inverting the plate over the sink. Repeat this wash step twice more. 
Pre Amp Hybridization  
Using a 15 ml tube, 36µl of 2.0 Pre-Amplifier was added to 12mls of Amplifier Diluent to 
make up the 2.0 Pre-Amplifier Working Reagent.  100µl of this solution was added to each 
well of the Magnetic Separation Plate.  The plate was sealed with a foil plate sealer and 
removed from the Hand Held Magnetic Plate Washer.  The plate was vortexed at 800 rpm 
for 1 min at room temp to ensure beads were resuspended.  The plate was incubated for 1 
hour at 50°C with shaking at 600rpm.   
After 1 hour the plate was removed from the incubator, the seal removed and it was 
inserted into the Hand Held Magnetic Plate Washer.  The plate was washed as described 
above 
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Amplifier Hybridization  
To make up the 2.0 Amplifier Working Reagent 36µl of 2.0 Amplifier was added to 12ml 
Amplifier Diluent and mixed several times and 100µl was added to each well.  The plate was 
sealed with a foil plate sealer and removed from the Hand Held Magnetic Plate Washer.  The 
plate was vortexed at 800 rpm for 1 min at room temp to ensure beads were resuspended.  
The plate was incubate for 1 hour at 50°C with shaking at 600rpm.  After 1 hour the plate 
was removed from the incubator and the seal removed and inserted into the Hand Held 
Magnetic Plate Washer.  The plate was washed as described above. 
Hybridize Label Probe 
To make up the Label Probe Working Reagent 36µl of Label Probe was added to 12ml of 
Label Probe Diluent and was mixed several times.  10µl of this mixture was added to each 
well of the Magnetic Separation plate.  The plate was sealed with a foil plate sealer and 
removed from the Hand Held Magnetic Plate Washer.  The plate was vortexed at 800 rpm 
for 1 min at room temperature to ensure the beads were resuspended.  The plate was 
incubated for 1 hour at 50°C with shaking at 600rpm.  The plate was then removed from the 
incubator, the seal removed and it was inserted into the Hand Held Magnetic Plate Washer.  
The plate was washed as described above. 
To make up the SAPE Wash buffer in a 15ml tube 36µl of SAPE was added to 12ml of SAPE 
Diluent.  It was mixed well and protected from the light.  The wash steps from (A-B) were 
repeated but SAPE Wash Buffer was used instead of 1xWash Buffer. 
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Analysis 
130µl of SAPE Wash buffer was added to each well.  The plate was sealed with a foil plate 
sealer and removed from the Hand Held Magnetic Plate Washer.  The plate was vortexed at 
800 rpm for 1 min at room temp to ensure beads were resuspended.  The plate was then 
analysed immediately on Luminex.   
 
2.12 miRNA Screen 
To isolate miRNA from different samples total RNA was initially isolated, including the 
miRNA.  The miRNA was converted to cDNA using specific miRNA reverse transcription 
primers.  Because of the small quantity of sample, the miRNA then had to be amplified to 
have enough sample to run on the Microfluidic cards. 
 
2.12.1 RNA Isolation 
To isolate the RNA the mirVana™ miRNA Isolation Kit [Invitrogen] was used.  The starting 
material was cells isolated on the MoFlo cell sorter and then pelleted and frozen at -70°C.  
The cells were thawed and 500µl of the Lysis/Binding Buffer was added.  A dilution of 10 part 
lysate to 1 part miRNA Homogenate Additive was mixed.  The mixture was left on ice for 10 
minutes and then a volume of Acid-Phenol:Chloroform that was equal to the lysate volume 
before addition of the miRNA Homogenate Additive (500µl) was added.  This mixture was 
vortexed for 60 seconds and then centrifuged for 5 minutes at 10,000xg at room 
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temperature.  The aqueous and organic phases were separated.  The aqueous phase was 
kept while the organic phase was discarded.  To isolate the total RNA 1.25 parts of 100% 
ethanol was added to 1 part aqueous phase.  This mixture was added to a filter cartridge and 
centrifuged for approximately 15 sec at 10,000xg to pass the mixture through the filter.  To 
wash the RNA bound to the filter 700µl of miRNA Wash Solution 1 was added to the Filter 
Cartridge and centrifuged for 5~10 seconds at 10,000xg.  The effluent was discarded.  500µl 
of Wash Solution 2/3 was added to the filter and centrifuged for 15 sec at 10,000xg to pass 
the mixture through the filter.  This was repeated once more and after discarding the flow-
through from last wash the filter cartridge was placed back in the same collection tube and 
spun for 1 min at 10,000xg to remove any residual liquid from the filter.  The filter cartridge 
was transferred into a fresh collection tube and 100µl of pre-heated Elution Solution was 
added to the centre of the filter.  The filter was spun for 30 seconds at max speed to recover 
RNA.   The RNA was store at -20°C. 
To make it possible to use the maximum amount of RNA in the reverse transcription step a 
DNAclear™ Kit was used to reduce the volume the RNA was eluted in.  To equilibrate a Micro 
Filter Cartridge 30μL of cDNA Binding Buffer was added to a Micro Filter.  This was incubated 
for 5 minutes at room temperature.  The sample volume was brought to 100μL with 
Nuclease-free Water.  250μL of cDNA Binding Buffer was added to each sample, and mixed 
thoroughly by gently vortexing.  It was applied to the equilibrated Micro Filter Cartridge.  The 
column was centrifuged for 1 min at 10,000xg after which the flow-through was discarded.  
The Micro Filter Cartridge was washed with 500μL of cDNA Wash Buffer and again 
centrifuged for 1 min at 10,000xg.  The flow-through was discarded and the Micro Filter 
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Cartridge was spun for an additional minute to remove trace amounts of ethanol.  The RNA 
was eluted with 2 aliquots of preheated (55°C) Nuclease-free Water (2 x 8μL) in a total 
volume of 16μL.   The 8μL Nuclease-free Water was added to the filter and left for 2 min at 
room temperature and then centrifuged for 1 min at 10,000 x g.  This was repeated a second 
time and the double-stranded RNA was collected in the Micro Elution Tube. 
 
2.12.2 Reverse Transcription (RT) 
For this reaction 1-350ng of RNA was needed.  As I was unable to measure the RNA 
concentration I had to assume that the RNA isolation was efficient and that at least 1 ng/μL 
of RNA had been eluted.  The RT mix was made up according to the table below in a PCR 
tube. 
RT reaction Mix 
Components 
Volume for One Sample 
(µL) 
Megaplex RT primers (10x) 0.8 
dNTPs with dTTP (100mM) 0.2 
MultiScribe Reverse 
Transcriptase (50U/µl) 
1.5 
10x RT Buffer 0.8 
MgCl2 (25mM) 0.9 
RNase Inhibitor (20U/µl) 0.1 
Nuclease-free water 0.2 
Total 4.5 
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To the RT mixture 3µl of RNA was added bring the total volume for the reaction to 7µl.  The 
mixture was mixed well and spun briefly to collect the mixture at the bottom of the tube.  
The tube was incubated on ice for 5 minutes before being added to the thermo-cycler.  The 
conditions for the thermo-cycler are shown below.  Ramp Rate: 1.5°C/s 
Stage Temp Time 
Cycle 
(40 cycles) 
16°C 2 mins 
42°C 1 min 
50°C 1 sec 
Hold 85°C 5min 
Hold 4°C hold 
  
Once the reaction was finished the samples were then amplified straight away. 
 
2.12.3 Pre-amplification Reaction 
The pre-amplification reaction has a final volume of 25μL and contains 2.5μL RT product and 
22.5μL PreAmp reaction mix. 
PreAmp Reaction Mix 
Components 
Volume for one sample 
(µl) 
TaqMan PreAmp Master 
Mix (x2) 
12.5 
Megaplex PreAmp 
Primers (10x) 
2.5 
Nuclease-free water 7.5 
Total 22.5 
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The reaction mixture was made up in a PCR tube and mixed by inverting six times.  The tube 
was spun briefly and added to the thermo-cycler.  The conditions for the pre-amplification 
reaction were as follows: 
Ramp Rate: 1.5°C/s 
Stage Temp Time 
Hold 95 °C 10 min 
Hold 55 °C 2 min 
Hold 72 °C 2 min 
Cycle 
(12 Cycles) 
95 °C 15 sec 
60 °C 4 min 
Hold (inactivate enzymes) 99.9°C 10 min 
Hold 4°C hold 
 
Once the reaction was finished the tubes were briefly centrifuged and 75µl of 0.1XTE pH 8.0 
was added to each sample.  The Sample was kept at -70°C until the microfluidic cards were 
ready to be run.   
 
2.12.4 TaqMan MicroRNA Microfluidic Cards 
To run the samples on the array the PCR master mix was made up to which the amplified 
miRNA sample was added.  The mixture was made up in a 1.5ml micro centrifuge tube. 
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Component Volume for One Array (µl) 
TaqMan Universal PCR Master Mix No 
AmpErase UNG 2x 
450 
Diluted PreAmp product 9 
Nuclease Free water 441 
Total 900 
 
The tube was inverted six times to mix the reaction and briefly centrifuged.  To each port on 
the TaqMan MicroRNA Array 100µl was added.  The microfluidic card was centrifuged and 
then sealed.   
The TaqMan® Array Human MicroRNA Card v3.0A contained a total of 384 TaqMan® 
MicroRNA Assays.  The cards were run on the Applied Biosystems 7900HT Systems and 
analysed using the SDS software. 
  
CD4
+ 
T Cell Cytokine and Transcription Factor Expression  
91 
 
CHAPTER 3 
EXPRESSION OF LINEAGE DEFINING CYTOKINES AND 
ASSOCIATED TRANSCRIPTION FACTORS IN CD4+ T 
CELLS 
3.1 Introduction 
T helper lineage are often defined by the cytokines they express upon stimulation.  For 
example TH1 cells secrete IFNγ, TH2 cells secrete IL-5, IL-4 and IL-13, and TH17 cells secrete IL-
17A, while TH22 cells express IL-22.  At the start of this study there was emerging data 
demonstrating an element of plasticity in the cytokine a TH lineage could secrete.  CD4
+ cells 
in particular, but also CD8+ T cells, have been shown in certain situations to co-express 
cytokines associated with a different lineage.  Within memory T cells there are lineage 
defining transcription factors that control the expression of these cytokines as well as other 
features (e.g.  chemokine receptors) of the different lineage.   
The aims of this chapter are: 
 to investigate the co-expression of effector cytokines within CD4+ and CD8+ T cells. 
 to phenotype the expression of these transcription factors in CD4+ T cells and 
specifically in situations in which two lineage defining effector cytokines are co-
expressed.   
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T cell phenotypes were investigated using intracellular cytokine/transcription factor staining 
and flow cytometry.  These methods allowed the analysis of cytokine(s) expressed, ex vivo, 
in single cells, and gave information about the co-expression of other elements such as 
transcription factors and surface markers.   
Additionally, a method was required to isolate viable cytokine secreting cells to analyse the 
true expression of genes at a transcriptional level.  Within the literature there were many 
who were isolating TH populations based on surface markers, such as chemokine receptors, 
or were using cultured cells, both of which often gave heterogeneous populations86,99,148,196.  
In contrast this work has used cytokine capture, a method in which pure populations of ex 
vivo cytokine secreting cells were isolated.   
 
3.2 Cytokine Production by CD4+ and CD8+ Peripheral Blood T Cells 
T lymphocytes were identified using a FS and SS gate, shown in Figure 2.3.  Single cells were 
identified using a FS and pulse width gate.  To identify the proportion of T lymphocytes that 
had encountered antigen the cells were stained for a differentially spliced isoform of CD45, 
CD45RO.  CD45 is a protein tyrosine phosphatase expressed on the surface of 
lymphocytes197.  Naïve T cells express the isoform CD45RA.  Upon antigen encounter the 
exon coding for the extracellular domain of CD45 is spliced to become the shorter CD45RO 
isoform.  This shortening may allow the TcR to more readily associate with MHC29.  
Peripheral blood mononuclear cells (PBMC) were stimulated with PMA and ionomycin.  
These two reagents activate cells non-specifically and independently of TcR stimulation, 
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ensuring that all T cells are activated.  PMA activates cells by utilising the intracellular 
signalling pathways protein kinase C, while ionomycin raises intracellular calcium (Ca2+) 
levels198.  This activation stimulates cells to produce cytokines as well as inducing 
proliferation.  Brefeldin A is a naturally produced product from fungi that inhibits proteins 
transport from endoplasmic reticulum (ER) to Golgi and induces retrograde protein transport 
from the Golgi apparatus to the endoplasmic reticulum.  Addition of Brefeldin A to the PMA 
and ionomycin treated cells leads to accumulation of cytokines inside the ER, instead of 
them being released, allowing their measurement by flow cytometry. 
Within the stimulated PBMC approximately 50% of total lymphocytes expressed CD45RO, a 
marker of antigen experienced T cells (gated for CD4+ Figure 2.3 and Figure 3.1).  Without 
stimulation CD4+ T cells did not secrete detectable cytokine ex vivo (Figure 3.1 A).  The 
majority of effector cytokines were produced by the CD45RO+ fraction except IL-2 which was 
also secreted by naïve T cells (CD45RO-) (Figure 3.1 C).  IFNγ (median % of CD4+CD45RO+ 
secreting IFNγ =29.32%, range 18.74% - 40.43%), IL-5 (0.79%, 0.14%-1.32%), IL-10 (0.93%, 
0.21%-1.37%) and IL-17A (2.27%, 1.12%-3.5%) are all effector cytokines associated with 
distinct T helper lineages (Figure 3.1 A, B).  The data shows that CD4+ T cells also secreted 
IL2, IL-22, TNF-α, GM-CSF and IL-21 (Figure 3.1 C).   
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Within the CD8+ T cell compartment IFNγ and IL-17A expression (median % of 
CD4+CD45RO+IFNγ+ cells=61.62% Range=57.66%-79.14%, median IL-17+= 0.72%, range= 
0.19%-0.85%) was detected.  IFNγ was the principal cytokine expressed by CD8+ T cells, 
though it was not restricted to CD45RO+ cells, 7.88% of CD45R0- cells expressed IFNγ.  Co-
staining for IFNγ and IL-17A identified an overlap in expression within the CD8+CD45RO+ cells 
(CD4+CD45RO+IFNγ+IL-17+=0.59% Range=0.19%-0.79%, Figure 3.2 B,C). 
 
3.3 Co-staining of Transcription Factor and Cytokine Staining in CD4+ T cells 
The three human lineage defining transcription factors T-bet, GATA-3 and RORC relate to the 
lineage TH1, TH2 and TH17, respectively 
47,60,84.  Based on a matched isotype control there was 
a strong association of the TH1 cytokine, IFNγ, and transcription factor T-bet in CD4
+ T cells 
(Figure 3.3 A).  Although some cells that were negative for IFNγ expressed T-bet, the highest 
expression of T-bet appeared to be in the cells that also expressed IFNγ (T-bet MFI IFNγ+ 
=6.22, MFI IFNγ-=2.52-Figure 3.3).  Very few cells that expressed IL-5 expressed levels of T-
bet at a detectable level based on the isotype (T-bet MFI IL-5+=2.45, MFI IL-5-= 2.88).  When 
staining for T-bet in the IL-17A+ population the cytokine positive cells appeared to have an 
intermediate level of expression of T-bet (T-bet MFI IL-17+=3.99, IL-17-MFI= 2.93).  
Approximately half of IL-17A+ cells appeared to have levels of T-bet above detection of the 
isotype.  Approximately 2/3 of IL-10 secreting cells expressed T-bet to a detectable degree (T-
bet MFI IL-10+=2.73, IL-10-=2.88 - Figure 3.3 B).   
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GATA-3 had a strong association with IL-5 in CD4+ T cells (Figure 3.3 C).  There were low 
levels of GATA-3 in IFNγ+ cells compared to IL-5+ cells (GATA-3 MFI IL-5+ =1.62, IFNγ+= 1.01).  
(Figure 3.3 D).   
To confirm the T-bet expression within IFNγ secreting cells and that the T-bet staining was 
within the nucleus the Image Stream technology was used to visualise T-bet staining.  
Transcription factors work through interaction with DNA affecting the transcription of genes, 
so the co-staining of these cells with a nuclear stain will give us some confidence in the 
transcription factor antibody specificity.  The Image Stream combines the fluorescence 
sensitivity of single cell analysis of the flow cytometer and the ability to produce images of 
every cell, similar to microscopy.   The processing of the PBMC cells was similar to flow 
cytometry, apart from the addition of a nuclear stain (Po-Pro 1) to allow identification of the 
nucleus on the images.  I gated on the CD4+ population (Figure 3.4 A) and analysed the 
association of IFNγ and the co-localisation of T-bet and the nuclear stain.  Analysis of T-bet 
expression using the Image Stream showed that T-bet associated with nuclear staining and 
with IFNγ (Figure 3.4 B).  In Figure 3.4 C there are representative plots of IFNγ+ cells and their 
T-bet expression.  Within a CD4+ T cell, the nucleus takes up a large percentage of the cell 
and there was only a small amount of visible cytoplasm.  However, when you compare the 
CD4 surface staining to T-bet it was clear that the T-bet staining was not at the surface.  This 
was confirmed in Figure 3.4 E as representative images of T-bet (orange) and the nuclear 
stain (green) were overlapping, indicating nuclear localisation of T-bet (yellow).  In the IFNγ- 
population the T-bet staining appears to be less intense as compared to the IFNγ+ cells, 
which supports the flow cytometry data (Figure 3.4 D).   
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RORC is the transcription factor associated with TH17 cells.  Within the literature there was 
very little flow data on RORC expression, with the preference to analyse RORC expression by 
PCR or immunofluorescence analysis.  In ex vivo PBMC, RORC expression was not detectable 
above the matched isotype control (Figure 3.5 A).  There appeared to be a shift for the IL-17+ 
cells to have higher MFI (MFI isotype IL-17+= 0.81 MFI RORC IL-17+=1.56) than the isotype 
control in the RORC channel.  When IFNγ was co-stained with RORC there also appeared to 
be a shift of the IFNγ population compared to isotype, however this was still not to a level 
that exceeded the isotype control and the cytokine negative population also appeared to 
shift (MFI isotype IFNγ+= 0.60 MFI RORC IFNγ+=0.88).   
Analysis of the co-localisation of RORC with nuclear stain in ex vivo cells using the Image 
Stream highlighted that there were very few cells in which there was a similarity in the 
positioning of the nuclear stain and RORC (Figure 3.6 A).  The localisation of RORC appeared 
to be more cytoplasmic, (Figure 3.6 C) especially when compared to localisation of CD4 
surface staining.  The IL-17 staining was also weak (Figure 3.6 B).  This suggests that the 
RORC antibody staining, at least at this level of expression, was not specific for the nuclear 
transcription factor RORC.   
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To further check if the antibody was specific, cells were cultured in TH17 polarising 
conditions in an effort to up-regulate RORC expression in TH17 cells.  Initially, isolated total 
CD4+ T cells were cultured with anti-CD3 and anti-CD28 stimulating antibodies for 3 days to 
induce proliferation.  The stimulation was removed and the cells were allowed to rest for a 
further 4 days.  The cytokines that induce TH17 differentiation are IL-23, IL-1β and IL-6.  
Various combinations of these cytokines were added to the cell culture for the full 7 days of 
culture.  A control of no cytokines and a TH1 polarising culture (+IL-12) was used to compare 
the induction of IL-17 secreting cells.  Figure 3.7 demonstrates a representative example of a 
7 day culture of CD4+ T cells, after which they were stimulated and stained for IFNγ and IL-17 
expression.  The highest percentage of IL-17+ cells occurred with IL-1β, IL-6 and IL-23 
although it was only marginally higher than the no cytokine control.  Furthermore the 
addition of IL-23 increased the percentage of IFNγ+IL-17+ cells compared to the control 
culture, whereas the addition of IL-1β, IL-6 and IL-23 reduced this percentage.  Interestingly, 
in the cultures with IL-23 or IL-1β and IL-6 there were only approximately 14% IFNγ cells, 
whereas in the IL-1β, IL-6 and IL-23, the no cytokine control and the IL-12 culture there was 
approximately 20-25% IFNγ secreting cells.  The culture of cells with IL-12 resulted in a 
reduction of IL-17 secreting cells compared to the control.   This suggest that IL-23 is an 
inducer of IL-17 expression in total CD4+ T cells, and the addition of IL-1β and IL-6 can 
increase the percentage of IL-17 secreting cells.  IL-23 also affects the stimulation of IFNγ+IL-
17+ cells, though conversely not IFNγ single secretors.  As expected TH1 polarising conditions 
was detrimental to the induction of IL-17.          
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There were variable results within the repeats of the TH17 cultures.  Figure 3.8 A was the 
IFNγ and IL-17 expression of cultured CD4+ T cells with TREG (CD4
+CD25+) or with the TREG 
removed (bead isolated).  There was a significant increase in the percentage of IL-17 
secreting cells within this particular culture.  Approximately 9% of cells that expressed IL-17, 
approximately half of them also co-expressed IFNγ.  This is an increase of approximately 7% 
on the previous culture using the same culture conditions, but different donor.  Comparisons 
of the cultures with and without TREG highlighted that more memory T cells expressed IL-17 
when TREG were removed from the culture, although this was not limited to the IL-17 
population as the IFNγ+ and the IFNγ+IL-17+ population had increased in percentage as well 
(Figure 3.8 A).  Again, highlighting the variability obtained by using different donors, the 
cultures in Figure 3.8 B were the same culture conditions as in Figure 3.8 A.  The culture 
without TREG again showed poor IL-17 production, with only 0.81% of cells secreting IL-17.  
When TREG were added to the culture at a ratio of 1:100 (TREG:T effector cells),  this increase 
IL-17 production.  It also gave a slight reduction in the percentage of IFNγ+ cells, although not 
of the percentage of IFNγ+IL-17+ cells.  Following on from this when TREG were added at a 
ratio of 1:10 (TREG:T effector cells) there was again a reduction in the percentage of IFNγ
+ 
cells and an increase in the percentage of IL-17+ cells, although this time the percentage of 
IL-17+IFNy+ cells also were reduced.         
After culturing CD4+CD25- cells in TH17 polarising conditions for 7 days (culture from Figure 
3.9 A), RORC expression was analysed.  Over all, compared to the isotype staining, the MFI 
for RORC in IL-17 cells increased (MFI Isotype IL-17+=0.51 MFI RORC IL-17 =5.45) (Figure 3.9 
A).  However, this increase was also seen in the negative population and in the IFNγ+ cells 
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(MFI Isotype IFNγ+=0.50 MFI RORC IFNγ+ =3.95).  (Figure 3.9 A, B).  This suggests that 
although the staining for RORC was increased after culture the staining was no more specific 
after culture than before.   
 
3.4 Optimisation of Cytokine Capture Protocol      
To further analyse the phenotype of CD4+ T helper subsets a method (Miltenyi Biotech) was 
optimised in which a bivalent antibody binds to CD45 on the surface of all lymphocytes.  The 
second binding site of the antibody is for the cytokine of interest.  In these experiments two 
bivalent antibodies were used either specific for IFNγ or IL-17.  Any cytokine that is released 
from the cell will be captured on the cells surface by the antibody.  A second, fluorescently 
labelled, antibody binds to the captured cytokine and identifies a cytokine secreting cell.  
This method is described in more detail in Figure 3.10.   
Initially, to identify the stimulation agent that would provide a balance between the most 
accurate staining of the cytokine produced by each individual cell and providing a high yield 
of cells, three methods of stimulation were tested. These were Cytostim (Miltenyi Biotech), 
Staphylococcal Enterotoxin B and PMA/ionomycin.  Cytostim is a super-antigen, which was 
used at 20µl/ml, the concentration recommended by the supplier.  It stimulates a proportion 
of CD4+ T cells by crosslinking the TcR and MHC molecules independently of certain Vβ 
domains.  Miltenyi Biotech quote that approximately 75% of CD4+ T cells unregulated CD69 
after 3 hours of stimulation with Cytostim, which increases to 90% CD69+ CD4 T cells after 6 
hours.  SEB is also a super-antigen which crosslinks MHC II and TcR. PMA and ionomycin 
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activate cells non-specifically and independently of TcR stimulation, ensuring that all T cells 
are activated.   
The results of these experiments are as follows.  Cytostim gave small percentage of IL-17 and 
IFNγ secreting cells (Figure 3.11 A) in proportion to intracellular staining (Figure 3.14 D), and 
was variable between donors.   Although the staining for IFNγ and IL-17 looked clean for SEB 
and the different populations were easily identifiable, the population of cells that were 
stimulated were small, meaning they did not give enough cells after sorting.  (Figure 3.8 B).  
Using either of these stimulation types would lead to an increased chance of the populations 
not being homogeneous, especially the IL-17+.  If only a small fraction of the IFNγ+ cells are 
labelled there is more of a chance that cells expressing IL-17 and IFNγ will be labelled for 
only IL-17 and contaminate this populations.  Due to the small percentage of IL-17 cells any 
cells contaminating this population will have a greater impact on any analysis than if IL-17 
cells contaminated IFNγ population.  Using a stimulation agent, such as PMA and ionomycin, 
which increases the labelling of IFNγ cells increases the chance of getting a pure IL-17+ 
population.   
PMA and ionomycin stimulation for cytokine capture stimulated all the cells and resulted in a 
detectable percentage of cells secreted IFNγ and IL-17 (Figure 3.8 C).  A time course was 
undertaken to optimise the time for stimulation with PMA and ionomycin.  The longer the 
cells were left to stimulate the higher the percentage of IL-17 secreting cells that were 
positively labelled.  After two hours there was very little increase in the percentage of 
positive cells for IFNγ.  However, the shift of the IFNγ cytokine capture staining towards 
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higher MFI (MFI IFNγ capture 0.5hr=0.2, 1hr=0.4, 2hr=2.25, 3hr=3.98, 4hr=5.54) identifies 
false positive staining.  The shift indicates that all the negative cells not secreting cytokine 
were picking up the excess IFNγ that was being secreted by the true TH1 cells making it hard 
to identify the true TH1 cells (Figure 3.11 D).   
The protocol was optimised to remove the negative cells picking up the IFNγ on their 
surface.  After the surface cytokine staining the cells were left in Brefeldin A for 3 hours to 
prevent release of any excess cytokine. Then the cells could be intracellularly stained in an 
effort to identify true IFNγ positive cells.   
Within the protocol there was a stage during which the cells are cultured in media to allow 
IFNγ to be captured on the cell surface (Figure 3.10 C).  To investigate if it was at this stage 
that excess IFNγ in the system was staining IFNγ- cells, the cells were cultured at different 
cell densities to identify if the false positive would dilute out (Figure 3.12 A-D).  The cells that 
were cultured at different densities did not seem to make that much difference to the 
overall capture staining sensitivity.  Diluting the cells 10 fold only increased the percentage 
of true IFNγ positive cells by 1.66%, and decreased the IFNγ false positive cells by 0.35% 
(Figure 3.12 B, D).   
The surface bivalent antibody was added to the cells in suspension for 10 minutes in a small 
volume (Figure 3.10 B).  To investigate if it was at this stage the cells were picking up excess 
IFNγ the supernatant from the cells was either removed or added to un-stimulated cells to 
identify if the negative cells picked up any IFNγ.  The data showed that adding the 
supernatant to un-stimulated cells did not result in any significant false positive staining 
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(Figure 3.13 C).  Removing the IFNγ capture-antibody supernatant from the cells seemed to 
increase the true positive staining of IFNγ cells compared to the normal capture protocol 
(Figure 3.13 A, B).  There was no non-specific binding of IFNγ (e.g.to IFNγR) to the surface of 
the cells, as there was no staining of stimulated cell without the capture antibody (Figure 
3.13 D).    
PMA and ionomycin is a strong stimulus for CD4+ T cells, one of the reasons why it was so 
useful in cytokine capture.  After stimulation the protocol from the supplier states to only 
wash the cells once before proceeding with the rest of the protocol (Figure 3.10 between 
the stages of A and B).  By washing the cells three times, to try to fully remove any excess 
PMA/ionomycin, the cells no longer produced more IFNγ after this step in the protocol.  This 
was highlighted by the lack of any intracellular staining for IFNγ (Figure 3.14 A, B) but 
appeared to bring the IFNγ background staining back to the base line.   
The final stage of optimisation of cytokine capture was to check whether the washing step 
had any effect on IL-17 staining, and also to test the effects of different fluorescence 
molecules on the intensity of the staining for IFNγ.  Using an FITC conjugated secondary 
antibody led to cleaner staining than using APC as the background was reduced (Figure 3.14 
E,F).  The washing step appeared to make no difference to IL-17 staining as there was still up 
to 1.5% IL-17 secreting cells. 
  
CD4
+ 
T Cell Cytokine and Transcription Factor Expression  
112 
 
  
CD4
+ 
T Cell Cytokine and Transcription Factor Expression  
113 
 
 
 
  
CD4
+ 
T Cell Cytokine and Transcription Factor Expression  
114 
 
  
CD4
+ 
T Cell Cytokine and Transcription Factor Expression  
115 
 
  
CD4
+ 
T Cell Cytokine and Transcription Factor Expression  
116 
 
  
CD4
+ 
T Cell Cytokine and Transcription Factor Expression  
117 
 
3.5 Analysis of Co-expression of Lineage Defining Cytokines    
Multi-colour flow cytometry can stain stimulated PBMC for several different cytokines at 
once to analyse the co-expression of effector cytokines.  Furthermore, the optimisation of 
the IFNγ and IL-17 cytokine capture method allowed me to analyse the gene expression 
within small homogeneous populations of IFNγ and IL-17 secreting cells and equate it with 
the flow cytometry data.   
Using this technique there were several cytokines that were not detectably co-expressed.  
These were IL-10 and IL-17, IL-17 and IL-5 and IL-5 and IL-10 (Figure 3.15).  IFNγ appeared to 
be co-expressed with several different cytokines associated with other lineage, namely IL-5, 
IL-17A or IL-10 (Figure 3.16, 3.17, 3.18).  IFNγ and IL-5 were co-expressed by a small 
percentage of cells (IFNγ+IL-5+ median=0.09% Range= 0.1%-0.24%) (Figure 3.16 B).  The MFI 
of IFNγ was significantly reduced (p=0.006) in a cell that secretes both IFNγ and IL-5 (mean 
IFNγ MFI in IFNγ+IL-5+=66.06) compared to a single IFNγ secreting cell (mean IFNγ MFI 
IFNγ+=128.79- Figure 3.16 C).  This reduction was also found in the IL-5 MFI.  The MFI of IL-5 
was significantly reduced (p=0.015) in cells that co-expressed IFNγ and IL-5 (mean IL-5 MFI 
IL-5+=26.78) compared to cells that just secreted IL-5 (mean IL-5 MFI IL-5+=42.09-Figure 3.16 
B, C).   
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Following on from this, approximately half of the IL-10 secreting cells also co-secreted IFNγ 
(IFNγ+IL-10+ median= 0.11% range=0.01%-0.27% Figure 3.17 A, B).  However in this case the 
co-expression of IFNγ and IL-10 made no significance difference to the MFI of either 
cytokines (p≤0.05) (mean MFI of IFNγ in IFNγ+ =168.83, IFNγ+IL-10+=143.53, mean MFI of IL-
10 in IL-10+ =43.635, IFNγ+IL-10+=51.34-Figure 3.17 C).   
Co-staining for IL-17A and IFNγ gave a small but easily identifiable population of IFNγ+IL-17A+ 
cells (median=0.24% range=0.05%-0.51%, Figure 3.18 A, B).  There was a statistically 
significant decrease for IFNγ when IL-17A was co-expressed compared to single IFNγ+ T cells 
(mean MFI of IFNγ in IFNγ+ =143.72, IFNγ+IL-17+=72.36, mean MFI of IL-17 in IL-17+ =77.68, 
IFNγ+IL-17+=59.23-Figure 3.18 C).  To identify if the reduction in IFNγ was at an mRNA level 
as well as at the protein level, cytokine secreting cells were isolated using the cytokine 
capture method.  Once the cytokine secreting populations were isolated, mRNA was isolated 
from the cells and converted to cDNA.  To analyse the amount of message of each cytokine, 
qRT-PCR was undertaken.  The house keeping gene GAPDH was used to give a relative 
expression of the cytokine mRNA (Figure 3.19 A).  The lower IFNγ protein in the dual IFNγ+IL-
17+ cells was replicated at the mRNA level (Figure 3.19 B).  This showed there was no 
significant difference in the IL-17 MFI in IFNγ+IL-17+ and IL-17+ cells (Figure 3.18 C), which 
was replicated at the mRNA level (Figure 3.19 B).   
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There are 6 isoforms of IL-17, IL-17A-F.  IL-17A was expressed by CD4+ T cells with IL-17F also 
expressed, but only by a small proportion of cells.  The CD4+ T cells were analysed for IFNγ, 
IL-17F and IL-17A to identify if co-expression of IFNγ and IL-17F occurs in a similar manner to 
IFNγ and IL-17A.  Figure 3.20 A shows IL-17F was always co-expressed with IL-17A, although 
IL-17A was expressed alone.  IL-17F and IFNγ was co-expressed in a population of CD4+ T 
cells (Figure 3.20 B).  20% of cells that co-expressed IL-17A and IFNγ also co-expressed IL-17F 
(Figure 3.20 C), which was approximately the same percentage of IL-17A cells expressing IL-
17F. 
IL-21 and IL-22 have previously been described as TH17 associated cytokine before they were 
attributed to a lineage of their own116,199.  To determine how similar or different the IFNγ+IL-
17+ cells were from the IL-17+ cells, IL-21 and IL-22, as well as IL-2 and GM-CSF, were stained 
for (Figure 3.20 D).  More than 30% of both single IL-17+ and IFNγ+ IL-17+ expressed IL-21 and 
IL-22.  There was very little IL-21 or IL-22 expressing in single IFNγ+ T cells.  GM-CSF was more 
highly expressed in IFNγ+IL-17+ cells, while only 30% of IL-17+ cells and 20% of IFNγ+ cells co-
expressed these cytokines.  IL-2 was expressed in all populations, however approximately 
60% of IL-17+ and IFNγ+IL-17+ cells expressed IL-2 compared to the 40% of IFNγ+ single 
secretors (Figure 3.20 D). 
The next step was to investigate if cells that secreted two lineage defining cytokines had 
been recently activated.  This was achieved by staining for the markers CD71, which is a 
transferrin receptor that is up regulated upon activation to transport iron into the cell, and 
CD69 which plays a role in negatively regulating the activation of T cells.  CD4+ T cells 
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expressing CD45RO and CD69 (Figure 3.21 A) or CD71 (Figure 3.21 B) were isolated using the 
MoFlo cell sorter from ex vivo PBMC.  The cells could not be stimulated with PMA and 
ionomycin as this would up-regulate CD69 and CD71 expression on all cells.  The isolated 
populations were then stimulated and their expression of IFNγ and IL-17 was analysed 
(Figure 3.21).  Initially, a ratio of the percentage of IFNγ+, IL-17+ and IFNγ+IL-17+ cells in the 
CD69+ and CD69- was calculated.  The ratio for the IL-17+ and IFNγ+ populations were all 
below 1, showing that these single cytokine secreting populations were not enriched in the 
recently activated populations (Figure 3.22 A, D).  This experiment also showed that there 
was no enrichment of dual IFNγ+IL-17+ cells in the recently activated CD69+ or CD71+ 
population (Figure 3.22 A, D).  This was also the case for cells co-secreting IL-10 and IFNγ 
(Figure 3.22 B, E).  Since all the ratios for these cytokine secreting populations was less than 
1 it suggests that there was a reduction in cytokine secreting populations in CD69+ or CD71+ 
recently activated T cells. When looking at IL-5 and IFNγ expression in recently activated cells 
there appeared to be an enrichment of single IL-5 secreting cells in both the CD69+ and 
CD71+ populations, and the ratio for two out of the three replicates for IFNγ+IL-5+ in the 
CD69+ population were greater than 1 (Figure 3.22 C, F).  This result shows that dual 
cytokine secreting cells do not represent recently activated T cells.   
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3.6 Analysis of Co-expression of Lineage Defining Transcription Factors    
It is well documented that T-bet controls IFNγ secretion in CD4+ T cells47, as RORC controls IL-
17 expression84.  Flow cytometry and qRT-PCR analysis were undertaken to analyse the 
expression of these two transcription factors within the IFNγ and IL-17 secreting populations 
(Figure 3.23).  T-bet was analysed in ex vivo memory CD4+ T cells.  It showed that there was 
no significant difference in the level of T-bet protein in single IFNγ+ cells (median % T-bet+= 
81.27), compared to IFNy+IL-17+ cells (median % T-bet+=73.92).  There was a trend for a 
decrease in the mRNA levels of T-bet in IFNy+IL-17+ compared to IFNγ+ cells, however this 
was not significant.  There was a significant difference in the protein and mRNA levels of T-
bet between IFNγ+ and IL-17+ T cells (p=0.0156 - Figure 3.23 A, C).   
RORC protein analysis on in vitro cultured CD4+ T cells showed a significant reduction in the 
levels of RORC in IFNγ cells (median % RORC+ = 32.8%) compared to both IFNγ+IL-17+ and IL-
17+ T cells (median % RORC+ = 69.87%, 69.38% respectively).  The levels of RORC, both 
protein and mRNA, between IFNγ+IL-17+ and IL-17+ T cells were not different (Figure 3.23 B, 
D). 
Further protein analysis of T-bet was undertaken in IFNγ cells co-expressing IL-5 or IL-10.  
Figure 3.24 B and C highlights that even when IFNγ was co-expressed with other lineage 
defining cytokines, there was no significant difference in the levels of T-bet expressed.  This 
was also the case for GATA-3 when IL-5 was co-expressed with IL-5.   
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3.7 Discussion 
In this chapter it has been demonstrated that IL-17 can be co-secreted with IFNγ, consistent 
with published data from several groups1,144,145.  A reduction in the amount of IFNγ being 
produced by the IFNγ+IL-17+ cells compared to single IFNγ secreting cells has been identified 
in this work.  The data within this chapter supports the literature 77,116  that these cells co-
express both lineage defining transcription factors, RORC and T-bet, and are a stable 
phenotype.   Dual secreting cells are not recently activated cells, suggesting that the co-
expression of two cytokines such as IFNγ and IL-17 is not a transient phenotype.  IFNγ+IL-17+ 
cells express IL-17A, IL-17F, IL-22 and IL-21 to a similar degree to TH17 cells, but reduced IFNγ 
per cell, suggesting that these cells have a phenotype closer to a TH17 cell than a TH1.  This 
concept is supported in the literature1,144,200.    
 
3.7.1 Similarities between TH17 Cells and IFNγ
+IL-17+ Cells 
TH17 cells have been implicated in several autoimmune conditions.  Additionally, JIA
145 and 
Crohns disease1 patients have CD4+ T cells that co-express IFNγ and IL-17 at higher 
frequencies within affected tissues, compared to peripheral blood control cells.  Within JIA 
joints the percentage of cells that expressed CD161, IFNγ and IL-17 correlate with 
parameters of disease activity suggesting these cells were involved in the disease process.   
Within an inflammatory environment GM-CSF is thought to be a powerful inflammatory 
mediator released by TH17 cells in both health and disease.  It is thought to play a role in the 
disease pathogenesis in MS173,201,202.  It has been shown in this work that three populations 
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of CD4+ T cells, IFNγ+, IFNγ+IL-17+ and IL-17+, have the ability to secrete GM-CSF.  However, a 
higher percentage of IFNγ+IL-17+ and IL-17+ cells secreted GM-CSF compared to IFNγ+ cells.  
This identifies a similarity in the two populations (IFNγ+IL-17+ and IL-17+).   
CD4+ T cells in mice that co-secrete IFNγ and IL-17 have been shown to develop from TH17 
cells that had become responsive to environmental IL-12 (i.e.  expressed IL-12R)144.   In 
humans CD161+IL-17+IFNγ- cells cultured in synovial fluid (SF) from JIA patients acquired the 
ability to produce IFNγ.  CD161+IL-17+IFNγ- cells cultured with SF from these patients, along 
with an antibody to neutralise IL-12, resulted in reduced expression of IFNγ.  This suggests 
that in this pathogenic environment IL-12 has the ability to switch on IFNγ production in 
TH17 cells, and this plasticity in TH17 cells is a physiological phenomenon 
145.  Conversely, TH1 
could not be converted to switch on IL-17 production in TH17 polarising conditions.  This 
information suggests that IFNγ+IL-17+ T cells may be more closely linked to TH17 cells than 
TH1 cells.   
This work shows that IFNγ+IL-17+ cells can co-express other TH17 related cytokines, IL-17F, IL-
22 and IL-21 to a similar degree to IL-17+ cells and to a greater extent than IFNγ+ cells.  
Annunziato et. al 1 also showed other similarities between IFNγ+IL-17+ cells and TH17 cells by 
demonstrating that human clones of IFNγ+IL-17+ cells maintained the ability to proliferate  in 
the presence of TREG suppression.  IFNγ
+IL-17+ could also aid B cell class switching and had 
low cytotoxic potential similar to TH17 cells 
1.   
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3.7.2 T-bet and RORC Expression in IFNγ+IL-17+ Cells 
The results shown suggest that IFNγ+IL-17+ cells have a reduced ability to secrete IFNγ 
compared to single IFNγ+ cells, whereas they are able to secrete a similar level of IL-17 to 
single IL-17+ cells.  Furthermore, there is a reduction in T-bet levels in IFNγ+IL-17+ cells 
compared to IFNγ+ cells, although this did not reach significance.  There is a strong RORC 
signal within IFNγ+IL-17+ cells.  If these cells had developed from TH17 cells the RORC 
transcriptional profile would be well established. 
Sustained stimulation of cells by IL-12 plays an important role in the development of TH1 
cells203.  As mentioned IL-12 also plays a role in IFNγ induction in TH17 cells, therefore the 
level of IL-12R expression could play a vital role in T-bet and IFNγ induction in these TH17 
cells.  The literature shows that on IFNγ+IL-17+ clones there was a similar IL-12R expression 
to IL-17+ cells1.  However, Lexberg et al 143 have revealed in mice that culturing cells makes 
TH17 cells more likely to switch on IFNγ, so using clones may not give us a clear idea of the 
true expression of IL-12R in vivo on these cells.  In equal measures, IL-23 is important for 
maintenance of a TH17 phenotype so the balance between signals from IL-12 and IL-23 may 
play an important role in the phenotype of IFNγ+IL-17+ cells.   
Transcriptional mechanisms have been identified in which the TH1 phenotype can suppress a 
TH17 profile.  T-bet has been shown to suppress RORC activity by interaction with RUNX1.  
Blocking RUNX1 mediated transactivation of RORC.  When RUNX1 was overexpressed in T-
bet expressing TH17 cells, then IL-17 expression was restored
137.  Conversely, there have 
been no mechanisms identified for TH17 cells to suppress T-bet and the TH1 profile.  The 
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emergence of miRNAs offers a potential mechanism.  miR155 has been identified as playing 
a role in TH17 and TH1 induction in mice
192, and miR-29ab1 has been shown to be involved in 
a negative feedback loop for T-bet and IFNγ expression191.  These are potential candidates 
that may be controlling IFNγ and T-bet expression in IFNγ+IL-17+ cells. 
 
3.7.3 Are Dual Cytokine Secreting Cells a Transitional Phenotype Induced by 
Recent Activation? 
One hypothesis was that IFNγ+IL-17+ cells acquired the ability to secrete IFNγ after re-
activation, and that the ability to co-express IFNγ was therefore a transient phenotype 
associated with TcR activation.  To test this hypothesis the recent activation status of 
IFNγ+IL-17+ cells was analysed.  The CD4+ T cells that secrete IFNγ and IL-17 were not 
enriched in recently activated populations of CD69+ or CD71+.  Furthermore, it was later 
shown Annunziato et al.  that these cells have a stable phenotype1,  as the cells could be 
cultured and cloned.  The fact that these cells up-regulate T-bet suggests that this phenotype 
is controlled at a transcriptional level.  Identification of epigenetic alterations in TH17 cells 
after IL-12 treatments suggest that IFNγ production by these cells may be a heritable, stable 
phenotype204.   
There did appear to be an enrichment of IL-5 and IFNγ+IL-5+ secreting cells in the CD69+ and 
CD71+CD45RO+ population.  In the individual donors this may be specific activation of TH2 
cells due to a recent allergic response or vaccination.  This finding would need to be 
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investigated further in healthy and atopic subjects, and in a controlled study following 
vaccination and identification of antigen-specific cells.   
When comparing the cytokine production in recently activated and non-activate CD4+ T cells 
the ratios (Figure 3.22) were less than one, with the exception of IL-5.  This result suggests 
there is a reduced cytokine production in the recently activated populations.  This may mean 
that recently activated populations, CD69+ or CD71+, are refractory to PMA/ionomycin 
stimulation that normally induces production of IFNγ, IL-10 and IL-17.  An alternative 
explanation may be that the cells are in a proliferative state and produce less inflammatory 
cytokines and more IL-2.  CD69+ and CD71+ cells may have been proliferating at the time of 
stimulation, though the levels of IL-2 were not measured in this experiment.  
If the cells are refractory to stimulation this may have consequences for the analysis of 
cytokine production using PMA/Ionomycin stimulation.  There may be other T cell 
populations present that, although not still expressing CD69 or CD71, may be refractory to 
producing cytokines following a relatively recent activation.  
A recent paper by Sallusto et al. stimulated antigen specific CD4+ TH17 cell
 clones with 
antigen and analysed their cytokine production over a number of days.  This highlighted that 
when T cells were specific for an antigen from C. albicans the cells produced both IFNγ and 
IL-17A.   However when the T cells were specific for an antigen from S. aureus  they 
produced IL-17 but around the day 5 mark transiently down regulated expression and up 
regulated IL-10 production147.  The CD69+ or CD71+ cells may be in this transient phase of 
cytokine down-regulation, which brings into question CD4+ T cell plasticity.  It will be 
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important in the future to identify if the dual cytokine production is a transient phenomenon 
or a committed lineage.  It may also be possible that there cells that are committed to a dual 
phenotype (e.g. TH1/TH17) may at some point transiently down regulate one cytokine and 
appear to be a single cytokine secreting cell.    
 
3.7.4 Cells that Secrete Both IFNγ and IL-5  
In mice lymphocytic choriomeningitis virus specific TH2 cells were stable when cultured in 
TH1 polarising conditions, but they could be re-programmed to secrete IFNγ upon re-
activation with LCMV.  This phenotype was maintained over several months in culture.  This 
work shows CD4+ T cells that were IFNγ+IL-5+, and expressed T-bet and GATA-3 protein to a 
similar level as single IFNγ+ and  IL-5+ cells respectively.  Also, the amount of IFNγ and IL-5 in 
cells where they were co-expressed was significantly lower than single secretors.  As I have 
shown that IFNγ+IL-5+ cells co-express T-bet and GATA-3, this might suggest a level of 
competition in the transcriptional profile of these cells.  These two lineage defining cytokines 
have been shown to compete at certain genes, including the IFNG and IL4 gene135.   
 
3.7.5 CD8+ T cell Cytokine Production  
As expected the vast majority of CD8 T cells secreted IFNγ, apart from the small but 
detectable Tc17 cells.  The Tc17, IL-17 secreting cells CD8+ T cells, were within the CD45RO+ 
population, showing Tc17 is not contained within the TEMRA population.  Within mice Tc17 
expressed CCR6, which was needed for the recruitment to the lungs205, as well as CXCR3.  
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The double secreting IFNγ+IL-17+ CD8+ T cells are more similar to Tc17 than conventional 
CD8+ T cells as neither population expressed lytic enzymes.  Again, in mice there are 
similarities in the development of Tc17 and TH17 cells, with STAT-3 activating cytokines being 
important in their induction, and RORγt being up-regulated 40,41. 
 
3.7.6 Cytokines Not Co-expressed in CD4+ T cells 
The co-expression of several cytokines was not detected.  IL-5+IL-10+ cells and IL-10+IL-17+ or 
IL-5+IL-17+ cells could not be detected in this study.  In humans TH2 cells can, under TH17 
polarising conditions, be promoted to secrete IL-17.  The IL-17+TH2 cells in humans were 
isolated based on CRTH2 and CCR6, and expressed RORC.  These cells were at an increased, 
but low, frequency in patients with atopic asthma206.  TH2 cells as well as secreting IL-5 also 
can co-secrete IL-4 and IL-13.  Although the literature identified that the CCR6+CRTH2+ cell 
also can secrete IL-5 (using ELISA), the cells were identified based on the co-secretion using 
flow cytometry of IL-4 and IL-17.  The overlap of IL-4, IL-5 and IL-13 within TH2 cells has been 
shown to not always be homogeneous207.  This suggests that if IL-4 had been stained for in 
this study there might have been some overlap with IL-17. 
In naïve human T cells that have been primed with Staphylococcus aureus pulsed monocytes, 
a reciprocal production of IL-17 and IL-10 is seen.  TH17 cells are induced by the IL-1β, IL-6 
and IL-23 produced by the S.aureus pulsed monocytes, however around 5 days after re-
activation the cells down regulate IL-17 and RORC expression. Instead up-regulate IL-10 
cytokine which is thought to be dependent on IL-2 activation of STAT-5 via CD25147,208.  This 
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suggests that in an infectious environment there may be situations in which TH17 cells can 
transiently co-express low levels of IL-10.  This would support the flow data in Figure 3.15 A 
that shows these cells are not detectable in a healthy individual.    
 
3.7.7 TH17 Cultures 
Within the TH17 polarising cultures that were used there was a significant amount of 
variability in the percentage of IL-17 secretion obtained.  Each experiment used different 
donors and was done on different days, though the culture conditions were kept the same.  
The activation strength via the TcR can make a difference to TH17 induction.  Using a low 
stimulating environment, such as low numbers of CD3/CD28 beads, leads to significantly 
more TH17 induction.  High activation leads to induction of FoxP3, transforming growth 
factor β–latency-associated peptide and inability of NAFTc1 (nuclear factor of activated T 
cells 1) to bind to the IL-17 promoter101.  Within these experiments the amount of 
stimulation occurring via CD3/CD28 antibodies was not investigated.   
Furthermore, by using total CD4+ T cells it was not clear if TH17 cells were being induced or if 
there was an expansion of a pre-existing TH17 population.  If within the cultures a pre-
existing population of TH17 cells was being expanded, and there was a difference in the 
starting population of TH17 cells of each donor, this could account for some of the 
differences in percentage of TH17 cells.  Several groups have used antigen pulsed APC to 
induce TH17 from naïve T cells which also would increase the yield of IL-17 producing cells
147. 
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TREG cells have a reduced suppressive effect on TH17 cells 
1,209.  Interestingly, within the 
cultures when TREG were titrated in at different ratios with effector cells, there was a 
relationship between IFNγ and TH17 production.  With more TREG added there were less IFNγ 
secreting cells, and more cells secreting IL-17.  Although this was only repeated once this 
supports TREG (CD25
+) being unable to suppress TH17 cells.  Additionally, this could be due to 
the suppressive effect of TREG on the TH1 cell proliferation, resulting in less TH1 cells, and less 
IFNγ to suppress TH17 differentiation.   
In mice, due to the high level of TGF-β produced, TREG can induce IL-17 production in CD25
- T 
cells in the presence of IL-6210.  Furthermore, the same TREG cultured in IL-6 rich environment 
are induced to secrete IL-17 themselves211.  Within a human system in the presence of IL-2, 
IL-15 and IL-1β TREG cells can start to secrete IL-17 and acquire CCR6 expression
212.  The 
cultures shown in Figure 3.8  were not stained for FoxP3 or CCR6 so it cannot be determined 
how much the TREG added to the IL-17
+ cells. 
  
3.7.8 Cytokine Capture Purity 
The cytokine capture protocol allows isolation of pure cytokine secreting cells, which have 
been used within the literature by several groups143,213,214.  Using PMA and ionomycin to 
stimulate these cells, I was able to stimulate the whole population.  However, the 
percentage of cells that were captured did not equate to the intracellular stained cells.  This 
means that there are some cells that have either been missed or mis-labelled.  The only 
population that might be contaminated to any degree would be the IL-17 cells.  If IFNγ+IL-17+ 
CD4
+ 
T Cell Cytokine and Transcription Factor Expression  
141 
 
cells were only labelled with IL-17, then this will contaminate the IL-17 population to a larger 
degree than if only IFNγ is picked up on the cell.  The data for IFNγ gene expression levels 
gave only a very small signal in the single IL-17 population and the error bars were small.  
This result suggests only a small level of contamination of IFNγ expressing cells in the IL-17 
population.   
Several papers that use cytokine capture to isolate IL-17 secreting cells may suffer from this 
contamination due to inappropriate stimulation.  For example, when using cytokine capture 
Unutmaz et al. stimulated their cells with anti-CD3 and anti-CD28 antibodies to isolate 
CCR6+IL-17+ and CCR6+IL-17- cells, only picking up a small percentage of IL-17 secreting cells.  
It is not possible to completely rule out that there was contamination of the CCR6+IL-17-
populations with TH17 cells.   They go on to conclude that γ-chain cytokines can induce IL-17 
expression in the CCR6+IL-17- population. They may just be expanding an already existing 
population of IL-17 secreting cells that were not detected by the cytokine capture method.  
In summary, the studies in this chapter have documented a stable population of cells that 
co-express IFNγ and IL-17 that retain features more similar to TH17 cells.  These cells have a 
strong RORC expression, and this TH17 profile may be playing a role in maintaining a lower 
IFNγ production within the cell.   
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CHAPTER 4 
PHENOTYPIC AND FUNCTIONAL FEATURES OF 
CCR6+IFNγ+ CELLS 
4.1 Introduction 
A fate-mapping model in mice has shown that cells that initially secreted IL-17 became single 
IFNγ secreting cells.  In humans there is no direct evidence this can happen.  However there 
is a population of CD161+TH1 cells that express RORC.  This information led to the hypothesis 
that these CD161+TH1  cells are differentiated from TH17 cells
105,213.   
Both CD161 and CCR6 can be used as a marker for TH17 cells.  CCR6 functions as a 
chemokine receptor, giving the T cell the potential to migrate into tissues expressing CCL20.  
CD161 is expressed on NK cells and the interaction of CD161 and its ligand LLT1 inhibits NK 
cell functions.  The function of CD161 on T cells is less clear though it is thought to play a role 
in their co-stimulation7.  
CCR6 plays an important role in the initial wave of migration of inflammatory T cells into the 
CNS in multiple sclerosis.  This led to the question of whether in multiple sclerosis there is a 
populations of CCR6+TH1 cells and if they also had characteristics of TH17 cells  
The aims of this chapter are: 
 To investigate the relationship between CCR6 and CD161 and IFNγ in healthy 
controls. 
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 To characterise the phenotype of CCR6+TH1 cells in comparison to classical TH1 and 
TH17 cells. 
 To investigate if CCR6+TH1 cells are present in the blood of and CSF of MS patients.    
 
4.2 CCR6 and CD161 Expression in CD4+ Memory T cells 
Flow cytometry was used on ex vivo PBMC to investigate the relationship of the TH17 
associated markers, CCR6 and CD161, and the effector cytokines IFNγ and IL-17.  CCR6, the 
chemokine receptor associated with TH17 cells, is often used in cultures to enrich for TH17 
cells.  CD161 is considered a TH17 marker as all CD4
+CD161+ cells from umbilical cord blood 
(UCB) can be converted into IL-17+ cells85.  The CCR6 staining needed to be optimised as 
upon stimulation with PMA and Ionomycin the CCR6 expression was down regulated.  It was 
noted that if the cells were pre-stained for CCR6 antibody both before and after stimulation 
(both at room temperature), the down regulation of CCR6 was not observed (Figure 4.1 A).   
The vast majority of IL-17A secreting memory CD4+ T cells expressed CCR6 (Figure 4.1 B). 
There was a high expression level of CCR6 on these cells (Figure 4.1 C).  Approximately 25% 
of IFNγ secreting memory CD4+ T cells expressed CCR6.  It was noticeable that the IFNγ MFI 
on CCR6+ cells appeared to be reduced (MFI of IFNγ in CCR6-= 3.54 CCR6+= 3.18).  The CCR6 
expression on IFNγ+ cells was reduced compared to the IL-17+ and IFNγ+IL-17+ cells (Median 
CCR6 MFI for: IFNγ+=4.69, IL-17+=14.51, IFNγ+IL-17+=10.95) although this was not a 
significant difference (p>0.05).  Cells that expressed IFNγ and IL-17 together expressed CCR6 
to a similar MFI to single IL-17 expressing cells (Figure 4.1 C). 
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Interestingly, when using this antibody and staining method, not all IL-17+ expressing CD4+ T 
cells expressed CD161.  Approximately 35% (median % CD161-IL-17+=35.44%) of the IL-17+ 
cells did not express CD161.  There was a large percentage of IFNγ+ cells that expressed 
CD161 (median=31.67%, range=7.28%-38.81%).  The CD161+IFNγ+ cells expressed a higher 
amount of IFNγ per-cell (IFNγ MFI= 4.54) than the CD161- cells (MFI=2.90) (Figure 4.1 D). 
To identify the crossover of CCR6 and CD161 in the contribution of IL-17 secreting cells, ex 
vivo PBMC were stained for CCR6 and CD161 as well as CD4 and CD45RO.  For one donor of 
CD4+CD45RO+ cells the four different populations based on CCR6 and CD161 expression were 
isolated using the MoFlo cell sorter.  The isolated cells were stimulated and stained for the 
expression of IFNγ and IL-17 (Figure 4.2).   
The results from this single experiment showed (Figure 4.2 B) that the CCR6+CD161+ and 
CCR6+CD161- populations were enriched for IL-17+ cells with respectively 14.9% and 7.95% of 
each population expressing IL-17.  Interestingly, the CCR6-CD161+ population did not express 
a substantial number of IL-17 secreting cells.  There were no IL-17 cells in the CD161-CCR6- 
population.  There were IFNγ secreting cells in all 4 populations.  The largest enrichment of 
IFNγ cells was in the proportion of CCR6-CD161+ with 64.76% of the cells secreting only IFNγ.  
The IFNγ MFI for the CD161+CCR6- population was a great deal higher than the IFNγ MFI for 
both the CCR6+ populations and the CCR6-CD161- population.  There was an enrichment of 
IFNγ+IL-17+ cells in both the CCR6+CD161- and CCR6+CD161+ populations.   
It has been shown in the literature that CD161+IFNγ+ cells express RORC at the 
transcriptional level105,213.  After identifying that all the IL-17 cells were within the CCR6 
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population and that there was a population of CD161+CCR6- cells that only expressed IFNγ, it 
was decided to reconfirm this finding.  CD161+ cells were isolated based on IFNγ and IL-17 
using cytokine capture. The gene expression of IFNγ, IL-17, T-bet and RORC were analysed in 
each population, relative to GAPDH. (Figure 4.3 A-D).   
The highest expression of the IFNγ gene was in the CD161+IFNγ+ cells, with a reduced but 
substantial expression in the CD161-IFNγ+ cells.  Similar to results in Chapter 1 (Figure 3.19 
B), the dual CD161+IFNγ+IL-17+ cells expressed lower levels of IFNγ and there was no 
detectable level of IFNγ gene expression in the CD161+IL-17+ cells (Figure 4.3 A).  There was 
a detectable level of IL-17A gene expression in the CD161+IL-17+ and CD161+IFNγ+IL-17+ 
populations (Figure 4.3 B).  There was no detectable IL-17A gene expression in the 
CD161+IFNγ+ and CD161-IFNγ+ cells, confirming expression detected at the level of protein.   
The gene expression levels for T-bet were intriguing due to the similarities in the 
CD161+IFNγ+, CD161+IFNγ+IL-17+ and CD161+IL-17+ cells.  CD161-IFNγ+ cells expressed the 
highest levels of T-bet (Figure 4.3 C).  There was considerable RORC expression in the 
CD161+IL-17+ and CD161+IFNγ+IL-17+ cells. There was equally low level of RORC in the 
CD161+IFNγ+ and CD161-IFNγ+ cells (Figure 4.3 D).  These results do not agree with published 
data. 
This data lead to the conclusion that CD161 was not specific enough in these experiments to 
identify IL-17 secreting cells and cells that expressed a ‘TH17’ gene expression profile.   
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4.3 CCR6+TH1 Cells Express the Genes RORC, IL-23R, IL4I1 and IL-12Rβ2 
A similar process of cytokine capture and cell sorting  was undertaken using CCR6 to identify 
if it made any difference which marker was used to identify TH17 cells.  The cells were 
stained for CCR6 and cytokine capture was used to identify the IFNγ and IL-17 secreting cells 
(Figure 4.4 A).  The MoFlo cell sorter was used to isolate the cells which were then analysed 
for the gene expression of IFNγ, IL-17, RORC and T-bet, relative to GAPDH.  There was a 
detectable level of IFNγ in all three IFNγ+ populations, and although not statistically 
significant there was a reduction in the IFNγ gene expression in CCR6+IFNγ+IL-17+, compared 
to CCR6+IFNγ+ and CCR6+IFNγ- cells.  This was comparable to results in the Chapter 1 (Figure 
3.19 B).   
In Chapter 1 no difference was identified in IL-17 mRNA levels between IL-17+ and IFNγ+IL-
17+ cells.  The data in this chapter however identified a reduction in the level of mRNA for IL-
17 in cells that co-expressed CCR6+IFNγ+IL-17+ compared to single CCR6+IL-17+ cells (Figure 
3.19 B).  This reduction was not statistically significant.  There was detectable expression of 
T-bet in all four populations. The T-bet mRNA expression was not significantly different in 
any population, though the highest level was in the CCR6+IFNy+IL-17+ and CCR6+IFNy+ cells, 
and there was a reduced level in CCR6-IFNγ+ cells.    
In Figure 4.4 D there was a slight increase in the expression level of T-bet in CCR6+IFNγ+ 
compared to CCR6-IFNγ+ cells.  From ex vivo PBMC the protein expression of T-bet in CCR6+ 
and CCR6- cells was analysed.  Figure 4.5 demonstrates that there was no significant 
difference in the T-bet expression at the protein level between CCR6+IFNγ+ and CCR6-IFNγ+ . 
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The principal difference when looking at the CCR6+IFNγ+ expression data, compared to the 
CD161+IFNγ+ expression data, was that RORC was detectable in the CCR6+IFNγ+ population. 
The RORC expression level in CCR6+IFNγ+ cells was detectable to a similar level to 
CCR6+IFNγ+IL-17+ and CCR6+IL-17+ cells.  In addition there was a significant difference in 
RORC expression in the CCR6+IFNγ+ cells compared to the CCD6-IFNγ+ cells (p=0.0067).  More 
gene expression was undertaken to identify if the CCR6+IFNγ+ cells expressed any other 
characteristics of TH17 cells.  
When using cytokine capture only a small number of cells can be isolated from large 
volumes of blood.  The use of qRT-PCR would only have allowed investigation of a few TH17 
related genes.  A novel method of Multiplex Gene Expression Assay using Luminex 
technology was tried.  This method measured direct RNA quantity so no reverse 
transcription was required. It also reduced the loss of RNA material through inefficient 
conversion to cDNA.  The process used luminex beads with a specific capture probe for the 
RNA sequence of interest.  Once the RNA was captured the sequence was labelled and there 
was a series of signal amplification steps (using streptavidin phycoerythrin - SAPE) to allow 
detection of the quantity of RNA for the gene expressed.  Each bead has a second distinct 
fluorochrome signature to allow detection of the different genes of interest.  As all the beads 
can be put in one well of an analysis plate less material was needed.  In principle up to eighty 
target genes can measure per well. 
Eight genes of interest were initially chosen to test the luminex technology; RORC, T-bet, IL-
17A, IFNγ, IL-17F, RUNX1, IL-12Rβ2 and IL-23R.  RUNX1 was chosen as it is known to interact 
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with RORC to aid IL-17 expression. T-bet is known to bind RUNX1 to suppress RORC 
activation137.  Finally, as IL-12 and IL-23 responsiveness is important for TH1 and TH17 
induction respectively, IL-12Rβ2 and IL-23R were chosen.  IL-12Rβ2 was chosen as this 
subunit of IL-12R is up regulated by IFNγ, while IL-12R1 is constitutively expressed by T cells.   
Figure 4.6 shows the experimental triplicates of the gene of interest relative to a reference 
gene (delta MFI of the SAPE signal).  Although all the genes gave a signal, there was a large 
variation in the triplicates resulting in large error bars. This was especially noticeable for the 
smaller CCR6+IL-17+ and CCR6+IFNγ+IL-17+ populations.  There were some similar patterns for 
T-bet, RORC, IL-17A and IFNγ compared to previous qRT-PCR data.  IL-17A and IL-17F 
expression was found in both CCR6+IL-17+ and CCR6+IFNγ+IL-17+ populations as expected 
(Figure 4.6 A, B) as was IFNγ (Figure 4.6 C).  RORC was detectable in CCR6+IFNγ+ cells, 
alongside CCR6+IL-17+ and CCR6+IFNγ+IL-17+ populations (Figure 4.6 E).  Using this method 
RUNX1 appeared to be expressed in all subsets (Figure 4.6 F).  The error bars for IL-12Rβ2 
and IL-23R were too large to make any firm conclusions about their expression.  Overall the 
method was not consistent.  Using a different control gene, HPRT, gave very different results 
(not shown).  This suggests a level of inconsistency in the experimental results.  Several 
genes that were probably important for TH17 and TH1 profiling were identified and qRT-PCR 
was used again to identify any difference in the CCR6 expressing populations.   
IL-12Rβ2, IL-23R, IL-1R1 (IL-1 receptor, type 1) and IL4I1 (interleukin 4 induced 1) were 
identified in the literature as differentially expressed in TH1 cells compared to TH17 cells
105.  
IL-1R1 has been shown to be related to the ability of a CD4+ T cell to secrete IL-17103.  IL4I1 is 
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a phenylalanine oxidase that is thought to be only expressed on TH17 cells and reduces the 
cells ability to proliferate104.   The expression of these genes in CCR6+ populations was 
investigated using qRT-PCR relative to GAPDH expression.  IL-12Rβ2 was expressed to the 
highest degree in the CCR6+IFNγ+ cells.  There was low expression in the other three subsets, 
with the lowest expression in the CCR6+IFNγ+IL-17+ subset (Figure 4.7 A).  IL-23R expression 
was only detectible in CCR6+IL-17+ cells and a low but detectable expression in CCR6+IFNγ+ 
cells (Figure 4.7 B).  IL-1R1 was expressed in both CCR6+IL-17+ and CCR6+IFNγ+IL-17+ subsets, 
although on the CCR6+IFNγ+IL-17+ cells the expression was lower (Figure 4.7 C).  IL4I1 was 
expressed in all three CCR6+ subsets, although with lower expression within the CCR6+IFNγ+ 
subset (Figure 4.7 D). 
 
4.5 TH17 Related Cytokine Expression in CCR6
+TH1 Cells 
IL-17F, IL-22 and IL-21 are all TH17 related cytokines and are expressed at a higher frequency 
in cells that expressed IL-17A.  To identify if any of these cytokines were more highly 
expressed in the CCR6+IFNγ+ populations, PBMC were stimulated and stained for these 
cytokines, as well as IFNγ, IL-17 and CCR6.  Approximately 30% (CCR6+ IFNγ+IL-17+ 
median=28.57%, CCR6+IL-17+ median=33.05) of the CCR6+IL-17+ and CCR6+IFNγ+IL-17+ co-
expressed IL-17F, whereas there was very low expression of IL-17F by CCR6+IFNγ+ and CCR6-
IFNγ+ cells  (Figure 4.8 A).  This was also the case with IL-22 (CCR6+IFNγ+IL-17+ 
median=32.46%, CCR6+IL-17+ median=17.20%) (Figure 4.8 B) and IL-21(CCR6+IFNγ+IL-17+ 
median=30.05%, CCR6+IL-17+=16.92% - Figure 4.8 C).   
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GM-CSF, IL-2, IL-5 and IL-10 expression was also analysed (Figure 4.9) to identify if there 
were any other similarities or differences in the other cytokines these populations secreted. 
GM-CSF was expressed across the board at a similar percentage in three of the populations.  
There was an increase in the percentage to 63.77% (median) in CCR6+IFNγ+IL-17+ cells 
(Figure 4.9 A).  The expression of IL-2 was uniform in all populations (Figure 4.9 B) and there 
was very little detectible expression of IL-10 (Figure 4.9 C) and IL-5 (Figure 4.9 D) in any of 
the populations.   
 
4.6 CCR6+TH1 Cells Express CXCR3 to the Same Level as CCR6
-TH1   
CCR6 is a chemokine receptor that gives the cells the potential to migrate towards CCL20 
(also known as Macrophage Inflammatory Protein-3).  As mentioned before CCR6 is 
associated with TH17 cells while CXCR3 is a chemokine receptor associated with TH1 cells.  
Stimulated PBMC were co-stained with CCR6 and CXCR3, alongside IFNγ and IL-17 to identify 
if there was any difference in the expression of CXCR3 in CCR6+IFNγ+ cells compared to CCR6-
IFNγ+ cells.  Figure 4.10 A shows the strong co-association of IFNγ and CXCR3.  There was 
also a small subset of IL-17 secreting cells that had high expressed CXCR3, although the 
majority of cells had low CXCR3 expression.  There was a relatively even split of memory 
CD4+ T cells expressing CCR6 and CXCR3, with approximately 18% of cells co-expressing both 
chemokine receptors (Figure 4.10 B).  Figure 4.10 C shows representative plots gated on the 
CXCR3 and CCR6 expressing populations.  When gating on CCR6+ cells that do not express 
CXCR3, there was very little IFNγ expression.  There was an enrichment of IL-17 secreting 
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cells, although a large proportion of cells do not secrete either cytokine.  When gated on 
CXCR3+CCR6+ cells, there was noticeably more IFNγ secreting cells, cells expressing IL-17 
alone, and IL-17 with IFNγ.  The CXCR3+CCR6- population produced IFNγ or were IFNγ-IL-17-.  
Figure 4.10 D and E highlights that the majority of both CCR6+ and CCR6- IFNγ secreting cells 
expressed CXCR3, and to a similar level per cell.  Approximately 60% of the CCR6+IFNγ+IL-17+ 
cells expressed CXCR3, although at a lower level than single IFNγ secreting cells.   
 
4.7 CCR6+TH1 can Migrate Towards CCL20  
The levels of CCR6 expressed on CCR6+IFNγ+ cells was reduced (Figure 4.1 B) compared to IL-
17 expressing cells.  To investigate if this made a difference to the migration of CCR6 
expressing IFNγ cells, compared to IL-17 cells, a migration assay using a trans-well plate was 
set up.  Initially, to test if CCR6+ cells could be isolated before the migration assay, total CD4+ 
T cells were either stained for CCR6 or left unstained.  These were added to the top well of 
the transwell plate, while CCL20 was added to the bottom well.  A control well in which no 
CCL20 was added to the bottom well was also constructed.  After the cells were collected 
and stimulated for IFNγ and IL-17 expression the percentage migration was calculated for 
the total cells and the individual cytokine secreting populations.  Figure 4.11 A and B 
demonstrates that staining for CCR6 reduces the ability of the cells to migrate towards 
CCL20.  This reduced migration was not specific to one population.  This meant that for the 
migration assay an assumption was made that the amount of CCL20 specific migration was 
considered to be the degree of migration above medium alone. 
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A 10 fold dilution of CCL20 and CXCL12, ranging from 0 – 1000ng was added to the bottom 
wells of a migration assay.  CXCL12, the chemo-attractant for CXCR4 expressing cells, was 
used as a control, as a large percentage of cells can migrate towards CXCL12.  There was a 
background migration of total CD4+ T cells independently of any chemotactic gradient being 
added to the wells.  This was considered non-specific migration and the CCL20/CXCL12 
specific migration was considered to be anything above medium alone, indicated by the line 
across the graphs.  (Figure 4.12).  There was a gradual dose dependent increase in total CD4+ 
T cells that migrated towards CCL20.  15.40% of the CD4+ T cells migrating towards 1000ng 
of CCL20 (above baseline - Figure 4.12 A).  CXCL12 being present resulted in more CD4+ T 
cells migrating in response. Up to 58.94% (above baseline) of the CD4+ T cells migrated 
towards 100ng of CXCL12.  At 1000ng of CXCL12 there was a reduction in the percentage of 
cells that migrate (14.53% above baseline - Figure 4.12 D).  This is a known phenomenon in 
which the chemokine receptor is down regulated at high concentrations of chemokine215.  
When the cells were stimulated and stained for cytokine production there was a great deal 
of IL-17 specific migration in a dose dependent fashion.  The migration of IL-17 cells 
plateaued at 100ng and remained at approximately 48.33% above baseline at 1000ng 
(Figure 4.12 B).  There was an increase in the percentage of IL-17+ cells that migrated up to 
100ng of CXCL12.  At 100ng there were 61.34% of IL-17+ cells migrating (above baseline) 
which reduced to 11.84% at 1000ng of CXCL12 (Figure 4.12 E).  Only 17.59% of IFNγ+ cells 
migrate towards CCL20 at 1000ng (above baseline - Figure 4.12 C).  This was in the region of 
the percentage of IFNγ+ cells that expressed CCR6.  There was a large percentage of IFNγ+ 
cells that migrate towards CXCL12 at 100ng. Again there was a reduction in the percentage 
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of IFNγ cells that migrated to 1000ng (Figure 4.12 F).  Overall, these data suggest that 
CCD6+IFNγ+ cells have a similar ability as CCR6+IL-17+ cells to migrate towards CCL20.   
It has been shown above that there was less CCR6 expression on IFNγ+ cells compared to IL-
17+ T cells.  To investigate if the CCR6 expression on the IFNγ+ cells was stably expressed in 
culture, the CCR6 expression levels of the cells were analysed after 7 days in different culture 
conditions.  CCR6+ and CCR6- cells were isolated from CD4+CD45RO+ cells and cultured with 
IL-2, IL-23 or no cytokines, and with TcR stimulation.  After 7 days the CCR6 expression levels 
for all the CCR6- cells were negative, with the MFI never surpassing 0.39.  Within the CCR6+ 
population the CCR6 MFI was maintained (Figure 4.13 C).  The higher CCR6 expression is 
maintained on IL-17+ cells compared to IFNγ+ cells (Figure 4.13 D). The CCR6 expression is 
also maintained on IFNγ+ cells (Figure 4.13 E). The maintenance of CCR6 does not appear to 
be cytokine dependent.  However this is an experiment that needs repeating as there was an 
increase in CCR6 MFI compared to IL-2 and no cytokine culture in one experiment, but this 
was not seen in the second repeat.         
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4.8 Functional Consequences of IL-23R Expression on CCR6+IFNγ+ Cells 
The IL-23R gene was expressed in CCR6+IFNγ+ cells.  In an effort to confirm this expression ex 
vivo stimulated CD4+ T cells were analysed for IL-23R expression by flow cytometry.  There 
was very little detectable IL-23R expression on the CD4+ T cells.  Analyses of CD45RO 
expression showed an intermediate level of expression on the IL-23R+ cells (Figure 4.14 A).  
All the cells that expressed IL-23R were CCR6+, but these cells did not express either IL-17 or 
IFNγ (Figure 4.14 B). IL-23R expression was increased on the CD45RO+ population after 
culture with IL-1β, IL-6 and IL-23.  Approximately half of the IL-23R expression was on CCR6- 
cells.  There was a small overlap of IL-23R expression on the IL-17 and IFNγ cells (Figure 4.14 
C). 
To identify if there was any effect of IL-23 on the different populations, isolated CCR6+ IFNγ+, 
CCR6+IL-17+ and CCR6-IFNγ+ cells were cultured with IL-23 and compared to a culture with IL-
7 and IL-15.   The CCR6+IFNγ+ cells maintained their IFNγ expression, with a few cells losing 
the ability to produce IFNγ or IL-17 after stimulation.  There was conversion of the CCR6+IL-
17+ cells to secreting IFNγ with IL-17 or just IFNγ alone, but this was not differentially 
affected by IL-7/IL-15 and IL-23.  In both cultures with IL-23 and IL-7/IL-15 there were a small 
percentage of CCR6+IFNγ+ cells that secreted IL-17 (Figure 4.15).   
Data from this study (Figure 4.7 D) have shown that CCR6+IFNγ+ cells expressed IL4I1 to a 
similar level to CCR6+IL-17+ cells.  IL4I1 is a gene for secreted L-phenyl-alanine oxidase, 
associated with the reduced ability of TH17 cells to proliferate in humans
104.  Cytokine 
capture could not be used to isolate the cells as they would have to be stimulated with 
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PMA/ionomycin. This stimulation has been shown to remove any effect of IL4I1 on 
proliferation.  Instead, isolated CCR6+ and CCR6- CD4+ T cells were stimulated with anti-
CD3/anti-CD28 antibody, and then cultured with either no-cytokines, IL-2 or IL-23.  
There appeared to be no difference in the proliferation between the CCR6+ and CCR6- 
populations when the cells were treated with different cytokines (Figure 4.16 A-C). There 
was a difference in the percentage of undivided cells, with a higher percentage in the CCR6- 
fraction.  It cannot be ruled out that this was due to higher mortality of the cells in the CCR6+ 
cells rather than more proliferation.   
  
4.9 CCR6 TH1 cells are Found in the CSF of MS Patients  
As previously described in Section 1.8.3, CCR6+TH17 expressing cells play an important role in 
the first wave of migration of T cells into the CNS in EAE, the murine model of autoimmune 
disease MS157.  Some TREG also express CCR6 and it has been suggested that CCR6 is involved 
in the migration of TREG into the CNS to control EAE
2.  However to our knowledge there has 
been very little analysis of IFNγ expression in CCR6+ cells in RR-MS patients.  In this study the 
cellular components of the blood of 17 patients with suspected MS, 9 of which had matching 
CSF samples, was analysed. The CSF fluid was taken through a diagnostic lumbar puncture 
which meant that there was very little chance that the patient was in relapse at the time.  
The blood from 8 healthy controls was also analysed, but were not age or sex matched to 
the RR-MS patients.  Table 4.1 gives the diagnosis of the patient, received after analysis.    
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CCR6 expression was analysed alongside the IFNγ and IL-17 secretion in the CD4+ memory 
cells within each sample.   Figure 4.17 shows the CCR6 expression within the bloods of 
(Figure 4.17 B) MS and (Figure 4.17 A) healthy controls, and (Figure 4.17 C) CSF from MS 
patients. Furthermore the IFNγ and IL-17 expression in both CCR6- and CCR6+ populations 
are shown.  
Figure 4.18 A analyses the overall IFNγ and IL-17A secretion within the samples, highlighting 
that the majority of the CD4+ T cells within the CSF are IFNγ secreting.  There are very few IL-
17A secreting cells within the CSF.  There appears to be a reduction in the number of IL-17 
secreting cells in the blood of MS patients compared to controls, although not significantly 
different.  The proportion of IFNγ cells that express CCR6 was analysed.  Within the MS 
blood there was a reduced presence of CCR6+IFNγ+ cells compared to control blood (MS 
Blood, median=13.91% and range=1.47%-22.78%, Control blood, median= 37.22%, range= 
1.08%-46.60%).  Within the CSF there was a large presence of CCR6+IFNγ+ (median=44.5% of 
IFNγ cell expressing CCR6) and CCR6-IFNγ+ cells (Figure 4.17 B and Figure 4.18 B).  There was 
significantly higher percentage of CD4+CD45RO+CCR6+ cells in the CSF compared to both the 
peripheral blood of healthy and MS samples (Figure 4.17 C and Figure 4.18 C).  The MFI of 
CCR6 was similar in all the populations (Figure 4.18 D).  There was a reduction in the 
percentage of CCR6+IFNγ+ cells in the MS blood compared to healthy controls, although this 
was not significant.  However, there was a significant increase in the percentage of IFNγ cells 
expressing CCR6 in the CSF compared to matched peripheral blood of MS patients (Figure 
4.18 E).  Where there were cells that expressed IL-17 within the blood and CSF of MS 
patients, the large majority were CCR6+ (Figure 4.18 F). 
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Correlation analysis of the CCR6+IFNγ+ , CCR6+IL-17+ and CCR6-IFNγ+ populations showed that 
there was only a statistical correlation between CCR6+IFNγ+ and CCR6-IFNγ+ in healthy 
bloods, MS bloods and MS CSF (Figure 4.19 A-C).    
GM-CSF can be produced by TH17 cells and in the context of MS is thought to be one of the 
molecules that cause the pathology within the CNS.  Within TH17 cells the expression of GM-
CSF is induced by IL-23.  To identify if CCR6+IFNγ+ cells could also be a source of GM-CSF 
within the CNS the expression of this cytokine was analysed in MS bloods and CSF fluid. In 
the previous chapter it was shown that both CD4+ CCR6+ and CCR6- TH1 cells can secrete GM-
CSF (Figure 3.20 D). As expected within the blood of MS patients both CCR6+ and CCR6- IFNγ 
cells secreted GM-CSF. Roughly half of the CCR6+IFNγ+ cells secreted GM-CSF. All the IL-17+ 
cells were within the CCR6+ population and roughly half of these cells co-secreted GM-CSF 
(Figure 4.20 A, C). 
The CSF contained very few IL-17 cells, but the few cells that did secrete IL-17 were GM-CSF+.  
Of the CCR6+IFNγ+ cells roughly 60% expressed GM-CSF, while approximately 50% of the 
CCR6-IFNγ+ cells co-expressed GM-CSF (Figure 4.20 B, C).  
This data highlights that the IFNγ secreting cells within the CSF of RR-MS patients can be a 
significant source of GM-CSF, a potentially pathologically active cytokine.  
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4.10 Discussion 
4.10.1 Is CD161 or CCR6 a Better Marker for TH17 cells? 
Within the literature CCR6 and CD161 are quoted as markers for TH17 cells, although neither 
is solely specific to IL-17+ cells.  Within this study CCR6 was used to describe TH1 cells with 
‘TH17’ characteristics. However Annunziato et al. use CD161 as a marker to identify these 
cells TH1 cells.  In CD161
+IFNγ+ cells Annunziato demonstrated expression of TH17 related 
genes105. The expression pattern of these genes was very similar to the gene expression data 
presented in this study in CCR6+IFNγ+ cells.  This is to be expected as on T cells there is large 
overlap of expression of CD161 and CCR6.   
From our experiments the vast majority of the CD161+CCR6- population expressed IFNγ but 
no IL-17.  The IFNγ MFI on these cells is greater than the IFNγ MFI on CCR6+ cells.  The 
difference characteristic of CD161+CCR6- cells compared to CCR6+ cells may suggest they are 
separate populations.  This is something that would be worth investigating by isolating 
CD161+CCR6-IFNγ+ and CCR6+CD161-IFNγ+ cells and identifying if there were any differences 
in T-bet or RORC expression.  The CD161+CCR6-IFNγ+ population may have been why there 
was very little RORC expression found in CD161+ cells (Figure 4.3 D).  There are variations in 
the CD161 and CCR6 expression between donors. As the experiment was only done on one 
donor this particular donor might have had a large CD161+CCR6- population.  If this 
hypothesis is right, and CD161+CCR6+ cells do not express RORC, these cells would dilute the 
RORC signal of the CD161+CCR6+ population.  From these data the CCR6 appears to be a 
better marker for TH17 cells and cells with ‘TH17’ gene expressions.            
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4.10.2 Similarities and Differences when Comparing CCR6+IFNγ+ Cells to TH17 
and TH1 Cells  
The literature suggests that TH1 cells that express the marker CD161 are derived from a TH17 
cell and are known as non-classical TH1
105,213.  The hypothesis is that non-classical TH1 cells 
have lost the ability to secrete IL-17 and instead secrete IFNγ.  However, because of the 
transcriptional history, they maintain CD161 and RORC expression as well as other features 
of TH17 cells.  Within this chapter the phenotypic and functional characteristics of CCR6
-IFNγ+ 
cells and CCR6+IL-17+ cells are compared to CCR6+IFNγ+ cells.  The aim was to identify 
similarities and differences in the different populations to try to better understand the 
CCR6+IFNγ+ cell.    
Wedderburn and Annunziato both showed that CD161+IFNγ+ cells express IL-23R alongside 
RORC105,213.  Annunziato went on to show that they also expressed other TH17 related 
markers (IL4I1, IL-17RE and CCR6) to a greater extent than ‘classical’ TH1 (CD161
-IFNγ+)105.  
Their paper did not show the expression of these genes compared to TH17 cells.  Although 
CCR6 was used in this study to identify ‘non-classical’ TH1, the data presented in this chapter 
are very similar to Annunziato’s work.  The CCR6+IFNγ+ cells have a significantly higher 
expression of RORC compared to CCR6-IFNγ+ cells, with a comparable level of expression in 
both IL-17+ populations.  This raises the possibility that RORC, either directly or indirectly, 
may be controlling the CCR6 expression.  In RORγt-/- mice there is still CCR6 expression on 
TH17 cells.  However a RORγt/α
-/- mouse does not express CCR6216, suggesting RORα may 
control or be able to replace RORγt in controlling   CCR6 expression.  There is no evidence in 
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these mice of the effects on CCR6 expression in TH1 cells.  It has not been identified if the 
CCR6+IFNγ+ cells express RORα.   
The expression level of CCR6 is lower on TH1 cells compared to TH17 cells.  Nevertheless, the 
receptor is functional on CCR6+IFNγ+ cells.  It was shown (Figure 4.13) that CCR6 expression 
was maintained in culture, though the expression level on TH1 cells after culture was still at a 
lower level compared to TH17 cells.  CCR6 expression could not be induced on CCR6
- cells, 
with the culture conditions tried.  A non-coding region of the human CCR6 locus has been 
identified to be fully unmethylated in CCR6+ lymphocytes.  Even when the CCR6 expression 
was down regulated by TcR activation there was no alteration in the methylation status of 
this region, suggesting a level of stability in CCR6 expression.  In cells where CCR6 expression 
had been induced the expression was unstable217 due to the fact that the non-coding region 
was only partly demethylated.  As the expression of CCR6 on the CCR6+IFNγ+ cells was stable, 
this suggests that the methylation status of non-coding region of the CCR6 gene was 
unmethylated. 
At a transcriptional level there was expression of T-bet in all the IL-17+ and IFNγ+ CD4+ T cells 
(Figure 4.4), although notably lower in the IL-17+ cells compared to IFNγ+ cells.  As expected, 
when the protein expression of T-bet was analysed all the IFNγ+ cells had high expression of 
T-bet (Figure 4.5).  In the IFNγ- cells there was a gradual spread of expression of T-bet, not 
two distinct populations of T-bet+ and T-bet- cells.  This protein and PCR data suggests that 
most cells express some level of T-bet.  IL-17 cells that express T-bet are said to be more 
pathogenic in an EAE model218.  This raises the possibility that there is a spectrum of T-bet 
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expression in TH17 cells.  In the EAE model this gives the TH17 cells that ability to induce 
worse EAE, highlighting the expression of T-bet can change the phenotype of these cells.  
It is intriguing that the highest levels of T-bet are within the CCR6+IFNγ+IL-17+ cell and 
CCR6+IFNγ+ cells.  One possibility for this phenomenon may be that high T-bet expression is 
in response to competition with RORC.  The CCR6+IFNγ+IL-17+ cells may need a stronger T-
bet presence to express IFNγ in a dominant TH17 transcriptional phenotype.  In the 
CCR6+IFNγ+ cells higher levels of T-bet may be needed to suppress the RORC transcriptional 
profile to prevent IL-17 expression.  It would be interesting to investigate if a TH17 
phenotype would develop in a CCR6+IFNγ+ cells if T-bet was knocked-down.  
There was also expression of IL-23R, IL4I1, but not IL-1R1 in CCR6+IFNγ+ cells at a 
transcriptional level.  IL-23R expression by protein could not be detected in any IL-17+ or 
IFNγ+ cells ex vivo.  IL-23 is an important cytokine in maintaining the TH17 phenotype
73.  In 
CCR6+IFNγ+ cells the binding of IL-23 to IL-23R may be maintaining the RORC expression.  T-
bet has been proposed to directly affect IL-23R expression on TH17 cells
219.  T-bet expression 
was found in both populations that expressed IL-23R.  There was no detectable expression of 
IL-23R on CCR6+IFNγ+IL-17+ cells.  Conversely, in the literature IL-23R gene expression has 
been shown in IFNγ+IL-17+ cells1,220, although both of these situations were after culture.   
On naïve T cells the expression of IL-1R1 has been shown to be an important factor in the 
induction of a TH17 phenotype
103.  The lack of IL-1R1 expression on the CCR6+IFNγ+ cells may 
be the reason why these cells cannot express IL-17, but due to their IL-23R can express other 
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TH17 related genes such as RORC.  It is important to determine if both IL-23R and IL-1R are 
functional on these cells.   
A preliminary experiment was done to see if in culture with IL-23 there was any change in 
the cytokines expressed by CCR6+IFNγ+, CCR6-IFNγ+ and CCR6+IL-17+ cells.  However, none of 
the populations were altered in culture with IL-23, compared to a culture with IL-7/IL-15 
present.  The CCR6+IFNγ+ cells, after culture, contained more IL-17 secreting cells compared 
to CCR6-IFNγ+ cells.  Also after culture there were IL-17-IFNγ+ cells in the CCR6+IL-17+ 
population.  It is very difficult, using the cytokine capture method, to be sure that a true 
homogeneous population has been isolated.  This means that in these cultures (Figure 4.15) 
it cannot be rule out that the cells that have changed phenotype were not contaminating the 
original cell population.   
IL-12Rβ2 was highly expressed on the CCR6+IFNγ+ cells.  However the levels of IL-12Rβ2 were 
on the border of detection in the other subsets studied.  This expression data mirrors 
Annunziato’s data, as there was higher expression of IL-12Rβ2 in CD161+IFNγ+ cells 
compared to CD161-IFNγ+ cells105.  The CCR6+IFNγ+ cells may need to be responsive to IL-12 
to maintain the T-bet expression as there could possibly be competition with the RORC 
transcriptional programme.  In comparison the reason there may be very little IL-12Rβ2 
expression in the CCR6-IFNγ+ cell is they express no RORC and so do not require IL-12 
signalling to stabilise T-bet expression.  IFNγ+IL-17+ cells have been shown to be induced 
from TH17 cells by IL-12 
1. However, the data presented in Figure 4.7 A suggests at a 
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transcriptional level there is very little IL-12Rβ2 expression on these cells.  It is not known if 
the receptor is down regulated on the dual secreting cells once IFNγ expression is induced. 
The expression of the gene IL4I1, which codes for the secreted protein L-phenyl-alanine 
oxidase, is associated with reduced proliferative ability specifically in TH17 cells
104.  The 
expressions of this molecule at a gene level in all the CCR6+ populations led to an 
investigation into whether its expression affected the proliferation of CCR6+IFNγ+ compared 
to CCR6-IFNγ+ cells.  It was not possible to directly isolate CCR6+IFNγ+ cells as cytokine 
capture involves PMA/Ionomycin stimulation, which has been shown to overcome the 
effects of IL4I1 on proliferation.  Instead, CCR6+ and CCR6- cells were isolated. Anti-
CD3/CD28 stimulating antibodies were used and their proliferative ability compared.  
Annunziato et al isolated the CD161+IFNγ-IL-17+ population and showed there was a 
significant reduction in proliferation compared to CD161-IFNγ+IL-17- cells104.  However, in the 
culture conditions used in this study there was very little difference in the proliferative 
ability of CCR6+ and CCR6- populations.  This discrepancy may have been due to the strength 
of the stimulation used.  PMA/ionomycin stimulation is strong enough to overcome the 
effects of IL4I1 which may have occurred with the amount of anti-CD3/28 used in this study.  
The CCR6+IFNγ+ cells do not express other TH17 related cytokines, such as IL-22, IL-21 and IL-
17F, to the same degree as TH17 cells.  This suggest that based on this cytokine co-expression 
data the CCR6+IFNγ+ cells are more like TH1 than TH17 cells.  In contrast, due to the 
expression of RORC, IL-23R and IL4I1, transcriptionally the CCR6+IFNγ+ cells have some 
features of TH17 cells.      
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4.10.3 Are CCR6+TH1 Cells ‘ex-TH17’ or TH1 Cells with TH17 Phenotypic 
Characteristics?  
There is a murine fate mapping model that suggest that the transition of a TH17 to a TH1 cell 
is possible in response to specific inflammatory cues.  IL-17 expressions induced the 
expression of YFP in the T cells.   After the induction of EAE there were cells that were 
negative for IL-17A protein, positive for YFP and secreted IFNγ.  Conversely, these cells were 
not found when the mice were infected with Candida albicans, a resolving model of 
inflammation.  Within the paper the level of IL-17 gene expression that was needed to 
activate the YFP expression was not determined. This means that there is no evidence that 
the YFP+ cells had been truly committed to a TH17 lineage, and not just transiently expressed 
IL-17, before switching on IFNγ expression. 
In humans it is not possible to map the development of TH17 cells.  In vitro there have been 
experiments demonstrating IFNγ expression can be induced in TH17 cells, but IL-17 
expression cannot be induced in TH1 cells
221 .  Wedderburn and Annunziato both suggest 
that CD161 in humans is a marker that tracks the passage of TH17 cells to a TH1 phenotype.  
Both these papers identify RORC expression in CD161+TH1 cells
105,213.  No significant 
expression of RORC was found in CD161+IFNγ+ cells in this study, although no conclusions 
can be drawn from this as it was from one donor.  As mentioned in Section 4.10.1 there is 
variation in the percentage of cells expressing CD161 and CCR6 between donors.  There 
might have been very few CCR6+ cells within the CD161+ population within this donor, 
resulting in a reduced RORC signal.          
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Wedderburn cultured CD161+TH17 cells with IL-12 and the cells were induced to secrete 
IFNγ, with a small population only secreting IFNγ.  They showed that all these cells still 
expressed CD161.  It is difficult with this type of work to ensure there is no contamination of 
the IFNγ+ cells in the population before culture.  Wedderburn et al analysed the TcR 
sequence of one donor in the different populations.  The data showed shared sequences 
between CD161+IFNγ+ cells and CD161+IL-17+ cells.  Their repertoire overlap was relatively 
low213.  This is something that could be interesting to identify if CCR6+IFNγ+ and CCR6+IL-17+ 
cells had similar TcR sequences, although it is not a conclusive test as there are situations in 
which different subsets can share TcR.  An example of this is when one cell divides and the 
two cells differentiated down different lineages.   
Overall there has not been conclusive evidence in humans that a TH17 cell can convert to 
become a full TH1 cell, that either expresses CD161 or CCR6.  The data reported here cannot 
support or refute the hypothesis that CCR6+IFNγ+ cells are ex-TH17 cells.  To support the idea 
that CCD6+IFNγ+ were related to TH1 cells there is a correlation in the percentage of 
CCR6+IFNγ+ cells and CCR6-IFNγ+ cells in both healthy controls and MS patients.  However the 
data reported here does not prove this.  It would be interesting to further look, at a 
transcriptional level, at the CCR6+IFNγ+ cells.  Methylation of genes can, in some cases, be an 
indicator of the history of the cells.  An example of this is the methylation status of the FoxP3 
gene, which can identify if a cell was a natural TREG of inducible TREG
132,222.  It would be 
interesting to investigate the methylation status of IL-17 within CCR6+IFNγ+ cells compared 
to CCR6+IL-17+ and CCR6-IFNγ+. 
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4.10.4 Multiple Sclerosis  
CCR6 is a vital molecule for the induction of EAE, in that inflammatory T cells use CCL20 to 
migrate across the choroid plexus157. It is unknown if this is also the case in MS. TH17 cells 
switch on IFNγ production in a chronic inflammatory environment145,147.  The link that was 
suggested between non-classical TH1 (CD161
+IFNγ+ or CCR6+IFNγ+) and TH17 cells led to the 
hypothesis that CCR6+TH1 cells may be present in MS.   
We have shown there is a significant enrichment of CCR6+ TH1 cell in the CSF of MS patients 
compared to peripheral blood. Furthermore CCR6+IFNγ+ cells were significantly enriched 
within the CSF fluid compared to matched blood.  There could have got there in at least 
three possible ways.  Firstly, CCR6 dependent migration is said to be the first wave of 
migration of inflammatory cells into the CNS. The data presented in Chapter 4 showed that 
at least in healthy blood these cells have the potential to migrate towards CCL20 to a similar 
extent as TH17 cells.  In a CCR6
-/- model of EAE there is a reduction in both IL-17 and IFNγ 
production by the cells in the brain, which is only restored with the introduction of wild-type 
CD4+ T cells157. These data suggest that CCR6 dependent migration of IFNγ cells into the CNS 
is possible.  
Secondly, the cells could have differentiated from TH17 cells that were already present in the 
CSF. To determine if this was the case the TcR pattern could be sequenced, to determine the 
overlap of TcR sequences in CCR6+TH1 and CCR6
+TH17 cells.  
Thirdly, the cells could have migrated in the secondary wave of cells, independently from 
CCR6.  This would be dependent on CCR6+TH17 cells migrating in to the CNS.  Unfortunately 
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these patients were most likely in the relapsing-remitting stage of MS so there has most 
likely been inflammation in the CNS for a while.  There are CCR6- cells present in all the CSF 
samples suggesting that the BBB is already letting cells into the CNS through other migratory 
pathways.    
It has been published that there is an expansion in the percentage of TH17 cells within the 
CSF in relapse in MS patients, which is not seen in the blood 223. Unfortunately in this study 
due to timing and logistics by the time the lumber puncture samples are taken for analyses 
of the CSF the patients are most likely back in remission.  This could be why there were 
virtually undetectable levels of TH17 cells. It would be intriguing to see if there was an 
expansion in the percentage of CCR6+TH1 in relapse as well as TH17 cells, to suggest a 
common differentiation factor.  
Correlations between the cells within the CSF shown there may be a developmental 
relationship between CCR6+IFNγ+ and CCR6-IFNγ+. There was no correlation between 
CCR6+IFNγ+ and CCR6+IL-17+ cells.  However, because there were so few cells that expressed 
IL-17 in CSF any conclusions drawn from this data may be unreliable. 
The data presented in this chapter highlights that GM-CSF can be produced by the 
CCR6+IFNγ+ and CCR6-IFNγ+ CD4+ cells within the CSF of MS patients.  In CSF2-/- mice, that 
cannot produce GM-CSF, there is a reduced morbidity within an EAE model.  In another 
murine model IL-17-/-IFNγ-/- MOG-specific T cells were introduced into a wild type mice and 
EAE was induced201.  This data suggested that the cells induced disease through their 
production of GM-CSF.  
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 The production of GM-CSF by TH17 cells is part of an amplification loop for inflammation.  T-
bet is proposed to induce IL-23R expression in TH17 cells
219.  IL-23 induces GM-CSF 
production in TH17 cells and in turn the GM-CSF induces IL-23 expression in APC.  Microglial 
cell activation has been shown to be GM-CSF dependent which is important for the induction 
of EAE202. It was thought that GM-CSF in TH17 cells was dependent on RORγt
201, however 
RORγt-/- mice can secrete GM-CSF. TH17 cells that express T-bet have the potential to secrete 
IFNγ and it has been postulated that these are the pathogenic T cells.  TGF-β3 and IL-6 are 
thought , independently of IFNγ, to be able to induce a ‘pathogenic’ TH17 cell phenotype and 
induce EAE in mice174. IL-1β and IL-6 are said to induce TH1 and TH17 cells to secret GM-
CSF173.  
All of this data on GM-CSF uses an EAE model which is known to be strongly TH17 biased. It is 
important to recognised the there is a possibility of TH1 cells playing a role in the 
pathogenesis of this disease. If this is overlooked therapies to target TH17 cells might fall 
short of expected therapeutic value as it is not also treating TH1 cells based pathologies.  This 
data set needs to be repeated on more donors but clearly shows that TH1 cells, both CCR6
- 
and CCR6+, will be a source of GM-CSF within the CNS.  
In summary this study highlights that CCR6 expression on TH1 cells distinguishes a stable 
population of TH1 cells expressing parts of a TH17 transcriptional programme.  There is no 
direct evidence that these CCR6+TH1 cells develop from either a TH1 or TH17 background.  
Further work is needed to determine the heritage of these cells.  Within the CSF of MS 
patients there is a statistical increase in the percentage of CCR6 cells compared to matched 
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blood.  Furthermore, there are statistically a higher percentage of CCR6+IFNγ+ cells within 
the CSF compared to the peripheral blood of MS patients.  These cells are a source of GM-
CSF within the CNS, which raises the possibility that these cells contribute to the 
pathogenesis of MS.       
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CHAPTER 5 
MICRO-RNA EXPRESSION IN CCR6+TH1 CELLS IN 
COMPARISON TO CCR6-TH1 and CCR6
+TH17 CELLS  
 
5.1 Introduction 
MicroRNAs are small, endogenous, non-coding molecules that alter the expression of genes 
post-transcriptionally by targeting mRNA for degradation.  Research into these conserved 
molecules has uncovered several fundamental cellular processes that are controlled by 
microRNAs including cell proliferation, differentiation and death.  As a result, microRNAs 
have been directly implicated in the development and progression of human diseases, 
including cancer and autoimmune diseases.  The critical regulatory role of microRNAs 
suggests they offer an enormous potential for therapeutic targeting.   
MicroRNAs have been shown to play a particularly important role in relation to TH17 cells, 
especially in their differentiation.  The microRNA miR-326 mediates TH17 differentiation 
through inhibiting the expression of a negative regulator of TH17 differentiation (Ets-1)
194.  
However, currently there is no known role for microRNAs in CD4+ TH plasticity. 
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Within this chapter the aims are to: 
 identify microRNAs that are differentially expressed in CCR6+IL-17+, CCR6+IFNγ+IL-17+ 
cells compared to CCR6+IFNγ+ and CCR6-IFNγ+ cells and that may play a role in 
controlling the TH17/RORC or TH1/T-bet phenotype.   
 identify microRNAs that are differentially expressed in CCR6+IL-17+, CCR6+IFNγ+IL-17+ 
and CCR6+IFNγ+ cells compared to CCR6-IFNγ+ cells and that may play a role in 
controlling the CCR6 phenotype. 
 identify microRNAs that are differentially expressed in CCR6+IL-17+ compared to 
CCR6+IFNγ+IL-17+, CCR6+IFNγ+ and CCR6-IFNγ+ cells than may play a role in controlling 
the IFNγ expression.   
There were two major challenges to achieving these aims.  Firstly as the cell populations ex 
vivo are relatively rare, only a small quantity of RNA material was available.  Secondly, there 
are now many hundreds of miRNAs that have been identified. This would have limited us to 
only analysing a few miRNAs.   
These challenges were overcome using a method of amplification of material using 
microfluidic cards, which made it possible to screen the expression levels of 384 miRNAs.  
The amplification used miRNA specific primers to amplify up only the required transcripts.  A 
microfluidic card is a 384 well card in which TaqMan miRNA Assays have been dried in the 
array well.  Up to 8 cDNA samples per array can be added to 8 loading ports, allowing 
delivery of a single sample-specific reaction mix to 48 wells. Within this screen one 
microfluidic card was used per sample.  
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5.2 Data Analysis 
5.2.1. Normalising the Data  
From total PBMC from 3 different donors the CCR6+IL-17+, CCR6+IL-17+IFNγ+, CCR6+ IFNγ+, 
and CCR6-IFNγ+ populations were isolated using cytokine capture and cell sorting (Figure 4.4 
A).   
For the three different donors Figure 5.1 shows the spread of cycle values (Cp) across each 
subset.  A cycle value limit of 40 was chosen as a cut off for miRNAs that were below the 
detection limit.  The range was similar for most samples suggesting a good spread of 
expression levels in each subset.  The CCR6+IFNγ+IL-17+ population in Donor 3 does appear to 
have a very short range of expression suggesting either that this sample did not amplify well 
or that the quality of amplification was not optimum.  However the two other CCR6+IFNγ+IL-
17+ populations from the other donors have a good spread of Cp values.  The red line in 
Figure 5.1 indicates the average expression of the endogenous control, which in this 
experiment was U6 snRNA.  This is a small non-coding nuclear RNA component of U6 snRNP 
(small nuclear ribonucleoprotein), part of a larger complex involved in splicing pre-mRNA.  
There is a large variability in the expression levels of the endogenous control, suggesting that 
this is possibly not a good control to use.   
To analyse the similarity of the expression levels between the different subsets, correlation 
plots between each subset were produced.  Figure 5.2 is these plots from a representative 
donor. There is a strong positive correlation between the expressions for the miRNAs in each 
subset.  The coefficient of determination (R2) value gives a measure of the relative 
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association between different samples. R2 values of 1 means the samples exactly matched to 
each other.  All the correlations were significant, with R2 values of 0.59 and above.  However 
on some of the correlation graphs there is a shift away from the line for one population (e.g. 
in Figure 5.2 between CCR6-IFNγ+ and CCR6+IL-17+ there is a shift to the right of the line).  
Any spot that is not on the line means that there is a differential expression.  If the samples 
were not normalised, this would mean that all the miRNA would be more highly expressed in 
one sample.  
The average expression of the endogenous control was initially used to normalise the Cp 
values.  This was done to account for variation introduced to the system between samples 
and between runs.  By using this endogenous control there is an assumption that the 
expression of U6 snRNA is in no way different between the different subsets. The box and 
whisker diagrams after normalisation shows that the process has introduced more variation 
in the range of the samples (Figure 5.3).  These box and whisker plots are representative of 
all the samples run.   
Figure 5.4 shows representative correlation plots of the different subsets for Donor 1.  There 
was very little difference in the correlation of the normalised samples compared to the 
unaltered samples.  
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A second way to normalise the samples was tested to identify if this was more appropriate 
than the endogenous control.  The median of all the Cp values for a sample was used to 
normalise the sample.  The box and whisker plots showed that there was more uniformity in 
the range for the samples (Figure 5.5).  The correlations between each samples for each 
donor show a small improvement, shown by the R2 value being closer to 1. Representative 
correlations plots for Donor 1 are shown in Figure 5.6. Because of this reduced variation in 
the range of expression, it was decided use data that was normalised with the median Cp in 
the analysis.  
 
5.2.2 Differential Expression Between Subsets 
To identify the miRNAs of interest that were differentially expressed between the different 
subsets the relative expression (E) was analysed (Appendix).  The difference in normalised 
Cp between each combination of subsets was analysed (ΔCp).  The relative difference for 
each miRNA was calculated (2-ΔCp).  The miRNAs that were differentially expressed more 
than two fold between the subsets were selected (0.5 ≤ E ≤ 2).   The selected miRNAs were 
then manually checked to confirm that there was detectable expression of the miRNA in 
more than two replicates.  This gave a list of 79 miRNA that were differentially expressed 
between the different subsets (Appendix).   
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5.3 MicroRNAs Highlighted as Playing a Role in T Helper Differentiation 
Within the list of 79 miRNAs of interest were several that have previously been associated in 
the literature with TH17 or TH1 cell differentiation.  Three miRNAs, miR-155, miR-150, and 
miR- 146a193, which play a role in lymphocyte activation and differentiation, all came up in 
the screen.  miR-155 has been shown the inhibit IFNγ signalling193 and when knocked out in 
mice with EAE leads to a reduction in the severity of the disease192,224,225. The miR-155 TH17 
cells were shown to be hypo-responsive to IL-23 and had increased expression of the 
transcriptional repressor Ets-1 which reduced their pathogenic potential in EAE224. For 
effective TREG effectively suppression of TH1 cells miR-146a is an important miRNA, possibly 
due to effects on STAT-1226, a direct target.  With STAT-1 being an important factor in TH1 
induction and maintenance this microRNA could be important in TH cell induced 
inflammation.  Within this study there was expression of these three miRNAs within the 
CCR6-IFNγ+, CCR6+IL-17+ and CCR6+IFNγ+ populations.   The highest expression among them 
was within the CCR6-IFNγ+ population.  CCR6+IFNγ+ cells had roughly half the expression, and 
the CCR6+IL-17+ cells had reduced expression again (Figure 5.7 A). CCR6+IFNγ+IL-17+ and 
CCR6+IL-17+ cells had a similar level of expression of miR-150.  There was no detectable 
expression of miR-155 or miR-146a within the CCR6+IFNγ+IL-17+ cells.  
miR-181a was only detectable in CCR6-IFNγ+ cells, though at a very low level (Figure 5.8 C). 
miR-181 has been associated with modulating TcR sensitivity to antigen227. The cluster of 6 
microRNAs (miR-17-92, comprising miR-17, miR-18a, miR-20a, miR-19a, miR-19b-1, and miR-
92a-1) have been associated with the control of proliferation in cells189.  Within this screen 
miR-17, miR-19a, miR19b and miR92a were identified as differentially expressed. The 
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highest expression for all these miRNAs was within the CCR6-IFNγ+ population, with a lower 
but detectable expression within the CCR6+IFNγ+ cells. In most cases there was low but 
detectable expression of the microRNAs within the CCR6+IL-17+ population, and only miR-
19b and miR-92a had detectable expression within the CCR6+IFNγ+IL-17+ population (Figure 
5.7 B).   
Expression of miR-29a, b and c were all found in both TH1 subsets.  It is involved in the 
regulation of T-bet and IFNγ expression191 (Figure 5.7 A).  There are also several microRNAs 
that are associated with TH17 cell phenotype.  miR-21 and miR-301 were both, along with 
miR-155, shown to play a role in TH17 cells differentiation in response to MOG antigen
195.  
However, neither of these miRNAs was present in this screen at detectible level the IL-17 
secreting populations.  MicroRNA-21 was detectible in CCR6+IFNγ+ and CCR6+IFNγ+ cells, 
whereas miR-301 was barely detectable in any of the different subsets (Figure 5.8 B). 
In mice overexpression of has-let-7e enhanced TH1 and TH17 cells and aggravated EAE
228. 
Within the data set there was only expression of has-let-7e within the CCR6+IFNγ+ and CCR6-
IFNγ+ populations (Figure 5.8 D). 
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5.4 MicroRNAs Expressed in IL-17+ Secreting Cells 
Using information from a literature search, the remaining miRNAs were grouped based on 
their pattern of expression in the different subsets.  There were 4 miRNAs that were highly 
expressed in IL-17 secreting cells compared to the IFNγ secreting populations.  miR-184 
expression was found in both CCR6+IL-17+ and CCR6+IFNγ+IL-17+ cells. There was detectable 
expression in CCR6+IFNγ+ and CCR6-IFNγ+ cells, but it was lower than the IL-17 secreting 
populations (Figure 5.9 A).  Both miR-518 and miR-628 had similar expression patterns to 
miR-184 (Figure 5.9 C, D).  There was very high expression of miR324-3p in all the subsets.  
However, the highest level of expression was in the CCR6+IL-17+ cells (Figure 5.9 B).    
 
5.5 MicroRNAs Expressed in IFNγ+ Secreting Cells 
There were 3 miRNAs that were expressed to a similar level in both IFNγ secreting cell 
populations; miR-125a-5p, miR-195 and miR-598.  There was no detectable expression of 
any of these miRNA within the CCR6+IL-17+ or CCR6+IFNγ+IL-17+ populations (Figure 5.10 A, 
B, C).  miR-106 was expressed in CCR6+IFNγ+, CCR6-IFNγ+, and CCR6-IFNγ+ cells.  The highest 
expression was in the CCR6-IFNγ+ subsets with slightly lower expression in the CCR6+IFNγ+ 
cells.  The lowest expression of miR-106b was in the CCR6+IFNγ+IL-17+ cells.  There was no 
detectable expression within the CCR6+IL-17+ population (Figure 5.10 D).  
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5.6 MicroRNAs Expressed in CCR6- or CCR6+ Cells 
There were many miRNAs within this screen that were just expressed within the CCR6-
population.  The majority of these miRNAs were expressed at a relatively low level.  Further 
investigation will be needed to confirm that these miRNAs are solely expressed within the 
CCR6-IFNγ+ population (Figure 5.11, Figure 5.12 and Appendix).   
Interestingly, there were two miRNAs that were expressed only within the CCR6+IL-17+ and 
CCR6+IFNγ+ populations (Figure 5.13), although the replicates were not all consistent.  The 
expression within the CCR6+IL-17+ and CCR6+IFNγ+ populations of miR-136 and miR-454 were 
similar, with little or no expression in CCR6+IFNγ+IL-17+ or CCR6+IFNγ+ cells.   
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5.7 Other Expression Patterns of MicroRNAs 
There were two other detectible expression patterns that occurred within this screen.   
Firstly there were several miRNAs that were highly expressed within the CCR6-IFNγ+ 
population, with lower expression within the CCR6+IFNγ+ population, and no expression in 
either IL-17 secreting cell populations (Figure 5.14 - Appendix).  
Secondly there was high expression of the miRNAs within the CCR6-IFNγ+ populations. Again, 
there was lower expression within the CCR6+IFNγ+ but also detectable expression within the 
CCR6+IL-17+ population (Figure 5.15).     
This is only an initial screen of the expression of miRNAs within these subsets.  Having only 3 
donor’s means there is a limit to the statistical tests that can be done and the reliability of 
the data. All of the interesting and novel expression of miRNA within these subsets will need 
to be validated. Due do it being a study in humans there is not normally distributed and 
there is high variability between donors. This means that more samples would be needed to 
reach significance and the appropriate controls needed to test the reliability.  
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5.8 Discussion 
5.8.1 Normalisation and Analysis of the Data Set 
In most cases the highest expression of miRNA was in the CCR6-IFNγ+ populations.  It has to 
be noted that the CCR6-IFNγ+ population was always the largest population from the sorts.  
This could skew the data as miRNAs that only have a few copies will be amplified more 
efficiently in samples with more material.  The samples were normalised to the median 
expression to control for differences such as sample size.     
Statistical test were not undertaken on this data set.  The aim of this study was to identify 
interesting and novel miRNA which may be involved in T helper cell plasticity rather than 
finding significant differences in expression of the miRNA between subsets.  Furthermore, 
although triplicates in some setting can be sufficient to extract accurate significant data in 
this setting there were large variations between data sets.  These variations could either be 
the natural variation you get in humans or introduced by the amplification process. As this 
could not be controlled for we could not do reliable statistical test on the data set.  Further 
analysis of miRNA expression in the TH17 and TH1 subsets will be needed to confirm any 
findings from this study. 
 
5.8.2 Regulation of T Helper Cell Differentiation by Known MicroRNAs 
miR-29 plays an important role in TH1 differentiation
190,191 as it negatively regulates IFNγ 
production through interactions with Epsom and T-bet.  miR-29a, b and c were expressed 
solely in the CCR6+IFNγ+ and CCR6-IFNγ+ populations.  Most of the literature only gives the 
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data on the expression of miR-23a and miR-29b.  With mice CD4+ T cells, miR-29C is not 
highly expressed190.  miR-29c was highly expressed and miR-29b had the lowest expression 
within the two IFNγ secreting populations (Figure 5.8).  miR-29c was expressed more highly 
in CCR6+IFNγ+ cell compared to CCR6-IFNγ+ cells.  Both miR-29a and miR-29b are more highly 
expressed in CCR6-IFNγ+ than CCR6+IFNγ+ cells.  Within this human system it would be 
interesting to decipher if the different forms of miR-29 had any functional consequences on 
the TH1 phenotype.  Initially the expression levels of each miR-29 form would need to be 
confirmed. Due to its role in controlling T-bet expression it might be intriguing to knock 
down miR-29 in CCR6+IFNγ+ cells to identify if this had any effects on the ‘TH17’ phenotype of 
the cell.  
The miR-17-92 cluster has a host of different effects on the T helper cell, including roles in 
proliferation189, supporting IFN-γ production and suppressing regulatory T-cell 
differentiation in the periphery229.  The miRNAs miR-17 and miR-19b have been associated 
with having a pro-TH1 influence through the antagonism of the PI3K-Akt pathway.  Within 
this screen both miRNAs were detected in the CCR6-IFNγ+ with a lower expression within the 
CCR6+IFNγ+ population. miR-19b also had low but detectible expression within both IL-17 
secreting populations.   
The miR-17-92 cluster also has effects on TFH cell development independent of its effects on 
proliferation.  What is intriguing about this is that removing the expression of miR-17-92 
cluster in TFH cells led to the expression of genes that were normally not associated with a 
TFH phenotype. These genes included TH17 and TH22 associated genes, such as CCR6, IL1R1 
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and RORα.  This model showed that RORα was the direct target for miR-17-92230. The 
suppression of RORα by miR17-92 has in part controlled the CCR6 expression.   
Considering the CCR6 populations all the miR-17-92 cluster miRNAs are more highly 
expressed in CCR6- populations.  This might also explain the lower expression of this cluster 
of miRNAs within the CCR6+IFNγ+ population.  It was shown in the last chapter that these 
cells have a reduced level of CCR6 expression (Figure 4.1 C) which may in part be controlled 
by this cluster of miRNAs.  It also highlights that the expression of RORα in the CCR6+IFNγ+ 
subset might be worth investigating, as it may control the CCR6 levels.  hsa-let-7f is involved 
in IL-23R expression231. There was no detectable expression of hsa-let-7f in any of the 
subsets analysed.  
The role of miR-155 within the immune system has been well characterised. It appears to 
have many different methods of action within a range of both innate and adaptive immune 
cells.  Within T cells miR-155 has been shown to be important in the expression of IFNγRβ.  
This  miRNA has been shown to down regulate the expression of the receptor early on in TH1 
cell differentiation.  This suggests a potential role for miR-155 in controlling the pace of 
differentiation of TH1 cells
193.     
Within this data set it would appear that the expression of miR-155 is highest in classical TH1 
cells (CCR6-IFNγ+) cells.  When overexpressed in mice miR-155 has been shown to promote a 
TH1 response.  One target for miR-155 is SOCS1.  A high level of SOCS1 is known to suppress 
TH1 response and promote TH2 differentiation, but also suppress TH17 and TREG 
differentiation232.   
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Within TH17 differentiation miR-155 is involved in the regulation of Ets-1, a negative 
regulator of TH17 differentiation.  This miRNA is also shown to correlate with IL-23R 
expression.  There was expression of miR-155 in both the subsets in which IL-23R gene 
expression was found in Chapter 4 (namely CCR6+IL-17+ and CCR6+IFNγ+).  Further work is 
needed to identify the true targets of miR-155 in these different subsets in humans.  
miR-326 also targets the negative regulator of TH17 differentiation, Ets-1
194.  In this data set 
there was no detectable expression of miR-326 in any of the subsets analysed.  miR-301a 
also enhances TH17 induction by targeting an inhibitor of STAT-3
195.  miRNA was not highly 
expressed in any of the subsets in this screen, although in contrast to the literature194 it was 
detected in the CCR6-IFNγ+ population.    
 
5.8.3 Identification of Novel miRNA in T Helper Cell Subsets 
MicroRNAs are involved in fundamental cellular processes, such as proliferation and death, 
in many different cell types.  As a result, microRNAs have been directly implicated in the 
development of many cancers. The majority of the other differentially expressed miRNAs 
identified in this screen have at some point been implicated in controlling cancer, and a few 
target molecules have been identified which the miRNA bind to.  In relation to the T helper 
subsets in this screen there is limited data.  The next step  in future work would be to 
validate the expression of the miRNAs on samples that have not been amplified using qRT-
PCR.  Using a system to knock-down the miRNA within the T cells could also be used to 
identify if the miRNAs have a significant impact on the cell phenotype. 
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The miRNAs that were highly expressed within IL-17 secreting cells were miR-184, miR-324-
3p, miR-518d and miR-628-5p.  miR-184 was expressed in both IL-17 secreting subsets.  It 
has been suggested in mice that this controls the differentiation and proliferation of adult 
neural stem cells233.  Within the stem cells high levels of miR-184 promote proliferation but 
prevent differentiation233.  miR184 has been identified as targeting the nuclear factor(s) of 
activated T cells-1 (NFAT1) protein through its complementary sequence binding with 
NFATc2 mRNA (without transcriptional degradation).  Expression of miR-184 in CD4+ T cells 
from the UCB has been associated with reduced inflammatory cytokine expression in these 
cells due to lower NFAT-1 expression234.  A further target on miR-184 was found to be the 
microRNA miR-204. Interaction of these two miRNA led to increased SHIP2 expression in 
keratinocytes235 and resulted in increased proliferation.  Although direct targets for miR-324 
and miR-518b have not been identified they are thought to be oncogenes.  When expressed 
they suppress the proliferation of different cells types.  It is known that TH17 cells have 
reduced proliferative ability103 so it may be possible that these miRNA are also involved in 
controlling the proliferation within the T cell subsets.  Finally miR-628-5p has been 
associated with acute myeloid leukaemia and was up-regulated in response to GM-CSF, IL-3 
or G-CSF236.  One of the highly conserved predicted targets of miR-628-5p is Foxo3/Foxo3a. 
Within the miRNAs expressed exclusively in the TH1 cells, both CCR6
- and CCR6+, some have a 
role in aiding the immune cells in protecting against infection. miR-125a-5p has been 
identified in the human liver to have an anti-viral role against HBV237.  miR-598 has been 
postulated to be involved in the repair of lymphocytes after ionising radiation238. Aberrant 
expression of miR-195 has been associated with several different types of cancer. miR-106b 
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has an role in targeting Smad7 signalling to activate TGF-β signalling specifically in the setting 
of cancer239.  TGF-β is known to be involved in differentiation of T helper cells, especially TREG 
and TH17 cells, although not specifically TH1 cells.   
There were only two miRNAs that were associated with CCR6+ cells. These were miR-136 and 
miR-454.  miR-136 targets Bcl-2 and AEG-1 within glioma240, which are anti-apoptotic genes. 
miR-454 was a candidate miRNA found to be differentially expressed in the plasma of MS 
patients compared to controls.  miR-454 was also differentially expressed in MS patients at 
different stages of disease suggesting a possible role in the progression of MS241. This would 
be an interesting candidate to take further considering that CCR6 is involved in T cell 
migration into the CNS in MS157.  
In summary, within this chapter miRNAs that are differentially expressed between CCR6+IL-
17+, CCR6+IFNγ+IL-17+, CCR6+IFNγ+, and CCR6-IFNγ+ cells have been identified.  Using 
amplification of material and microfluidic cards has allowed analysis of the expression of 
over 300 miRNA in very small subsets of cells.  Several miRNAs highlighted from this screen 
had previously been associated with TH differentiation such as miR-155 and miR-29.  Other 
miRNA that were expected to be differentially expressed were not, such as miR-326 involved 
in TH17 differentiation
194.  Novel miRNAs that have not previously been associated with TH 
differentiation have also been identified.  The next stage for this screen will be to validate 
the expression of the miRNAs of interest using samples that have not been amplified. As the 
validation process has not yet been carried out, it cannot be ruled out that the amplification 
process has affected the expression levels in some samples.  
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CHAPTER 6 
GENERAL DISCUSSION 
6.1 Summary 
The identification of TH1 and TH2 cells by Mosmann and Coffman
43 led to the recognition that 
CD4+ T cells could differentiation down separate lineages.  Since this discovery several other 
subsets of TH cells have been identified, in the most part defined by the effector cytokines 
produced and the lineage defining transcription factor expressed (Figure 1.1).  The different 
TH phenotypes all play a part in controlling unwanted infection within the body. An example 
of this is TH1 cells which are vital for immunity against intra-cellular infection.  They produce 
IFNγ that drives the activation of macrophages.  This phenotype is controlled by T-bet, the 
TH1 lineage defining transcription factor
47,52.  TH17 cell are important primarily for protection 
against fungal infections but also play a role in protection against some extracellular 
bacterial infections.  They produce IL-17 and control neutrophil activity.  The lineage defining 
transcription factor that is involved in the induction and maintenance of the TH17 phenotype 
is RORC86.   
Although TH1 and TH17 cells are very distinct lineage with discrete properties, it has now 
been demonstrated that there are cells that have features and functions of both 
phenotypes.  At the start of this study there was very little known about TH17 cells and their 
ability to co-express IFNγ.  IFNγ+IL-17+ cells have now been characterised, both within this 
study and in the literature1,145,200,221.  However there are still questions to be answered as to 
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the level of plasticity exhibited by these T cells and in what situations they play an important 
role.  
There are several groups now suggesting that TH17 cells can fully convert to TH1 cells.  CD161 
has been suggested as a marker for TH1 cells that have a TH17 heritage
105, though this has 
not been proven directly in humans.  The data presented in this study has identified a novel 
subset of TH1 cells that express functional CCR6 and have other features of a ‘TH17’ 
transcriptional profile, although no IL-17 expression.   
Multiple sclerosis affects 2.5 million people worldwide.  If severely affects patient’s quality of 
life and reduces their life expectancy.  Both TH1 and TH17 cell are important in the initiation 
and maintenance of the disease242,243.  Data from this study has demonstrated that CCR6+TH1 
cells are present in the CSF of MS patients. The literature has shown the presence of TH1 
cells with TH17 phenotypic markers in the joints of arthritis patients
213.  It will be important 
to understand if CCR6+TH1 cells play a role in the pathogenesis of MS.    
 
6.2 Strength and Limitations of the Study 
Investigating the biology of TH cells within the human system lends this study both strengths 
and limitations.  These are highlighted when this study is compared to murine studies of TH 
cell plasticity and the murine model EAE.  There are variations between human individuals 
that cannot be controlled for in the same way as in murine experiments.  These variations 
are introduced both by genetic and environmental factors which in mice are tightly 
controlled. In humans it is not possible to control for these variations without using very 
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large cohorts of samples.  This study only uses a small number of patients and controls.  This 
leads to a lack of statistical significance in much of the data, such as in the miRNA study and 
some of the qRT-PCR data.  To confirm the results further work will be needed to consolidate 
the findings.  
In contrast to this however the use of human system means that the data is directly relevant 
and useful, especially in the study of MS.  Murine models, although related to human 
immune system, are not the same, so findings may not translate to human disease.  
Although EAE does have characteristic of MS it is by no means a true representation.  The 
requirement of an adjuvant to initiate EAE is one example that may be skewing the 
inflammatory process in this model.  To initially find an interesting subset of TH cells within 
the human system means it is a realistic therapeutic target to treat MS or other 
inflammatory diseases in humans.  Human samples can be difficult to obtain, as they require 
ethical approval and consenting patients.  The data from this study should be added to the 
pool of already published data on T cell plasticity and information on CSF T cell subsets.   
A further strength of this study is that it uses ex vivo populations of cells.  This highlights how 
the technology in this area is rapidly developing. The ability to isolate very small but pure 
populations of viable cytokine secreting T cells means that more reliable ex vivo analysis of 
the different cells types can be undertaken.   At the start of the study a lot of the information 
in the literature about plasticity in TH1 and TH17 cells was based on in vitro and clone 
systems.  TH17 cells in culture appear to become more plastic with the up regulation of IL-
12R, suggesting cultured cell may have altered biology to ex vivo cells.  Throughout this study 
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all the transcriptional analysis was done on ex vivo populations suggesting this is a true snap 
shot of the genes expressed by these cells in the body.     
Finally the use of PMA and ionomycin to stimulate cells to produce cytokines is a limitation 
of this study.  There can be no certainty that stimulating cells by bypassing the antigen-TcR 
pathway gives a true representation of the cell’s cytokine secreting potential.  This study has 
identified that there was less cytokine produced by recently activated T cells when they 
were stimulated by PMA/ionomycin than cells that had not been recently activated.  It is 
difficult to say if this phenomenon is real or an artefact of PMA/Ionomycin stimulation.  
Using antigen specific stimulation would not be a viable option in this human study as there 
are so few antigen specific cells. Many papers use antigen stimulation by using clones.  It was 
felt in this study that this would lead to undesirable consequences with the gene expression 
within these cells.   
Overall in this study there are some interesting, novel findings about T helper cell plasticity, 
both in health and disease. However further research is needed to confirm the relationship 
in humans between TH17 and TH1 cells, and their potential role in MS.  
 
6.3 Identification of TH17-like TH1 Cells 
 
As mentioned in Section 4.10.1 there is evidence in Chapter 4 that CCR6 may be a better 
marker to identify cells with a ‘TH17’ like phenotype and IL-17 secreting cells compared to 
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CD161.  CD161 has been used by the Annunziato group to identify TH1 cells with ‘TH17’ 
phenotype105,213.  
In this study CD161 appears to be associated with a significant increase of IFNγ in T cells 
(Figure 6.1).  TH1 cells that express CCR6 have a reduced IFNγ MFI in comparison to 
CD4+CD161+CCR6- cells.  On T cells when CD161 is stimulated by its ligand, LLT1, IFNγ 
production is increased244.  As CD161+CCR6+ cells secrete less IFNγ per cell than CD161+CCR6- 
cells there may be an effect of CCR6, or the related transcriptional programme, affecting the 
way CD161 is acting when it binds to its ligand.  LLT1 is known to be expressed by activated 
DC, B cells and T cells7 meaning it is possible that LLT1 was present in the cultures used in 
this study.  Although there is a large overlap in the expression of CCR6 and CD161, this 
suggests that TH1 CD161
+CCR6- cells may have a separate phenotype to TH1 cells expressing 
CCR6.  It would be intriguing to identify if CD161+CCR6- cells did in fact have a separate 
transcriptional profile to CD161+CCR6+ cells.  
Throughout the literature PMA/ionomycin is used to establish the cytokines produced by T 
cells.  In the experiments within this thesis PMA/ionomycin has also been used.  By using this 
type of TcR-independent stimulation there is an assumption that it is revealing the true 
phenotype of the T cells.  PMA/ionomycin has been shown to induce IFNγ secretion in 
anergic T cells245 and our data shows that recently activated cells produce less cytokine than 
cell that have not been activated recently. It was not determined if this was a 
PMA/ionomycin specific effect or a true reduction in cytokine production.  Using a system of 
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anti-CD3 anti-CD28 stimulating antibodies or antigen pulsed DC would allow for a more 
physiological TcR –dependent stimulation.   
6.4 Are CCR6+TH1 cells Derived From a TH1 or TH17 Cell? 
The literature has taken plasticity in TH17 cells a step further to infer that TH17 cells can fully 
convert to a TH1 cell, and that expression of CD161 or CCR6 on TH1 cells infers that the cells 
were once TH17 cells
105,145.  
Within the literature there are three main data sets that suggest that TH17 cells can convert 
to TH1 cells.  A murine fate mapping model labelled IL-17A expressing cells with YFP
146.  
When EAE was induced in the mice there were YFP+ cells that expressed only IFNγ suggesting 
a phenotype switch from TH17 to TH1.  Furthermore, in humans there was work on 
CD161+IFNγ+ cells that suggested RORC expression and other features such as IL-23R and 
IL4I1 expression inferred the cells were ex-TH17 cells.  CD161
+IL-17+ cells were isolated and 
cultured, and they showed that CD161+IFNγ+ cells arose in these conditions105. Finally, it is 
argued that TH1 cells have come from a TH17 background as in vitro TH1 cells cannot be 
converted to TH17 phenotype, but TH17 cell can be induced to switch on IFNγ
221.   
There is an issue with the fate mapping model in that there is no indication of what level of 
IL-17 expression is needed to induce the expression of YFP, and that therefore YFP 
expression may not indicate a committed TH17 cell
146.  A recent paper by Sallusto et al. has 
shown T cells stimulated with different pathogens transiently express certain cytokines 
depending on the pathogen147.  The cells that were IFNγ+YFP+ may have transiently 
expressed IL-17 and never been fully committed to the TH17 lineage.    
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The finding that in vitro TH1 cells cannot be converted to a TH17 phenotype does not prove 
that the conversion is not possible.  These CCR6+IFNγ+ cells have not switched on IL-17 
expression, just expression of what are considered ‘TH17-related’ genes.  It is also possible 
that the conditions needed to switch on ‘TH17’ gene expression in TH1 cells have not yet 
been found.  Several recent publications have demonstrated that a high salt environment 
boosts the induction of TH17 cells
246.  Serum/glucocorticoid-regulated kinase 1 (SGK1) was 
up regulated in cells treated to a high NaCl concentration. SGK1 phosphorylates the 
transcription factor forkhead box protein O1 (FOXO1)247.  The phosphorylation of FOXO1 
deactivates its suppressive effect on RORγt.  SGK1 is critical for IL-23R expression. The 
increased salt concentration results in the up-regulation of IL-23R, CCR6, RORα and RORC 
expression.  It would be interesting to investigate the possible effects of salt on TH1 cells 
(Figure 6.1). It is possible that under these conditions RORC, IL-23R and CCR6 are up 
regulated.  RORα is a gene that would be interesting to investigate the in CCR6+IFNγ+ cells, as 
it is also been suggested to control CCR6 expression216.  
In conclusion there is no solid evidence in this study or in the literature that in humans TH17 
cells can switch to become TH1 cells.  Identifying the methylation status of the IL-17A gene in 
the CCR6+IFNγ+ cells might hint at the cells history of IL-17A production.  A gene expressed in 
a cell that was fully de-methylated never becomes fully re-methylated. This was 
demonstrated in experiments investigating the methylation status of the CD8 gene in CD4+ T 
cells that have developed from a CD8+CD4+ precursor in the thymus. Within the CD4+ T cells 
the gene for CD8 was still partially de-methylated16.  Within the CCR6+IFNγ+ populations 
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there would be an expectation that the IL-17A gene will be only partially methylated if the 
cells came from a TH17 background, and mostly methylated if it was from a TH1 background.      
The next step for the study of CCR6+IFNγ+ cells would be to identify if there were any effects 
of knocking down RORC expression (Figure 6.1).  The hypothesis being that the cells would 
lose CCR6 expression, along with the expression of other ‘TH17’related genes, and develop a 
phenotype more closely related to the CCR6-IFNγ+ cells.  Following on from this the 
knockdown of T-bet within the CCR6+IFNγ+ cells might determine if it is possible for RORC to 
become the dominant transcription factor in these cells.  If T-bet is knocked down in 
CCR6+IFNγ+ cells, would they lose the ability to produce IFNγ and gain the ability to produce 
IL-17?   
Within this study there is evidence that the TH1 population is not homogeneous in their gene 
expression.  Based on this information can cytokine and transcription factor expression still 
be used to define TH subsets, and are these cells terminally differentiated?  
John J. O’Shea and William Paul developed the hypothesis that within CD4+ T cells there is a 
dynamic transcription factor expression248. The plasticity is no doubt driven by the lineage 
defining transcription factors but must be tightly controlled by other factors.  The next stage 
is to understand what is controlling the plasticity of different CD4+ T cells.  
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Figure 6.1. Proposed model of TH1 and TH17 cell plasticity. TH17 cells are defined 
by IL-17 secretion and RORC expression, while TH1 cells secrete IFNγ and express 
T-bet. IFNγ+IL-17+ cells have been shown to differentiate from TH17 cells in 
response to IL-12. These cells express RORC and T-bet. Cells expressing CCR6 and 
CD161, TH17 related markers, also express RORC and T-bet but only secret IFNγ. 
It is not known if the CCR6+IFNγ+ cells differentiate from a TH1 or TH17 cell. There 
may be miRNAs that suppress the IL-17 expression in the CCR6+IFNγ+ cells. Salt 
can induce a ‘TH17’ gene expression pattern in naïve T cell. The effect of salt on 
TH1 cells is not known and if it may play a role in the induction of CCR6 and RORC 
in TH1 cells. The effects of RORC/RORα or T-bet knockdown in CCR6
+IFNγ+ cells is 
not known but will establish the role the transcription factors play in the 
phenotype of the cell. CD161+CCR6- cells secrete more IFNγ than CCR6 expressing 
TH1 cells. Further work is needed to understand if these cells have the same 
‘TH17 related’ phenotype as
 CD161+CCR6+ cells.    
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Comparisons between the different CD4+ T cell subsets are a vital tool to further understand 
plasticity in humans.  The difference between the IFNγ+IL-17+ cells and CCR6+TH1
+ will lead to 
a better understanding of what is specifically controlling IL-17 expression, for example 
(Figure 6.1).  This was one of the aims of the miRNA study, to identify specific miRNAs that 
may be controlling IL-17 expression.  If there was a miRNA that was differentially expressed 
between CCR6+IFNγ+IL-17+ cells and CCR6+IFNγ+IL-17-cells this could be a candidate for 
controlling IL-17 expression. 
Figure 5.9 and 5.10 shows either miRNAs that were highly expressed in CCR6-IFNγ+ and 
CCR6+IFNγ+ cells compared to CCR6 IFNγ+IL-17+ and CCR6+IL-17+ cells, or vice versa.  
CCR6+IFNγ+IL-17+ and CCR6+IL-17+ cells were associated in this comparison as it has been 
suggested from data presented in this study and in the literature that CCR6+IFNγ+IL-17+ cells 
are more related to TH17 cells
1.  These differentially expressed miRNAs may be involved in 
the TH17 and TH1 transcriptional profiles rather than controlling the cytokine expression.  
Conversely miR-324 was highly expressed in CCR6+IL-17+ cells with lower expression in all 
three IFNγ secreting populations. This could be a candidate miRNA to control the expression 
of either IL-17 or IFNγ.  
Many of the miRNAs are only expressed in CCR6-IFNγ+ cells (Figure 5.11 and 5.12).  These 
candidates could be controlling IFNγ/IL-17 expression. Conversely this could be an erroneous 
result introduced by the amplification process.  As the CCR6+IFNγ+ started with more 
material, genes expressed at a low level, they could be amplified more reliably than genes 
expressed at a low level in a population with less material.  A proportion of the miRNAs that 
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were only expressed in the CCR6+IFNγ+ cells have a very low relative expression.  The only 
way to verify if this is the case is to validate the expression of the miRNA by qRT-PCR on 
samples that have not been amplified.  
It may be hypothesised that the CCR6+IFNγ+ cells may up-regulate RORC or possibly RORα as 
a way to gain migratory ability into certain tissues.  There are many autoimmune disease 
such as MS157 and psoriasis249 where CCR6 has been shown to play a role in T cell migration 
in to the effected tissue.  If a miRNA was identified that targeted either the TH17 
transcriptional profile or specifically the CCR6 transcription it could have real therapeutic 
potential for these diseases.  However, as TREG also use CCR6 to migrate into the CNS
216, the 
effects of also removing these regulatory cells, as well as inflammatory TH cell,  from the CNS 
must be taken into account. 
 
6.5 The Presence of CCR6+IFNγ Cells in RR-MS 
In MS patients, TH17 cells have been shown to be increased with in the CSF compared to 
peripheral blood223. It has been shown within this thesis that there is also an increase in the 
percentage of CCR6+IFNγ+ cells in the CSF compared to peripheral blood of RR-MS patients.   
In EAE, the murine model of MS, there is an initial wave of TH17 cells using CCR6-dependent 
migration into the CNS via the choroid plexus.  As TH17 cells are considered the pathogenic 
cells in EAE, they attributed the attenuated EAE in CCR6-/- mice to the reduced ability of TH17 
cell to migrate into the CNS157.  However, the presence of CCR6+TH1 cells, which far 
outnumbers the TH17 cells, may also be important in the disease pathogenesis.  In the   
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CCR6-/- mice both the IL-17 and IFNγ secreting cells were reduced in the CNS after EAE 
induction157.   
However, the presence of CCR6+IFNγ+ cells does not prove that their method of entry into 
the CSF was CCR6 dependent.  Firstly almost half of the IFNγ cells did not express CCR6.  It 
has been shown in mice that only the first wave of cells migrating into the CSF are CCR6 
dependent.  As the patients used in this study were either RR-MS or SP-MS, the initial wave 
of cells infiltrating the CNS will have already occurred.  After the initial wave of CCR6 
dependent migration the inflammatory cells cause damage to the BBB allowing a second 
CCR6 independent wave of T cell migration to occur157. This could be the reason why only 
half of the IFNγ+ cells are CCR6+, and so does not give any clues as to how the CCR6+ cells 
entered the CSF.  
IL-17 secreting cells have been heavily implicated in the pathogenesis of MS. In humans the 
percentage of IL-17+ cells in the CSF and blood have been shown to increase in relapse and 
then reduce back to baseline again upon remission223,250.  This reference show there was no 
difference in the percentage of TH1 cells in either relapse or remission in MS patients 
223, 
however the percentage of CCR6+IFNγ+ cells was not directly studied.  It would be interesting 
to see if there is any change in the CCR6+IFNγ+ population upon relapse.  Due to the way in 
which the samples were collected for this study all the CSF samples were from patients who 
were likely to be in remission.   
Whether the CCR6+IFNγ+ cells are playing a role in the pathogenesis of MS is difficult to 
determine.  GM-CSF has been implicated as having pathogenic activity in MS173,201,202. TH17 
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cells have been shown to be a source of GM-CSF within the brain parenchyma. Within the 
data presented in this study CCR6+IFNγ+ and CCR6-IFNγ+ cells in the CSF can produce GM-CSF.  
All the samples from this data set are from RR-MS patients in remission, but this shows that 
TH1 cells rather than TH17 cells are probably the major source of GM-CSF.    
Within humans determining if any of the CCR6+IFNγ+ cells reacted against known auto-
antigens involved in MS would be an important step forward.  Using a murine model EAE, a 
conditional knockout of CCR6 in IFNγ secreting T cells, might give an indication if the cells 
were entering the CNS in a CCR6 dependent fashion, and if the cells were playing any sort of 
role in the pathogenesis of EAE.  This experiment has limitations in that the CCR6+IFNγ+IL-17+ 
cells would also lose CCR6 expression.  This would mean that the effects of the knockout 
could not be attributed to just one individual subset of CD4+ T cells.   
Identification of the antigen specificity of the CCR6+IFNγ+ cells within the CSF samples would 
also give an indication as to their role in disease pathogenesis. Identifying CCR6+IFNγ+ cells 
with specificity for antigens such as myelin basic protein (MBP), Myelin oligodendrocyte 
glycoprotein (MOG) and myelin proteolipid protein (PLP) would point towards them playing 
a role in the destruction of myelin251.  
There are several other autoimmune diseases where CCR6+IFNγ+ T cells may also play a role. 
The pathogenesis of psoriasis252, Crohns disease1 and JIA145 has been associated with both 
TH17 and TH1 cells, as well as IFNγ
+IL-17+ cells.  It may be interesting to see if there is an 
increased presence in these diseases of CCR6+IFNy+ cells.  The presence of RORC in CCR6+TH1 
cells leads to the conclusion that this is the transcription factor that is controlling the ‘TH17’ 
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like phenotype in the TH1 cells, as it does in TH17 cells
99. This suggest that in settings such as 
MS, and the other autoimmune disease, the knockdown of RORC in both TH17 and TH1 cells 
may have an impact on the pathogenesis of the disease,  but still leave a fully functional TH1 
response.  However, there would be consequences for other cell types if RORC was knocked 
down. CCR6 TREG cells also express RORC, and they have a CCR6 dependent migration in EAE. 
The reduction of these cells may cause uninhibited inflammation within the brain. RORC 
antagonists are already being considered as treatments for TH17 related disease
253.  
It is important to take into account the stages of the disease when assessing treatments such 
as a CCR6 targeted therapy.  Within MS there is the initial wave of CCR6 dependent 
migration of T cells through the choroid plexus157. If the treatment to target CCR6 was given 
after this initial wave would there be any effect on inflammation within the brain?  However 
it is possible that entry of CCR6 expressing cells is still needed to maintain inflammation. It 
will be important to understand if the expansion of the TH17 cell population in relapse was 
due to more cells migrating into the CSF or if it was due to TH17 cell proliferation within the 
tissue. This would have important implications for future treatments.  Furthermore, it has 
still not been ruled out that TH17 cells within the CSF are converting to CCR6
+TH1 cells, or 
vice versa. 
Situations such as this make it clear that understanding T cell biology in health is just as 
important as understanding T cell biology in disease settings.  Understanding the true plastic 
nature of T cells will be vital to producing more target therapies that have a greater chance 
of having long lasting effects.  
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So can cytokine and transcription factors still be used to define lineages? These markers are 
still an important aspect of a T cell’s phenotype. After all it is the cytokine that the cell 
produces that defines its ability to control an immune response.  However, now that it is 
becoming obvious there is overlap in cytokine secretion, it is going to be the level of 
expression and the combinations of transcription factors that are expressed that becomes 
important. Other factors, such as miRNAs, will become important in understanding what 
may be controlling a T cell.  Technology such as mRNA-seq254 (analysis of the transcriptome 
of a single cell), and Chip-Seq255 (analysis of protein and DNA interactions) will move the field 
of T cell plasticity forward.  Rather than trying to define a T cell by how it acts in vitro, it will 
become more important to understand how T cells act in vivo, both in disease and health, to 
truly understand what role T cells have within the immune system.   
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CCR6+IL-17+  vs. CCR6+IL-17+  vs. CCR6+IL-17+ vs. CCR6-IFNγ+ vs. CCR6-IFNγ+ vs. CCR6+IFNγ+  vs. 
CCR6+IFNγ+ CCR6-IFNγ+  CCR6+IFNγ+IL-17+ CCR6+IFNγ+ CCR6+IFNγ+IL-17+ CCR6+IFNγ+IL-17+ 
hsa-let-7d-002283 0.014638637 27.69942157 160.4566476
hsa-let-7e-002NA6 0.001831413 0.00036343 5.03924407 2751.560656 546.0264711
hsa-let-7g-002282 0.003878387 0.001509688 2.568999602 2807.077312 1092.673315
hsa-miR-101-002253 0.01370484 16.21028194 72.96692495
hsa-miR-106a-002169 0.00284539 0.000556425 5.113695773 11765.14992 2300.713699
hsa-miR-106b-000442 0.029074417 0.011984712 0.030527291 2.425958717 2.547186038
hsa-miR-125a-5p-002198 0.090127534 0.09200976 2.221453289 2.267846204
hsa-miR-126-002228 4.593989666
hsa-miR-136-000592 2.052618442 4.044026015 2.543126934
hsa-miR-142-3p-000464 0.10116721 0.05206174 19.14524654 9.852350821
hsa-miR-142-5p-002248 0.333855579 2.995307139
hsa-miR-146a-000468 0.023993474 0.006351056 0.453185161 3.777871594 71.35587605 18.88785108
hsa-miR-146b-001097 0.020547284 0.009200973 0.257661852 2.2331642 28.00376047 12.53994689
hsa-miR-150-000473 0.091425283 0.027280735 3.351276371 37.90991544 11.31208269
hsa-miR-155-002623 0.031000612 0.011707979 8.844412622 2.647819296 755.4175403 285.2979965
hsa-miR-16-000391 0.069725935 0.023272041 2.996124692 34.41877072 11.48776311
hsa-miR-17-002308 0.000969151 0.000108679 8.917590797 9201.447286 1031.831074
hsa-miR-181a-000480 0.218389246 5.450482483 13.22660369
hsa-miR-184-000485 2.185750406 2.848295181 0.448850529 0.157585679 0.205353058
hsa-miR-186-002285 0.004667959
hsa-miR-191-002299 0.034863733 0.012916433 4.135359651 2.699176528 320.1626665 118.6149417
hsa-miR-192-000491 0.1125949 4.36448614 8.881396927
hsa-miR-194-000493 0.042098979 23.75354518 23.75354518
hsa-miR-195-000494 0.030495392 0.028993589 57.60557802 54.76868278
hsa-miR-19a-000395 0.293585617 0.031942641 9.191025275 166.6525309 18.13209363
hsa-miR-19b-000396 0.042551413 0.010832156 3.928249779 98.76555924 25.14238269
hsa-miR-1NA-3p-002234 0.1965928 0.072844847 2.698788027 12.8949262 4.778043355
hsa-miR-203-000507 0.438065305 0.397523868 0.296210399
hsa-miR-20a-000580 0.015560039 11.46155703 35.8072414 736.6020547 20.57131535
hsa-miR-20b-001014 0.002653456 97.75473037 376.866936
hsa-miR-21-000397 0.049720129 0.012122137 3.65128766 4.101597717 301.2082494 73.43680929
hsa-miR-212-000515 9.03445019
hsa-miR-222-002276 0.14061665 0.03456384 8.308483298 4.068316726 240.3807913 59.08605636
hsa-miR-223-002295 0.451632016 2.654638967 2.569814102
hsa-miR-24-000NA2 0.243807599 0.097330515 2.098144441 2.504945127 21.55690268 8.605738487
hsa-miR-25-000NA3 0.02090121 0.00105011 19.90382775 267.2961556 13.42938449
hsa-miR-26a-000NA5 0.015596067 0.00199442 7.819850357 3233.810483 413.5386657
hsa-miR-26b-000NA7 0.307918617 0.030462606 11.81325915 10.10808507 387.7954173 38.36487473
hsa-miR-27a-000NA8 6.191894136
hsa-miR-28-000411 0.214217641 0.012795908 16.74110447 311.497135 18.60672547
hsa-miR-29a-002112 0.028013101 0.01757267 6.61653613 376.5242423 236.1943446
hsa-miR-29b-000413 0.39299055 0.280408735 21.01982779 14.99818076
hsa-miR-29c-000587 0.000703949 0.000115004 6.121089541 1420.557268
hsa-miR-301-000528 0.144478466 6.921446672 2.411738475
Table 8.1 List of 79 differentially expressed miRNAs in T
H
1 and T
H
17 CD4
+
 T cell 
subsets. Relative expression of miRNAs between each subset (2
-ΔΔCp
), normalised 
 to median Cycle value (Cp). 
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CCR6+IL-17+  vs. CCR6+IL-17+  vs. CCR6+IL-17+ vs. CCR6-IFNγ+ vs. CCR6-IFNγ+ vs. CCR6+IFNγ+  vs. 
CCR6+IFNγ+ CCR6-IFNγ+  CCR6+IFNγ+IL-17+ CCR6+IFNγ+ CCR6+IFNγ+IL-17+ CCR6+IFNγ+IL-17+ 
hsa-miR-302a-000529 0.000284283 138.7228345 30.12956222
hsa-miR-30b-000602 0.028040156 0.008931925 2.600941839 3.139318344 291.196111 92.75775157
hsa-miR-30c-000419 0.220841366 0.060379558 4.424986335 3.657551893 73.28616672 20.03694516
hsa-miR-31-002279 0.026130376 0.002735821 9.551200902 365.5209829 38.26963611
hsa-miR-320-002277 0.026748853 0.009407618 36.01140405 2.843318406 3827.898207 1346.278419
hsa-miR-324-3p-002161 3.136205293 4.508459828 564.3385679 125.1732497 179.9431208
hsa-miR-328-000543 0.033476737 0.004358565 7.680677992 329.9885779 42.96346992
hsa-miR-331-000545 0.00199463 166.8084941 501.3462139
hsa-miR-342-3p-002260 0.031112444 0.011209496 0.457088849 2.775543556 40.77693215 14.69151225
hsa-miR-345-002186 0.290119504 4.969472793 10.67854325
hsa-miR-374-000563 0.021806027 0.006857612 3.179827859 140.9178877 44.31620012
hsa-miR-375-000564 0.027702505 25.10305328 36.09781855
hsa-miR-376a-000565 0.275665736 0.263754911 0.013256054 0.050258985 0.04808742
hsa-miR-454-002323 487.6713716 421.4832453 0.00170825 505.9430317
hsa-miR-484-001821 0.020551451 0.0030024 6.84500692 450.5240393 65.81790852
hsa-miR-494-002365 0.045195086 22.12629942 22.12629942
hsa-miR-517b-001152 0.12535737 0.012211925 10.26516088 257.3281988 25.06811162
hsa-miR-518d-001159 49.27316158 2.433386244 20.24880419 0.247685274 0.012232094
hsa-miR-518f-002388 0.11375512 0.202828467 8.790813092 0.202828467
hsa-miR-523-002386 0.307620749 0.025201817 12.2062923 39.6796781 3.250756013
hsa-miR-532-3p-002355 0.153872187 6.49890028 6.49890028
hsa-miR-545-002267 0.028961592 0.450611132 34.52848855
hsa-miR-548a-001538 17.76421631 3.70480636 4.986364934 4.794910877 0.280697152
hsa-miR-548c-001590 22.18094742 13.07614538 17.41539888
hsa-miR-548c-5p-002429 3.856506684
hsa-miR-574-3p-002349 0.012633389 0.003334466 6.552256367 3.78872913 1965.0091 518.6459713
hsa-miR-590-5p-001984 0.01338881 8.401402224 9.7631404
hsa-miR-597-001551 0.147603571 0.057527644 12.63414508 0.389744256 0.030848487
hsa-miR-598-001988 0.091885311 0.109162208 9.160679475 10.88313236
hsa-miR-618-001593 0.014641389 31.82287507 15.8395006
hsa-miR-628-5p-002433 531.1438412 0.011570566 45904.74323 116.6822639 0.002541835
hsa-miR-636-002088 0.022738166 43.97892022 43.97892022
hsa-miR-708-002341 2.179368684 2.179368684
hsa-miR-92a-000431 0.032175778 0.012299381 2.616048583 113.3129919 43.31455946
hsa-miR-95-000433 0.298075257 8.600764748 8.600764748
hsa-miR-99b-000436 0.207686362 2.788274256 4.814952652
mmu-miR-1NA-001187 0.031512774 31.73316285 31.73316285
mmu-miR-374-5p-001319 0.069524457 0.04819987 20.74694407 14.38342763
mmu-miR-93-001090 0.085227553 11.73329474 11.73329474
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hsa-let-7a-000377 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-let-7c-000379 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-let-7d-002283 0.000 0.000 0.018 0.000 0.000 0.000 0.000 0.000 0.264 0.111 0.159 0.583
hsa-let-7e-002NA6 0.000 0.000 0.000 0.000 0.000 0.000 0.701 0.844 0.686 1.034 9.889 5.081
hsa-let-7f-000382 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-let-7g-002282 0.000 0.000 0.103 0.000 0.000 0.000 1.055 1.926 1.602 1.354 8.459 4.817
hsa-miR-1-002222 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.121 0.000
hsa-miR-9-000583 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-10a-000387 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-10b-002218 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
U6 snRNA-001973 638.914 28.155 151.439 266.838 25.308 154.916 58.274 1386.041 519.962 4131.569 2809.621 1326.055
U6 snRNA-001973 722.808 34.138 178.659 276.018 20.466 60.916 253.606 1214.039 638.852 3415.391 5066.789 1002.528
hsa-miR-15a-000389 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-15b-000390 0.000 0.000 0.009 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.164
hsa-miR-16-000391 1.464 0.000 0.959 0.381 0.096 0.102 2.983 1.272 1.481 3.245 7.309 6.370
hsa-miR-17-002308 0.000 0.000 0.000 0.000 0.000 0.000 0.293 1.955 4.785 6.637 15.312 19.117
hsa-miR-18a-002422 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-18b-002217 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-19a-000395 0.000 0.000 0.205 0.000 0.000 0.000 0.000 0.075 0.147 0.219 0.092 0.571
hsa-miR-19b-000396 3.218 0.000 1.455 2.467 0.000 1.550 2.255 7.622 4.796 11.057 17.777 25.420
hsa-miR-20a-000580 0.000 1.254 10.578 0.000 6.497 0.000 0.000 10.632 7.214 9.572 17.986 27.738
hsa-miR-20b-001014 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.078 0.264 0.221 2.290
hsa-miR-21-000397 0.068 0.000 1.000 0.079 0.018 0.000 0.150 2.361 2.112 0.847 10.416 5.833
hsa-miR-22-000398 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-23a-000399 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-23b-000NA0 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-24-000NA2 0.811 0.104 2.019 0.193 0.033 2.860 1.629 2.359 3.051 3.746 5.087 9.668
hsa-miR-25-000NA3 0.000 0.000 0.000 0.000 0.000 0.061 0.002 0.685 0.209 0.727 2.073 1.429
hsa-miR-26a-000NA5 0.000 0.000 0.364 0.000 0.000 0.000 0.062 1.822 1.552 2.022 6.367 6.552
hsa-miR-26b-000NA7 0.156 0.000 0.194 0.000 0.014 0.000 0.000 0.603 1.721 0.406 1.036 3.454
CCR6+IFNγ+ CCR6-IFNγ+CCR6+IL-17+ CCR6+IL-17+IFNγ+
Table 8.2 Relative expression (2
-ΔCp
) of 384 miRNAs, normalised to median Cycle value (Cp) 
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hsa-miR-27a-000NA8 0.000 0.000 0.000 0.849 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.322
hsa-miR-27b-000NA9 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.011
hsa-miR-28-3p-002446 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-28-000411 0.000 0.000 0.086 0.000 0.000 0.000 0.000 0.114 0.104 0.256 0.424 0.694
U6 snRNA-001973 720.530 30.224 205.337 232.757 20.769 97.063 168.076 1491.644 488.805 2891.365 3402.662 1458.761
U6 snRNA-001973 493.375 35.019 168.206 223.158 23.028 317.427 0.000 1095.472 236.895 3297.342 5382.423 641.586
hsa-miR-29a-002112 0.000 0.279 0.580 0.000 0.000 0.411 1.961 2.666 1.906 1.478 6.283 4.348
hsa-miR-29b-000413 0.000 0.000 0.278 0.000 0.000 0.000 0.000 0.034 0.181 0.000 0.097 0.177
hsa-miR-29c-000587 0.000 0.000 0.000 0.000 0.000 0.000 0.000 33.974 155.175 41.107 4.817 8.281
hsa-miR-30b-000602 0.075 0.000 0.316 1.000 0.000 0.000 1.034 1.419 1.000 1.584 5.428 5.281
hsa-miR-30c-000419 0.458 0.136 1.324 1.089 0.022 0.040 1.139 2.658 2.537 3.154 11.378 10.473
hsa-miR-31-002279 0.000 0.000 0.000 0.000 0.000 0.000 0.341 0.302 0.000 0.062 0.893 2.212
hsa-miR-32-002109 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-33b-002085 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-34a-000426 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-34c-000428 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-92a-000431 0.254 0.000 1.264 0.742 0.000 0.160 1.911 4.208 1.625 2.026 9.320 12.394
mmu-miR-93-001090 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.011 0.000 0.274
hsa-miR-95-000433 0.023 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.021 0.000 0.056
mmu-miR-96-000186 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-98-000577 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-99a-000435 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-99b-000436 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.007 0.013 0.000 0.016
hsa-miR-100-000437 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-101-002253 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.124 0.116 0.061 0.137
hsa-miR-103-000439 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-105-002167 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-106a-002169 0.000 0.000 0.380 0.000 0.000 0.000 0.962 6.798 4.642 7.346 25.804 21.425
RNU44-001094 4.930 0.000 10.157 3.051 0.000 0.000 9.386 33.502 23.144 26.760 75.957 59.366
hsa-miR-106b-000442 0.000 0.024 0.000 0.056 0.036 0.760 0.091 0.153 0.127 0.110 0.511 0.451
hsa-miR-107-000443 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-122-002245 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
mmu-miR-124a-001182 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
CCR6
+
IL-17
+
 CCR6
+
IFNγ
+
IL-17
+
 CCR6
+
IFNγ
+
 CCR6
-
IFNγ
+
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hsa-miR-125a-3p-002199 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-125a-5p-002198 0.000 0.000 0.000 0.159 0.000 0.000 0.042 0.000 0.059 0.058 0.000 0.041
hsa-miR-125b-000449 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-126-002228 0.476 0.000 0.000 0.000 0.000 0.000 0.043 0.000 0.000 0.000 0.023 0.008
hsa-miR-127-000452 0.000 0.000 0.000 0.000 0.000 0.000 0.056 0.000 0.000 0.000 0.000 0.000
hsa-miR-127-5p-002229 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-128a-002216 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.058 0.000 0.000 0.000 0.000
mmu-miR-129-3p-001184 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-129-000590 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-130a-000454 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-130b-000456 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-132-000457 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-133a-002246 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.472 0.000
hsa-miR-133b-002247 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
mmu-miR-134-001186 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-135a-000460 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-135b-002261 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-136-000592 0.008 0.002 0.018 0.000 0.003 0.000 0.000 0.007 0.008 0.067 0.000 0.000
mmu-miR-137-001129 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-138-002284 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-139-3p-002313 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-139-5p-002289 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-1NA-3p-002234 0.000 0.000 0.003 0.004 0.000 0.000 0.038 0.002 0.011 0.041 0.030 0.013
mmu-miR-1NA-001187 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.017 0.051 0.094
hsa-miR-141-000463 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-142-3p-000464 6.919 1.000 19.964 6.987 0.797 25.046 40.847 76.667 42.600 23.147 192.868 219.269
hsa-miR-142-5p-002248 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.010 0.000 0.025 0.000 0.002
hsa-miR-143-002249 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-145-002278 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-146a-000468 1.715 0.000 3.240 0.379 0.162 1.316 8.704 12.753 4.915 13.059 66.731 33.761
hsa-miR-146b-3p-002361 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-146b-001097 1.796 0.000 3.585 5.004 0.051 1.997 17.591 8.215 6.968 17.479 29.275 21.913
hsa-miR-147b-002262 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
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hsa-miR-148a-000470 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.027 0.000 0.000 0.000
hsa-miR-148b-000471 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-149-002255 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-150-000473 47.879 1.303 101.845 27.250 2.046 103.065 208.094 197.455 202.407 440.445 826.040 860.383
hsa-miR-152-000475 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.191
mmu-miR-153-001191 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-154-000477 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-181a-000480 0.033 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.019 0.003 0.067 0.030
hsa-miR-181c-000482 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-182-002334 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
RNU48-001006 83.431 2.174 51.182 31.341 2.008 23.165 172.832 203.260 92.921 238.339 562.758 287.227
hsa-miR-183-002269 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-184-000485 1.232 0.566 2.498 1.820 1.254 8.437 0.382 0.613 0.712 0.632 0.722 0.165
hsa-miR-185-002271 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-186-002285 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 13332.567 5151.504 0.000 0.000
mmu-miR-187-001193 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-188-3p-002106 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-190-000489 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-191-002299 0.063 0.000 0.638 0.000 0.000 0.418 2.864 0.605 0.740 2.887 3.544 2.463
hsa-miR-192-000491 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.011 0.000 0.000 0.013 0.101
hsa-miR-193a-3p-002250 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-193a-5p-002281 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-193b-002367 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-194-000493 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.055 0.000 0.448
hsa-miR-195-000494 0.000 0.000 0.078 0.017 0.000 0.000 0.260 0.127 0.153 0.131 0.132 0.338
hsa-miR-196b-002215 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-197-000497 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-198-002273 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-199a-000498 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-199a-3p-002304 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.019
hsa-miR-199b-000500 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-200a-000502 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-200b-002251 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
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hsa-miR-200c-002300 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-202-002363 0.000 0.000 0.000 0.005 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-203-000507 0.000 0.150 0.000 0.148 0.053 0.000 0.003 0.762 0.000 0.035 0.002 0.081
hsa-miR-204-000508 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.055 0.000 0.000
hsa-miR-205-000509 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-208b-002290 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-210-000512 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-214-002306 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-215-000518 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-216a-002220 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-216b-002326 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-217-002337 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-218-000521 0.674 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.031 0.000 0.000
hsa-miR-219-000522 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-221-000524 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-222-002276 0.586 0.148 1.168 0.305 0.000 0.426 3.314 2.952 3.722 8.443 22.794 12.739
hsa-miR-223-002295 1.332 1.328 0.361 10.160 0.254 0.158 0.967 0.517 0.740 3.044 1.464 1.555
hsa-miR-224-002099 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-296-3p-002101 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-296-000527 0.000 0.000 0.000 0.009 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-299-3p-001015 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-299-5p-000600 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-301-000528 0.000 0.000 0.000 0.032 0.000 0.000 0.000 0.000 0.000 0.000 0.128 0.005
hsa-miR-301b-002392 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-302a-000529 0.000 0.000 0.000 0.000 2158.057 0.000 0.000 0.000 22.110 403.472 0.000 198.391
ath-miR159a-000338 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-302b-000531 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-302c-000533 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 305.185 0.000 0.000
hsa-miR-320-002277 0.170 0.000 0.506 0.000 0.000 0.000 2.659 1.185 1.931 3.807 7.127 5.155
hsa-miR-323-3p-002227 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.017 0.000 0.000 0.000
hsa-miR-324-3p-002161 43176.270 26330.732 18254.455 10141.996 8395.363 0.000 16023.326 11854.909 3541.707 13024.424 7802.691 2228.381
hsa-miR-324-5p-000539 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-326-000542 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
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hsa-miR-328-000543 0.112 0.000 0.000 0.037 0.000 0.000 0.251 0.204 0.107 2.191 1.997 0.566
hsa-miR-329-001101 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-330-000544 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-330-5p-002230 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-331-000545 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.037 0.000 0.132 0.973 2.448
hsa-miR-331-5p-002233 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-335-000546 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.020
hsa-miR-337-5p-002156 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.000 0.017 0.000
hsa-miR-338-3p-002252 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-339-3p-002184 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-339-5p-002257 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-3NA-002258 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.002 0.000 0.000 0.000 0.000
hsa-miR-155-002623 2.178 0.000 1.925 0.000 0.069 0.088 6.340 8.133 3.700 10.890 20.976 15.503
hsa-let-7b-002619 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.078 0.000 0.000 0.128
hsa-miR-342-3p-002260 3.034 0.000 0.837 2.089 0.068 0.252 12.348 3.588 2.580 17.217 14.903 9.527
hsa-miR-342-5p-002147 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-345-002186 0.000 0.000 0.040 0.000 0.000 0.000 0.000 0.013 0.000 0.025 0.000 0.090
hsa-miR-361-000554 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-362-3p-002117 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-362-001273 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.020 0.000 0.000 0.181 0.000
hsa-miR-363-001271 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-365-001020 0.000 0.010 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-367-000555 0.000 0.000 2304.910 0.000 136.117 0.000 0.000 0.000 29.173 126.103 0.000 0.000
hsa-miR-369-3p-000557 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-369-5p-001021 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-370-002275 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-371-3p-002124 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-372-000560 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-373-000561 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-374-000563 0.000 0.000 0.238 0.000 0.000 0.264 0.427 0.519 0.191 0.456 2.895 1.028
mmu-miR-374-5p-001319 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.132 0.041 0.016 0.000 1.000
hsa-miR-375-000564 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.004 0.147 0.037 0.022
hsa-miR-376a-000565 1.791 0.000 16.205 9.423 7.088 252.912 0.292 2.044 3.143 1.635 1.218 1.077
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hsa-miR-376b-001102 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-377-000566 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
mmu-miR-379-001138 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-380-3p-000569 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-381-000571 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.040 0.000
hsa-miR-382-000572 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-383-000573 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-NA9-5p-002331 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-410-001274 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.022 0.036 0.000 0.000
hsa-miR-411-001610 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-422a-002297 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.142 0.000 0.000 0.177 0.000
hsa-miR-423-5p-0023NA 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-424-000604 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-425-5p-001516 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-429-001024 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-431-001979 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-433-001028 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-449-001030 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-449b-001608 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-450a-002303 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-450b-3p-002208 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.043 0.000
hsa-miR-450b-5p-002207 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
mmu-miR-451-001141 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.731 0.000
hsa-miR-452-002329 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-453-002318 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-454-002323 0.000 256972.776 475011.198 0.000 1202140.425 0.000 0.000 422503.568 499717.425 776094.067 0.000 0.000
hsa-miR-455-3p-002244 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-455-001280 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-483-5p-002338 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.058 0.000 0.000
hsa-miR-484-001821 0.427 0.000 0.000 0.173 0.000 0.000 1.307 0.395 0.175 6.753 2.132 2.017
hsa-miR-485-3p-001277 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-485-5p-001036 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-486-3p-002093 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
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hsa-miR-486-001278 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-487a-001279 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-487b-001285 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-488-002357 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-489-002358 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-490-001037 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-491-3p-002360 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
mmu-miR-491-001630 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.075 0.000 0.000 0.000
hsa-miR-493-002364 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-494-002365 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.095 0.210 0.000
mmu-miR-495-001663 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
mmu-miR-496-001953 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-499-3p-002427 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
mmu-miR-499-001352 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.023 0.000
hsa-miR-500-002428 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-501-3p-002435 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-501-001047 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-502-3p-002083 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-502-001109 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-503-001048 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-504-002084 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-505-002089 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-507-001051 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-508-001052 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-508-5p-002092 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-509-5p-002235 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-510-002241 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-512-3p-001823 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-512-5p-001145 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-513-5p-002090 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-515-3p-002369 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-515-5p-001112 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-516a-5p-002416 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
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hsa-miR-516b-001150 0.000 0.000 0.000 0.000 0.000 0.000 0.017 0.000 0.000 0.000 0.000 0.000
hsa-miR-517a-002NA2 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-517c-001153 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-518a-3p-002397 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-518a-5p-002396 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-518b-001156 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.000 0.000 0.000
hsa-miR-518c-002NA1 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-518d-001159 26.364 18.566 22.411 30.973 11.821 136.842 0.000 9.249 7.311 24.069 10.763 2.939
hsa-miR-518d-5p-002389 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-518e-002395 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-518f-002388 0.000 0.000 0.000 0.000 0.023 0.010 0.000 0.000 0.000 0.056 0.022 0.000
hsa-miR-519a-002415 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-519d-002NA3 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-519e-002370 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-520a-001167 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-520a#-001168 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-520d-5p-002393 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-520g-001121 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-521-001122 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-522-002413 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-523-002386 0.000 0.000 0.000 0.000 0.000 0.000 0.002 0.035 0.000 0.057 0.591 0.005
hsa-miR-524-5p-001982 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-525-3p-002385 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-525-001174 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-526b-002382 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-532-3p-002355 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.119 0.004
hsa-miR-532-001518 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-539-001286 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-541-002201 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-542-3p-001284 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.017 0.000
hsa-miR-542-5p-0022NA 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-544-002265 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-545-002267 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.576 0.131 5.108 0.000 0.000
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hsa-miR-548a-001538 0.215 0.047 0.201 0.243 0.050 0.000 0.006 0.045 0.000 0.274 0.108 0.000
hsa-miR-548a-5p-002412 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-548b-001541 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-548b-5p-002NA8 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.328 0.000
hsa-miR-548c-001590 0.038 0.013 0.055 0.000 0.000 0.000 0.057 0.171 0.000 0.026 0.033 0.006
hsa-miR-548c-5p-002429 0.000 0.000 0.023 0.000 0.000 0.000 0.022 0.000 0.000 0.002 0.051 0.000
hsa-miR-548d-001605 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-548d-5p-002237 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.008 0.017 0.000 0.000
hsa-miR-551b-001535 0.000 0.000 0.000 0.000 0.000 0.017 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-556-3p-002345 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-556-5p-002344 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-561-001528 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-570-002347 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-574-3p-002349 4.074 0.000 0.124 1.328 0.000 0.000 8.188 9.528 4.368 43.003 44.047 9.785
hsa-miR-576-3p-002351 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-576-5p-002350 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-579-002398 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-582-3p-002399 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-582-5p-001983 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-589-002NA9 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-590-5p-001984 0.000 0.000 0.000 0.000 0.000 0.607 0.017 0.000 0.077 0.047 0.168 0.131
hsa-miR-597-001551 0.000 0.972 2.310 1.203 1.464 9.071 0.000 0.799 0.433 2.303 1.000 0.411
hsa-miR-598-001988 0.000 0.000 0.000 0.000 0.000 0.000 0.037 0.000 0.064 0.000 0.058 0.024
mmu-miR-615-001960 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-615-5p-002353 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-616-002414 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-618-001593 0.000 0.000 0.000 0.109 0.000 0.000 0.000 0.000 0.013 0.212 0.172 0.022
hsa-miR-624-002430 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-625-002431 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-627-001560 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.134 0.000 0.000
hsa-miR-628-5p-002433 0.000 70352.984 199379.561 51316.601 111077.724 0.000 0.000 0.000 69029.050 13455.002 51730.840 17642.532
hsa-miR-629-002436 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-636-002088 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 1.132 0.000 0.138
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hsa-miR-642-001592 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.054
hsa-miR-651-001604 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-652-002352 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-653-002292 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-654-3p-002239 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.050 0.000
hsa-miR-654-001611 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-655-001612 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-660-001515 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-671-3p-002322 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-672-002327 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-674-002021 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-708-002341 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.017 0.000 0.001
hsa-miR-744-002324 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.026 0.000
hsa-miR-758-001990 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-871-002354 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-872-002264 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-873-002356 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-874-002268 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.073
hsa-miR-875-3p-002204 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-876-3p-002225 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-876-5p-002205 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-885-3p-002372 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-885-5p-002296 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-886-3p-002194 0.009 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-886-5p-002193 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-887-002374 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-888-002212 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-889-002202 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-890-002209 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-891a-002191 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-891b-002210 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-892a-002195 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-147-000469 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.182 0.000 0.000
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hsa-miR-208-000511 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-211-000514 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-212-000515 0.000 0.000 0.143 0.000 0.000 0.000 0.000 0.000 0.000 1.000 0.000 0.000
hsa-miR-219-1-3p-002095 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-219-2-3p-002390 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-220-000523 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-220b-002206 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-220c-002211 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-298-002190 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-325-0005NA 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-346-000553 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-376c-002122 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-384-000574 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-412-001023 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-448-001029 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-492-001039 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-506-001050 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-509-3-5p-002155 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-511-001111 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-517b-001152 0.042 0.000 0.000 0.000 0.000 0.000 0.004 0.019 0.519 0.123 1.050 0.329
hsa-miR-519c-001163 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-520b-001116 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-520e-001119 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
hsa-miR-520f-001120 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000
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